[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fywYTLQaE8aQA42HpHAorAbl-1mOaWuZmhpsRagd5KdA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":83,"rows":90},"Astellas Pharma Global Development, Inc.",[4],199,false,33,27,123852,64,7,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Healthy Volunteers",29,{"name":18,"count":19},"Healthy Subjects",20,{"name":21,"count":22},"Pharmacokinetics of Isavuconazole",18,{"name":24,"count":25},"Advanced Solid Tumors",10,{"name":27,"count":25},"Prostate Cancer",{"name":29,"count":30},"Acute Myeloid Leukemia (AML)",9,{"name":32,"count":12},"Hot Flashes",{"name":34,"count":35},"Acute Myeloid Leukemia",6,[37,42,46,51,56,61,66,71,76,79],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03504397","A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","2022-09-09","zolbetuximab",{"nctId":43,"briefTitle":44,"date":45,"intervention":41},"NCT03653507","A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","2022-10-25",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04184895","A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites","2022-12-22","ASP2390",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04223856","Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer","2023-08-08","Enfortumab vedotin",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04225117","A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)","2025-02-25","enfortumab vedotin",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06049797","A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats","2025-09-06","Fezolinetant",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05621616","A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity","2026-02-16","mirabegron",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05083481","A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","2026-06-30","ASP1570",{"nctId":77,"briefTitle":78,"date":74,"intervention":65},"NCT06440967","A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy",{"nctId":80,"briefTitle":81,"date":82,"intervention":41},"NCT06396091","A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer","2026-07-31",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,244,411,494,556,590,624,658,692,722,771,801,835,861,887,909,1037,1103,1137,1155,1173,1191,1209,1319,1428,1454,1476,1498,1694,1720,1742,1760,1778,1796,1814,1832,1855,1873,1891,1909,1927,1949,1990,2012,2030,2051,2069,2092,2110,2128,2146,2164,2182,2229,2261,2279,2297,2315,2333,2351,2369,2387,2405,2423,2441,2473,2491,2509,2527,2574,2619,2652,2690,2723,2741,2759,2777,2795,2813,2831,2849,2901,2934,2969,2997,3019,3060,3092,3120,3154,3176,3198,3220,3256,3274,3298,3316,3334,3352,3374,3392,3416,3434,3452,3470,3488,3506,3524,3542,3560,3578,3596,3614,3632,3650,3676,3694,3712,3738,3762,3933,3981,4023,4058,4098,4125,4147,4169,4204,4227,4251,4274,4298,4316,4334,4357,4381,4399,4424,4442,4466,4484,4502,4525,4543,4566,4584,4608,4630,4648,4666,4684,4709,4727,4755,4773,4791,4815,4833,4855,4873,4891,4909,4927,4945,4968,4986,5004,5027,5053,5071,5095,5119,5137,5161,5179,5197,5215,5233,5257,5275,5299,5317,5335,5360,5378,5404,5422,5440,5464,5487,5511,5529,5554,5572,5590,5608,5630,5648,5672,5690,5729,5751,5769],{"intervention":60,"totalTrials":92,"cells":93},11,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":125,"PHASE3":181,"PHASE4":220,"NA":234},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[99,110],{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":106,"conditions":107,"interventions":109},"NCT02091999","A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4","COMPLETED",[85],"2022-12-07","2014-05-14",213,[108],"Metastatic Urothelial Cancer and Other Malignant Solid Tumors",[60],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":124},"NCT05014139","A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)","TERMINATED",[85],"2025-09-22","2021-12-07",37,[119,120,121,122,123],"Urinary Bladder Neoplasms","Carcinoma in Situ","Carcinoma Transitional Cell","Non-muscle Invasive Bladder Cancer","NMIBC",[55],{"trials":126,"activeCount":180,"soonestReadout":59},[127,142,153,162],{"nctId":128,"briefTitle":129,"status":130,"phases":131,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},"NCT07287995","A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","RECRUITING",[85,86],"2029-06-30","2026-02-05",428,[136],"Locally Advanced or Metastatic Malignant Solid Tumors",[138,139,140,141],"ASP2998","Pembrolizumab","Enfortumab Vedotin","Carboplatin",{"nctId":143,"briefTitle":144,"status":130,"phases":145,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":152},"NCT07475806","A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder",[86],"2027-11-30","2031-04-30","2026-03-12",240,[151],"Muscle-invasive Bladder Cancer",[140,139],{"nctId":57,"briefTitle":58,"status":154,"phases":155,"primaryCompletion":59,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":160},"ACTIVE_NOT_RECRUITING",[86],"2026-09-30","2020-03-10",329,[136],[60,161],"pembrolizumab",{"nctId":163,"briefTitle":164,"status":113,"phases":165,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":176},"NCT03288545","A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer",[85,86],"2026-02-20","2017-10-11",348,[170,119,171,172,173,174,175],"Carcinoma, Transitional Cell","Urologic Neoplasms","Renal Pelvis Neoplasms","Urothelial Cancer","Ureteral Neoplasms","Urethral Neoplasms",[60,161,177,178,179],"cisplatin","carboplatin","gemcitabine",3,{"trials":182,"activeCount":219,"soonestReadout":54},[183,198,212],{"nctId":184,"briefTitle":185,"status":102,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":194},"NCT03474107","A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)",[87],"2020-07-15","2025-11-27","2018-06-27",608,[192,173,193],"Ureteral Cancer","Bladder Cancer",[140,195,196,197],"Docetaxel","Vinflunine","Paclitaxel",{"nctId":199,"briefTitle":200,"status":130,"phases":201,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":207},"NCT07566156","Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 )",[87],"2030-03-31","2032-02-29","2026-05-11",390,[173,119],[55,208,209,210,211,139],"Cisplatin","Fluorouracil","Mitomycin C","Gemcitabine",{"nctId":52,"briefTitle":53,"status":154,"phases":213,"primaryCompletion":54,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":218},[87],"2028-03-01","2020-03-30",886,[173],[55,139,208,141,211],2,{"trials":221,"activeCount":233,"soonestReadout":226},[222],{"nctId":223,"briefTitle":224,"status":130,"phases":225,"primaryCompletion":226,"completion":227,"start":228,"enrollment":229,"conditions":230,"interventions":232},"NCT06862219","A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer",[88],"2026-12-31","2027-12-31","2025-06-21",100,[231],"Metastatic Urothelial Carcinoma",[140],1,{"trials":235,"activeCount":96},[236],{"nctId":237,"briefTitle":238,"status":239,"phases":240,"conditions":241,"interventions":243},"NCT04136808","An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma","APPROVED_FOR_MARKETING",[],[242],"Locally Advanced or Metastatic Urothelial Carcinoma (UC)",[60],{"intervention":139,"totalTrials":245,"cells":246},16,{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":324,"PHASE3":382,"PHASE4":407,"NA":409},{"trials":248,"activeCount":96},[],{"trials":250,"activeCount":233,"soonestReadout":310},[251,264,274,285,295,306],{"nctId":252,"briefTitle":253,"status":102,"phases":254,"primaryCompletion":255,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":262},"NCT03954067","A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors",[85],"2024-04-19","2019-09-03",72,[259,260,261],"Metastatic Cancer","Solid Tumors","Advanced Cancer",[263,139],"ASP9801",{"nctId":265,"briefTitle":266,"status":113,"phases":267,"primaryCompletion":268,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":272},"NCT03799003","A Study of ASP1951 in Subjects With Advanced Solid Tumors",[85],"2023-07-06","2019-01-14",119,[24],[273,161],"ASP1951",{"nctId":275,"briefTitle":276,"status":102,"phases":277,"primaryCompletion":278,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":282},"NCT03565445","A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors",[85],"2023-03-27","2018-07-02",190,[24],[283,284,161],"ASP1948","nivolumab",{"nctId":286,"briefTitle":287,"status":102,"phases":288,"primaryCompletion":289,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":293},"NCT03260322","A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",[85],"2022-05-10","2017-09-08",169,[24],[294,139],"ASP8374",{"nctId":296,"briefTitle":297,"status":113,"phases":298,"primaryCompletion":299,"completion":299,"start":300,"enrollment":301,"conditions":302,"interventions":304},"NCT06171178","A Study of ASP1012 in Adults With Solid Tumors",[85],"2025-09-11","2024-05-15",15,[303],"Solid Tumor",[305,139],"ASP1012",{"nctId":307,"briefTitle":308,"status":130,"phases":309,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":317},"NCT05365581","A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer",[85],"2028-05-31","2022-06-07",398,[314,315,316],"Gastric Adenocarcinoma","Gastroesophageal Junction (GEJ) Adenocarcinoma","Pancreatic Adenocarcinoma",[318,139,319,320,209,321,197,322,323],"ASP2138","Oxaliplatin","Leucovorin","Ramucirumab","Irinotecan","Capecitabine",{"trials":325,"activeCount":381,"soonestReadout":59},[326,336,347,365,369,373,377],{"nctId":72,"briefTitle":73,"status":154,"phases":327,"primaryCompletion":74,"completion":74,"start":328,"enrollment":329,"conditions":330,"interventions":331},[85,86],"2021-10-19",226,[24],[75,161,332,333,195,319,320,334,322,335,141],"Trifluridine + Tipiracil","Bevacizumab","5-Fluorouracil","Pemetrexed",{"nctId":337,"briefTitle":338,"status":102,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT04837196","Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen",[85,86],"2024-06-21","2021-11-11",24,[344,261],"Advanced Malignancies",[346,139],"ASP7517",{"nctId":348,"briefTitle":349,"status":154,"phases":350,"primaryCompletion":82,"completion":351,"start":352,"enrollment":353,"conditions":354,"interventions":360},"NCT03505320","A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer",[86],"2027-05-31","2018-06-29",143,[355,356,357,358,359],"Pharmacokinetics of Zolbetuximab","Gastric Cancer","Gastro-esophageal Junction (GEJ) Cancer","Pharmacokinetics of Oxaliplatin","Pharmacokinetics of Fluorouracil Bolus (5-FU)",[41,361,362,363,139,364,284,195],"oxaliplatin","leucovorin","fluorouracil","folinic acid",{"nctId":128,"briefTitle":129,"status":130,"phases":366,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":367,"interventions":368},[85,86],[136],[138,139,140,141],{"nctId":143,"briefTitle":144,"status":130,"phases":370,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":371,"interventions":372},[86],[151],[140,139],{"nctId":57,"briefTitle":58,"status":154,"phases":374,"primaryCompletion":59,"completion":156,"start":157,"enrollment":158,"conditions":375,"interventions":376},[86],[136],[60,161],{"nctId":163,"briefTitle":164,"status":113,"phases":378,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":379,"interventions":380},[85,86],[170,119,171,172,173,174,175],[60,161,177,178,179],5,{"trials":383,"activeCount":180,"soonestReadout":54},[384,399,403],{"nctId":385,"briefTitle":386,"status":130,"phases":387,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":396},"NCT06901531","A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer",[87],"2028-09-30","2025-05-22",500,[392,393,394,395],"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer","Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer","Metastatic Gastric Adenocarcinoma or Cancer","Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma",[41,139,323,319,397,398],"Folinic acid","5-fluorouracil",{"nctId":199,"briefTitle":200,"status":130,"phases":400,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":401,"interventions":402},[87],[173,119],[55,208,209,210,211,139],{"nctId":52,"briefTitle":53,"status":154,"phases":404,"primaryCompletion":54,"completion":214,"start":215,"enrollment":216,"conditions":405,"interventions":406},[87],[173],[55,139,208,141,211],{"trials":408,"activeCount":96},[],{"trials":410,"activeCount":96},[],{"intervention":319,"totalTrials":30,"cells":412},{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":433,"PHASE3":457,"PHASE4":490,"NA":492},{"trials":414,"activeCount":96},[],{"trials":416,"activeCount":219,"soonestReadout":421},[417,429],{"nctId":418,"briefTitle":419,"status":130,"phases":420,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":426},"NCT07024615","A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer",[85],"2028-01-31","2025-10-16",25,[425],"Pancreatic Ductal Adenocarcinoma",[318,319,320,427,322,211,428,323],"5-FU","Nab-paclitaxel",{"nctId":307,"briefTitle":308,"status":130,"phases":430,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":431,"interventions":432},[85],[314,315,316],[318,139,319,320,209,321,197,322,323],{"trials":434,"activeCount":219,"soonestReadout":74},[435,449,453],{"nctId":436,"briefTitle":437,"status":102,"phases":438,"primaryCompletion":439,"completion":439,"start":440,"enrollment":441,"conditions":442,"interventions":446},"NCT01630083","Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer",[86],"2019-01-31","2012-07-19",252,[443,444,445],"CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction","CLDN18.2-positive Adenocarcinoma of Esophagus","CLDN18.2-positive Gastric Adenocarcinoma",[447,361,448,41],"epirubicin","capecitabine",{"nctId":72,"briefTitle":73,"status":154,"phases":450,"primaryCompletion":74,"completion":74,"start":328,"enrollment":329,"conditions":451,"interventions":452},[85,86],[24],[75,161,332,333,195,319,320,334,322,335,141],{"nctId":348,"briefTitle":349,"status":154,"phases":454,"primaryCompletion":82,"completion":351,"start":352,"enrollment":353,"conditions":455,"interventions":456},[86],[355,356,357,358,359],[41,361,362,363,139,364,284,195],{"trials":458,"activeCount":489,"soonestReadout":40},[459,473,479,485],{"nctId":460,"briefTitle":461,"status":130,"phases":462,"primaryCompletion":463,"completion":463,"start":464,"enrollment":465,"conditions":466,"interventions":470},"NCT07409272","A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer",[87],"2029-08-31","2026-02-17",614,[467,468,469],"Pancreatic Cancer","Metastatic Pancreatic Cancer","Metastatic Pancreatic Adenocarcinoma",[471,319,320,322,363,472],"Setidegrasib","liposomal irinotecan",{"nctId":38,"briefTitle":39,"status":154,"phases":474,"primaryCompletion":40,"completion":156,"start":475,"enrollment":476,"conditions":477,"interventions":478},[87],"2018-06-21",565,[392,393,394,395],[41,361,364,363],{"nctId":43,"briefTitle":44,"status":154,"phases":480,"primaryCompletion":45,"completion":156,"start":481,"enrollment":482,"conditions":483,"interventions":484},[87],"2018-11-28",507,[392,393,394,395],[41,361,448],{"nctId":385,"briefTitle":386,"status":130,"phases":486,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":487,"interventions":488},[87],[392,393,394,395],[41,139,323,319,397,398],4,{"trials":491,"activeCount":96},[],{"trials":493,"activeCount":96},[],{"intervention":41,"totalTrials":495,"cells":496},8,{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":508,"PHASE3":528,"PHASE4":542,"NA":544},{"trials":498,"activeCount":96},[],{"trials":500,"activeCount":233,"soonestReadout":82},[501],{"nctId":80,"briefTitle":81,"status":154,"phases":502,"primaryCompletion":82,"completion":82,"start":503,"enrollment":504,"conditions":505,"interventions":506},[85],"2025-09-24",12,[469],[41,507],"mFOLFIRINOX",{"trials":509,"activeCount":219,"soonestReadout":82},[510,514,518],{"nctId":436,"briefTitle":437,"status":102,"phases":511,"primaryCompletion":439,"completion":439,"start":440,"enrollment":441,"conditions":512,"interventions":513},[86],[443,444,445],[447,361,448,41],{"nctId":348,"briefTitle":349,"status":154,"phases":515,"primaryCompletion":82,"completion":351,"start":352,"enrollment":353,"conditions":516,"interventions":517},[86],[355,356,357,358,359],[41,361,362,363,139,364,284,195],{"nctId":519,"briefTitle":520,"status":154,"phases":521,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":526},"NCT03816163","A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer",[86],"2026-08-31","2019-03-15",393,[467,468,469],[41,527,179],"nab-paclitaxel",{"trials":529,"activeCount":180,"soonestReadout":40},[530,534,538],{"nctId":38,"briefTitle":39,"status":154,"phases":531,"primaryCompletion":40,"completion":156,"start":475,"enrollment":476,"conditions":532,"interventions":533},[87],[392,393,394,395],[41,361,364,363],{"nctId":43,"briefTitle":44,"status":154,"phases":535,"primaryCompletion":45,"completion":156,"start":481,"enrollment":482,"conditions":536,"interventions":537},[87],[392,393,394,395],[41,361,448],{"nctId":385,"briefTitle":386,"status":130,"phases":539,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":540,"interventions":541},[87],[392,393,394,395],[41,139,323,319,397,398],{"trials":543,"activeCount":96},[],{"trials":545,"activeCount":96},[546],{"nctId":547,"briefTitle":548,"status":549,"phases":550,"conditions":551,"interventions":555},"NCT06048081","Early Access Program for Zolbetuximab","AVAILABLE",[],[552,553,554,395],"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer","Locally Advanced Unresectable Gastric Adenocarcinoma Cancer","Metastatic Gastric Adenocarcinoma Cancer",[41],{"intervention":320,"totalTrials":381,"cells":557},{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":570,"PHASE3":580,"PHASE4":586,"NA":588},{"trials":559,"activeCount":96},[],{"trials":561,"activeCount":219,"soonestReadout":421},[562,566],{"nctId":418,"briefTitle":419,"status":130,"phases":563,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":564,"interventions":565},[85],[425],[318,319,320,427,322,211,428,323],{"nctId":307,"briefTitle":308,"status":130,"phases":567,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":568,"interventions":569},[85],[314,315,316],[318,139,319,320,209,321,197,322,323],{"trials":571,"activeCount":219,"soonestReadout":74},[572,576],{"nctId":72,"briefTitle":73,"status":154,"phases":573,"primaryCompletion":74,"completion":74,"start":328,"enrollment":329,"conditions":574,"interventions":575},[85,86],[24],[75,161,332,333,195,319,320,334,322,335,141],{"nctId":348,"briefTitle":349,"status":154,"phases":577,"primaryCompletion":82,"completion":351,"start":352,"enrollment":353,"conditions":578,"interventions":579},[86],[355,356,357,358,359],[41,361,362,363,139,364,284,195],{"trials":581,"activeCount":233,"soonestReadout":463},[582],{"nctId":460,"briefTitle":461,"status":130,"phases":583,"primaryCompletion":463,"completion":463,"start":464,"enrollment":465,"conditions":584,"interventions":585},[87],[467,468,469],[471,319,320,322,363,472],{"trials":587,"activeCount":96},[],{"trials":589,"activeCount":96},[],{"intervention":363,"totalTrials":381,"cells":591},{"EARLY_PHASE1":592,"PHASE1":594,"PHASE2":600,"PHASE3":606,"PHASE4":620,"NA":622},{"trials":593,"activeCount":96},[],{"trials":595,"activeCount":233,"soonestReadout":310},[596],{"nctId":307,"briefTitle":308,"status":130,"phases":597,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":598,"interventions":599},[85],[314,315,316],[318,139,319,320,209,321,197,322,323],{"trials":601,"activeCount":233,"soonestReadout":82},[602],{"nctId":348,"briefTitle":349,"status":154,"phases":603,"primaryCompletion":82,"completion":351,"start":352,"enrollment":353,"conditions":604,"interventions":605},[86],[355,356,357,358,359],[41,361,362,363,139,364,284,195],{"trials":607,"activeCount":180,"soonestReadout":40},[608,612,616],{"nctId":460,"briefTitle":461,"status":130,"phases":609,"primaryCompletion":463,"completion":463,"start":464,"enrollment":465,"conditions":610,"interventions":611},[87],[467,468,469],[471,319,320,322,363,472],{"nctId":38,"briefTitle":39,"status":154,"phases":613,"primaryCompletion":40,"completion":156,"start":475,"enrollment":476,"conditions":614,"interventions":615},[87],[392,393,394,395],[41,361,364,363],{"nctId":199,"briefTitle":200,"status":130,"phases":617,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":618,"interventions":619},[87],[173,119],[55,208,209,210,211,139],{"trials":621,"activeCount":96},[],{"trials":623,"activeCount":96},[],{"intervention":323,"totalTrials":381,"cells":625},{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":638,"PHASE3":644,"PHASE4":654,"NA":656},{"trials":627,"activeCount":96},[],{"trials":629,"activeCount":219,"soonestReadout":421},[630,634],{"nctId":418,"briefTitle":419,"status":130,"phases":631,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":632,"interventions":633},[85],[425],[318,319,320,427,322,211,428,323],{"nctId":307,"briefTitle":308,"status":130,"phases":635,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":636,"interventions":637},[85],[314,315,316],[318,139,319,320,209,321,197,322,323],{"trials":639,"activeCount":96},[640],{"nctId":436,"briefTitle":437,"status":102,"phases":641,"primaryCompletion":439,"completion":439,"start":440,"enrollment":441,"conditions":642,"interventions":643},[86],[443,444,445],[447,361,448,41],{"trials":645,"activeCount":219,"soonestReadout":45},[646,650],{"nctId":43,"briefTitle":44,"status":154,"phases":647,"primaryCompletion":45,"completion":156,"start":481,"enrollment":482,"conditions":648,"interventions":649},[87],[392,393,394,395],[41,361,448],{"nctId":385,"briefTitle":386,"status":130,"phases":651,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":652,"interventions":653},[87],[392,393,394,395],[41,139,323,319,397,398],{"trials":655,"activeCount":96},[],{"trials":657,"activeCount":96},[],{"intervention":211,"totalTrials":381,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":668,"PHASE3":678,"PHASE4":688,"NA":690},{"trials":661,"activeCount":96},[],{"trials":663,"activeCount":233,"soonestReadout":421},[664],{"nctId":418,"briefTitle":419,"status":130,"phases":665,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":666,"interventions":667},[85],[425],[318,319,320,427,322,211,428,323],{"trials":669,"activeCount":233,"soonestReadout":522},[670,674],{"nctId":519,"briefTitle":520,"status":154,"phases":671,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":672,"interventions":673},[86],[467,468,469],[41,527,179],{"nctId":163,"briefTitle":164,"status":113,"phases":675,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":676,"interventions":677},[85,86],[170,119,171,172,173,174,175],[60,161,177,178,179],{"trials":679,"activeCount":219,"soonestReadout":54},[680,684],{"nctId":199,"briefTitle":200,"status":130,"phases":681,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":682,"interventions":683},[87],[173,119],[55,208,209,210,211,139],{"nctId":52,"briefTitle":53,"status":154,"phases":685,"primaryCompletion":54,"completion":214,"start":215,"enrollment":216,"conditions":686,"interventions":687},[87],[173],[55,139,208,141,211],{"trials":689,"activeCount":96},[],{"trials":691,"activeCount":96},[],{"intervention":322,"totalTrials":489,"cells":693},{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":706,"PHASE3":712,"PHASE4":718,"NA":720},{"trials":695,"activeCount":96},[],{"trials":697,"activeCount":219,"soonestReadout":421},[698,702],{"nctId":418,"briefTitle":419,"status":130,"phases":699,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":700,"interventions":701},[85],[425],[318,319,320,427,322,211,428,323],{"nctId":307,"briefTitle":308,"status":130,"phases":703,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":704,"interventions":705},[85],[314,315,316],[318,139,319,320,209,321,197,322,323],{"trials":707,"activeCount":233,"soonestReadout":74},[708],{"nctId":72,"briefTitle":73,"status":154,"phases":709,"primaryCompletion":74,"completion":74,"start":328,"enrollment":329,"conditions":710,"interventions":711},[85,86],[24],[75,161,332,333,195,319,320,334,322,335,141],{"trials":713,"activeCount":233,"soonestReadout":463},[714],{"nctId":460,"briefTitle":461,"status":130,"phases":715,"primaryCompletion":463,"completion":463,"start":464,"enrollment":465,"conditions":716,"interventions":717},[87],[467,468,469],[471,319,320,322,363,472],{"trials":719,"activeCount":96},[],{"trials":721,"activeCount":96},[],{"intervention":195,"totalTrials":381,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":740,"PHASE3":750,"PHASE4":767,"NA":769},{"trials":725,"activeCount":96},[],{"trials":727,"activeCount":96},[728],{"nctId":729,"briefTitle":730,"status":113,"phases":731,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":735,"interventions":738},"NCT01705483","A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies",[85],"2014-06-11","2012-08-28",21,[736,737],"Pharmacokinetics of ASP9853","Non-hematologic Malignancies",[739,195,197],"ASP9853",{"trials":741,"activeCount":219,"soonestReadout":74},[742,746],{"nctId":72,"briefTitle":73,"status":154,"phases":743,"primaryCompletion":74,"completion":74,"start":328,"enrollment":329,"conditions":744,"interventions":745},[85,86],[24],[75,161,332,333,195,319,320,334,322,335,141],{"nctId":348,"briefTitle":349,"status":154,"phases":747,"primaryCompletion":82,"completion":351,"start":352,"enrollment":353,"conditions":748,"interventions":749},[86],[355,356,357,358,359],[41,361,362,363,139,364,284,195],{"trials":751,"activeCount":233,"soonestReadout":761},[752,756],{"nctId":184,"briefTitle":185,"status":102,"phases":753,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":754,"interventions":755},[87],[192,173,193],[140,195,196,197],{"nctId":757,"briefTitle":758,"status":759,"phases":760,"primaryCompletion":761,"completion":761,"start":762,"enrollment":763,"conditions":764,"interventions":766},"NCT07566052","A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation","NOT_YET_RECRUITING",[87],"2030-06-30","2026-04-30",356,[765],"Non-small Cell Lung Cancer (NSCLC)",[471,195],{"trials":768,"activeCount":96},[],{"trials":770,"activeCount":96},[],{"intervention":141,"totalTrials":489,"cells":772},{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":791,"PHASE4":797,"NA":799},{"trials":774,"activeCount":96},[],{"trials":776,"activeCount":96},[],{"trials":778,"activeCount":219,"soonestReadout":74},[779,783,787],{"nctId":72,"briefTitle":73,"status":154,"phases":780,"primaryCompletion":74,"completion":74,"start":328,"enrollment":329,"conditions":781,"interventions":782},[85,86],[24],[75,161,332,333,195,319,320,334,322,335,141],{"nctId":128,"briefTitle":129,"status":130,"phases":784,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":785,"interventions":786},[85,86],[136],[138,139,140,141],{"nctId":163,"briefTitle":164,"status":113,"phases":788,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":789,"interventions":790},[85,86],[170,119,171,172,173,174,175],[60,161,177,178,179],{"trials":792,"activeCount":233,"soonestReadout":54},[793],{"nctId":52,"briefTitle":53,"status":154,"phases":794,"primaryCompletion":54,"completion":214,"start":215,"enrollment":216,"conditions":795,"interventions":796},[87],[173],[55,139,208,141,211],{"trials":798,"activeCount":96},[],{"trials":800,"activeCount":96},[],{"intervention":471,"totalTrials":180,"cells":802},{"EARLY_PHASE1":803,"PHASE1":805,"PHASE2":819,"PHASE3":821,"PHASE4":831,"NA":833},{"trials":804,"activeCount":96},[],{"trials":806,"activeCount":233,"soonestReadout":82},[807],{"nctId":808,"briefTitle":809,"status":130,"phases":810,"primaryCompletion":82,"completion":82,"start":811,"enrollment":812,"conditions":813,"interventions":815},"NCT07395024","A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults",[85],"2026-02-03",54,[814],"Healthy Volunteer",[471,816,817,818],"Fluconazole","Carbamazepine","Itraconazole",{"trials":820,"activeCount":96},[],{"trials":822,"activeCount":219,"soonestReadout":463},[823,827],{"nctId":460,"briefTitle":461,"status":130,"phases":824,"primaryCompletion":463,"completion":463,"start":464,"enrollment":465,"conditions":825,"interventions":826},[87],[467,468,469],[471,319,320,322,363,472],{"nctId":757,"briefTitle":758,"status":759,"phases":828,"primaryCompletion":761,"completion":761,"start":762,"enrollment":763,"conditions":829,"interventions":830},[87],[765],[471,195],{"trials":832,"activeCount":96},[],{"trials":834,"activeCount":96},[],{"intervention":364,"totalTrials":180,"cells":836},{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":841,"PHASE3":847,"PHASE4":857,"NA":859},{"trials":838,"activeCount":96},[],{"trials":840,"activeCount":96},[],{"trials":842,"activeCount":233,"soonestReadout":82},[843],{"nctId":348,"briefTitle":349,"status":154,"phases":844,"primaryCompletion":82,"completion":351,"start":352,"enrollment":353,"conditions":845,"interventions":846},[86],[355,356,357,358,359],[41,361,362,363,139,364,284,195],{"trials":848,"activeCount":219,"soonestReadout":40},[849,853],{"nctId":38,"briefTitle":39,"status":154,"phases":850,"primaryCompletion":40,"completion":156,"start":475,"enrollment":476,"conditions":851,"interventions":852},[87],[392,393,394,395],[41,361,364,363],{"nctId":385,"briefTitle":386,"status":130,"phases":854,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":855,"interventions":856},[87],[392,393,394,395],[41,139,323,319,397,398],{"trials":858,"activeCount":96},[],{"trials":860,"activeCount":96},[],{"intervention":208,"totalTrials":180,"cells":862},{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":873,"PHASE4":883,"NA":885},{"trials":864,"activeCount":96},[],{"trials":866,"activeCount":96},[],{"trials":868,"activeCount":96},[869],{"nctId":163,"briefTitle":164,"status":113,"phases":870,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":871,"interventions":872},[85,86],[170,119,171,172,173,174,175],[60,161,177,178,179],{"trials":874,"activeCount":219,"soonestReadout":54},[875,879],{"nctId":199,"briefTitle":200,"status":130,"phases":876,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":877,"interventions":878},[87],[173,119],[55,208,209,210,211,139],{"nctId":52,"briefTitle":53,"status":154,"phases":880,"primaryCompletion":54,"completion":214,"start":215,"enrollment":216,"conditions":881,"interventions":882},[87],[173],[55,139,208,141,211],{"trials":884,"activeCount":96},[],{"trials":886,"activeCount":96},[],{"intervention":334,"totalTrials":219,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":899,"PHASE4":905,"NA":907},{"trials":890,"activeCount":96},[],{"trials":892,"activeCount":96},[],{"trials":894,"activeCount":233,"soonestReadout":74},[895],{"nctId":72,"briefTitle":73,"status":154,"phases":896,"primaryCompletion":74,"completion":74,"start":328,"enrollment":329,"conditions":897,"interventions":898},[85,86],[24],[75,161,332,333,195,319,320,334,322,335,141],{"trials":900,"activeCount":233,"soonestReadout":388},[901],{"nctId":385,"briefTitle":386,"status":130,"phases":902,"primaryCompletion":388,"completion":388,"start":389,"enrollment":390,"conditions":903,"interventions":904},[87],[392,393,394,395],[41,139,323,319,397,398],{"trials":906,"activeCount":96},[],{"trials":908,"activeCount":96},[],{"intervention":65,"totalTrials":92,"cells":910},{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":945,"PHASE3":966,"PHASE4":1015,"NA":1017},{"trials":912,"activeCount":96},[],{"trials":914,"activeCount":96},[915,926,936],{"nctId":916,"briefTitle":917,"status":102,"phases":918,"primaryCompletion":919,"completion":920,"start":921,"enrollment":9,"conditions":922,"interventions":924},"NCT04476849","A Study to Investigate the Effect of Renal Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Renal Function",[85],"2022-03-06","2022-03-11","2020-08-10",[15,923],"Renal Impairment",[925],"fezolinetant",{"nctId":927,"briefTitle":928,"status":102,"phases":929,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":933,"interventions":935},"NCT04482270","A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function",[85],"2021-03-22","2020-09-02",26,[934,15],"Hepatic Impairment",[925],{"nctId":937,"briefTitle":938,"status":102,"phases":939,"primaryCompletion":940,"completion":941,"start":942,"enrollment":245,"conditions":943,"interventions":944},"NCT04641260","A Study to Assess the Effect of Food With Fezolinetant in Healthy Female Participants",[85],"2021-02-12","2021-02-21","2020-11-20",[18],[65],{"trials":946,"activeCount":96},[947,957],{"nctId":948,"briefTitle":949,"status":102,"phases":950,"primaryCompletion":951,"completion":952,"start":953,"enrollment":954,"conditions":955,"interventions":956},"NCT06812754","A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause",[86],"2026-02-11","2026-03-05","2025-03-10",150,[32],[65],{"nctId":958,"briefTitle":959,"status":102,"phases":960,"primaryCompletion":961,"completion":961,"start":962,"enrollment":763,"conditions":963,"interventions":965},"NCT03192176","A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)",[86],"2018-09-19","2017-07-19",[964,32],"Menopause",[65],{"trials":967,"activeCount":233,"soonestReadout":74},[968,978,986,996,1005],{"nctId":969,"briefTitle":970,"status":102,"phases":971,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":977},"NCT04003142","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2",[87],"2020-07-30","2021-04-23","2019-07-10",501,[32],[65],{"nctId":979,"briefTitle":980,"status":102,"phases":981,"primaryCompletion":982,"completion":982,"start":974,"enrollment":983,"conditions":984,"interventions":985},"NCT04003389","A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause",[87],"2022-01-04",1831,[32],[925],{"nctId":987,"briefTitle":988,"status":102,"phases":989,"primaryCompletion":990,"completion":991,"start":992,"enrollment":993,"conditions":994,"interventions":995},"NCT04003155","A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause",[87],"2020-10-29","2021-08-11","2019-07-11",527,[32],[925],{"nctId":77,"briefTitle":78,"status":154,"phases":997,"primaryCompletion":74,"completion":998,"start":999,"enrollment":1000,"conditions":1001,"interventions":1002},[87],"2028-04-30","2024-07-31",984,[32],[65,1003,1004],"Tamoxifen","Aromatase inhibitor",{"nctId":1006,"briefTitle":1007,"status":102,"phases":1008,"primaryCompletion":278,"completion":1009,"start":1010,"enrollment":1011,"conditions":1012,"interventions":1014},"NCT05033886","A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause",[87],"2023-04-20","2021-11-08",453,[1013],"Vasomotor Symptoms",[925],{"trials":1016,"activeCount":96},[],{"trials":1018,"activeCount":233,"soonestReadout":64},[1019],{"nctId":62,"briefTitle":63,"status":154,"phases":1020,"primaryCompletion":64,"completion":1021,"start":1022,"enrollment":1023,"conditions":1024,"interventions":1025},[],"2026-05-31","2023-11-15",999,[32],[65,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036],"Paroxetine","Citalopram","Escitalopram","Desvenlafaxine","Venlafaxine","Gabapentin","Clonidine","Pregabalin","Oxybutynin","Any other SSRI\u002FSNRI not already specified","Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above",{"intervention":1038,"totalTrials":381,"cells":1039},"Mirabegron",{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1046,"PHASE4":1065,"NA":1101},{"trials":1041,"activeCount":96},[],{"trials":1043,"activeCount":96},[],{"trials":1045,"activeCount":96},[],{"trials":1047,"activeCount":233,"soonestReadout":69},[1048,1059],{"nctId":1049,"briefTitle":1050,"status":113,"phases":1051,"primaryCompletion":1052,"completion":1053,"start":1054,"enrollment":932,"conditions":1055,"interventions":1058},"NCT04641975","A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)",[87],"2023-07-07","2023-07-24","2021-03-15",[1056,1057],"Overactive Bladder (OAB)","Pharmacokinetics of Mirabegron",[1038],{"nctId":67,"briefTitle":68,"status":154,"phases":1060,"primaryCompletion":69,"completion":156,"start":1061,"enrollment":12,"conditions":1062,"interventions":1064},[87],"2024-02-28",[1063],"Neurogenic Detrusor Overactivity",[70],{"trials":1066,"activeCount":96},[1067,1080,1090],{"nctId":1068,"briefTitle":1069,"status":102,"phases":1070,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":1075,"interventions":1078},"NCT02757768","A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)",[88],"2018-08-14","2018-09-11","2016-06-13",715,[1076,1077],"Benign Prostatic Hyperplasia","Overactive Bladder",[1038,1079],"Tamsulosin Hydrochloride",{"nctId":1081,"briefTitle":1082,"status":102,"phases":1083,"primaryCompletion":1084,"completion":1085,"start":1086,"enrollment":1087,"conditions":1088,"interventions":1089},"NCT02216214","Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)",[88],"2017-11-29","2018-01-02","2014-10-07",888,[1056],[1038],{"nctId":1091,"briefTitle":1092,"status":102,"phases":1093,"primaryCompletion":1094,"completion":1095,"start":1096,"enrollment":1097,"conditions":1098,"interventions":1099},"NCT02138747","A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)",[88],"2015-10-29","2015-11-11","2014-07-24",376,[1056],[1038,1100],"Tolterodine ER",{"trials":1102,"activeCount":96},[],{"intervention":1104,"totalTrials":219,"cells":1105},"Roxadustat",{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1119,"PHASE3":1121,"PHASE4":1133,"NA":1135},{"trials":1107,"activeCount":96},[],{"trials":1109,"activeCount":96},[1110],{"nctId":1111,"briefTitle":1112,"status":102,"phases":1113,"primaryCompletion":1114,"completion":1114,"start":1115,"enrollment":342,"conditions":1116,"interventions":1118},"NCT03960489","A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation in Healthy Adult Subjects",[85],"2019-10-14","2019-07-31",[1117],"Healthy Adult Subjects",[1104],{"trials":1120,"activeCount":96},[],{"trials":1122,"activeCount":233,"soonestReadout":1127},[1123],{"nctId":1124,"briefTitle":1125,"status":130,"phases":1126,"primaryCompletion":1127,"completion":1127,"start":1128,"enrollment":229,"conditions":1129,"interventions":1132},"NCT05970172","A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease",[87],"2027-10-30","2024-01-16",[1130,1131],"Chronic Kidney Disease","Renal Anemia",[1104],{"trials":1134,"activeCount":96},[],{"trials":1136,"activeCount":96},[],{"intervention":472,"totalTrials":233,"cells":1138},{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1145,"PHASE4":1151,"NA":1153},{"trials":1140,"activeCount":96},[],{"trials":1142,"activeCount":96},[],{"trials":1144,"activeCount":96},[],{"trials":1146,"activeCount":233,"soonestReadout":463},[1147],{"nctId":460,"briefTitle":461,"status":130,"phases":1148,"primaryCompletion":463,"completion":463,"start":464,"enrollment":465,"conditions":1149,"interventions":1150},[87],[467,468,469],[471,319,320,322,363,472],{"trials":1152,"activeCount":96},[],{"trials":1154,"activeCount":96},[],{"intervention":1003,"totalTrials":233,"cells":1156},{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1163,"PHASE4":1169,"NA":1171},{"trials":1158,"activeCount":96},[],{"trials":1160,"activeCount":96},[],{"trials":1162,"activeCount":96},[],{"trials":1164,"activeCount":233,"soonestReadout":74},[1165],{"nctId":77,"briefTitle":78,"status":154,"phases":1166,"primaryCompletion":74,"completion":998,"start":999,"enrollment":1000,"conditions":1167,"interventions":1168},[87],[32],[65,1003,1004],{"trials":1170,"activeCount":96},[],{"trials":1172,"activeCount":96},[],{"intervention":1004,"totalTrials":233,"cells":1174},{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1181,"PHASE4":1187,"NA":1189},{"trials":1176,"activeCount":96},[],{"trials":1178,"activeCount":96},[],{"trials":1180,"activeCount":96},[],{"trials":1182,"activeCount":233,"soonestReadout":74},[1183],{"nctId":77,"briefTitle":78,"status":154,"phases":1184,"primaryCompletion":74,"completion":998,"start":999,"enrollment":1000,"conditions":1185,"interventions":1186},[87],[32],[65,1003,1004],{"trials":1188,"activeCount":96},[],{"trials":1190,"activeCount":96},[],{"intervention":210,"totalTrials":233,"cells":1192},{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1199,"PHASE4":1205,"NA":1207},{"trials":1194,"activeCount":96},[],{"trials":1196,"activeCount":96},[],{"trials":1198,"activeCount":96},[],{"trials":1200,"activeCount":233,"soonestReadout":202},[1201],{"nctId":199,"briefTitle":200,"status":130,"phases":1202,"primaryCompletion":202,"completion":203,"start":204,"enrollment":205,"conditions":1203,"interventions":1204},[87],[173,119],[55,208,209,210,211,139],{"trials":1206,"activeCount":96},[],{"trials":1208,"activeCount":96},[],{"intervention":1210,"totalTrials":495,"cells":1211},"Prednisone",{"EARLY_PHASE1":1212,"PHASE1":1214,"PHASE2":1252,"PHASE3":1313,"PHASE4":1315,"NA":1317},{"trials":1213,"activeCount":96},[],{"trials":1215,"activeCount":219,"soonestReadout":1245},[1216,1226,1241],{"nctId":1217,"briefTitle":1218,"status":102,"phases":1219,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":734,"conditions":1222,"interventions":1224},"NCT01711827","A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects",[85],"2012-03","2012-02",[18,21,1223],"Pharmacokinetics of Prednisolone",[1225,1210],"Isavuconazole",{"nctId":1227,"briefTitle":1228,"status":130,"phases":1229,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":1233,"interventions":1236},"NCT04729114","A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer",[85],"2029-05-31","2021-06-14",174,[27,1234,1235],"Metastatic Castration Resistant Prostate Cancer","Metastatic Castration-sensitive Prostate Cancer",[1237,1238,1239,1240],"PRL-02","prednisone","dexamethasone","enzalutamide",{"nctId":1242,"briefTitle":1243,"status":130,"phases":1244,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":504,"conditions":1247,"interventions":1250},"NCT07339267","A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer",[85],"2028-12-31","2026-01-20",[27,1248,1249],"Metastatic Castration-Resistant Prostate Cancer","Metastatic Hormone Sensitive Prostate Cancer",[1251,1210],"ASP5541",{"trials":1253,"activeCount":219,"soonestReadout":1307},[1254,1264,1281,1292,1303],{"nctId":1255,"briefTitle":1256,"status":102,"phases":1257,"primaryCompletion":1258,"completion":1258,"start":1259,"enrollment":1260,"conditions":1261,"interventions":1262},"NCT01650194","A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients",[86],"2018-01-04","2012-07-09",60,[1248],[1240,1263,1238],"abiraterone acetate",{"nctId":1265,"briefTitle":1266,"status":102,"phases":1267,"primaryCompletion":1268,"completion":1269,"start":1270,"enrollment":1271,"conditions":1272,"interventions":1275},"NCT02921789","Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients",[86],"2020-12-11","2021-05-18","2017-05-22",67,[1273,1274],"Kidney Transplantation","Primary Focal Segmental Glomerulosclerosis (FSGS)",[1276,1277,1278,1279,1280,1210],"Bleselumab","Basiliximab","Mycophenolate Mofetil","Tacrolimus","Methylprednisone",{"nctId":1282,"briefTitle":1283,"status":130,"phases":1284,"primaryCompletion":1285,"completion":1285,"start":1286,"enrollment":1287,"conditions":1288,"interventions":1289},"NCT07005154","A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer",[86],"2032-05-31","2025-06-19",218,[27,1248,1249],[1251,1210,1290,1263,1291],"Prednisolone","Adrenocorticotropic hormone",{"nctId":1293,"briefTitle":1294,"status":102,"phases":1295,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":1299,"conditions":1300,"interventions":1301},"NCT01780844","A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients",[86],"2014-06-30","2017-01-27","2013-03-05",149,[1273],[1302,1279,1278,1277,1280,1210],"ASKP1240",{"nctId":1304,"briefTitle":1305,"status":130,"phases":1306,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":1310,"interventions":1311},"NCT02960022","A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study",[86],"2029-07-31","2016-12-22",900,[27],[1240,1263,1238,1312],"Leuprolide acetate",{"trials":1314,"activeCount":96},[],{"trials":1316,"activeCount":96},[],{"trials":1318,"activeCount":96},[],{"intervention":1320,"totalTrials":92,"cells":1321},"Enzalutamide",{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1341,"PHASE3":1394,"PHASE4":1405,"NA":1426},{"trials":1323,"activeCount":96},[],{"trials":1325,"activeCount":233,"soonestReadout":1230},[1326,1330],{"nctId":1227,"briefTitle":1228,"status":130,"phases":1327,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":1328,"interventions":1329},[85],[27,1234,1235],[1237,1238,1239,1240],{"nctId":1331,"briefTitle":1332,"status":102,"phases":1333,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":342,"conditions":1336,"interventions":1337},"NCT04094519","A Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates of P-glycoprotein (Digoxin) and Breast Cancer Resistant Protein (Rosuvastatin) in Male Subjects With Prostate Cancer",[85],"2020-12-27","2020-01-27",[27],[1240,1338,1339,1340],"enzalutamide Placebo","digoxin","rosuvastatin",{"trials":1342,"activeCount":233,"soonestReadout":1307},[1343,1352,1361,1375,1379,1390],{"nctId":1344,"briefTitle":1345,"status":102,"phases":1346,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":1349,"conditions":1350,"interventions":1351},"NCT02799745","A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance",[86],"2020-08-28","2016-06-09",227,[27],[1320],{"nctId":1353,"briefTitle":1354,"status":1355,"phases":1356,"primaryCompletion":1357,"completion":1357,"start":1358,"enrollment":96,"conditions":1359,"interventions":1360},"NCT01663415","A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer","WITHDRAWN",[86],"2014-10","2012-08",[1248],[1320],{"nctId":1362,"briefTitle":1363,"status":102,"phases":1364,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":1369,"interventions":1373},"NCT02091960","A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer",[86],"2017-02-28","2024-01-30","2014-09-05",103,[1370,1371,1372],"HER2 Amplified","Advanced Breast Cancer","Human Epidermal Growth Factor Receptor 2 (HER2)",[1320,1374],"Trastuzumab",{"nctId":1255,"briefTitle":1256,"status":102,"phases":1376,"primaryCompletion":1258,"completion":1258,"start":1259,"enrollment":1260,"conditions":1377,"interventions":1378},[86],[1248],[1240,1263,1238],{"nctId":1380,"briefTitle":1381,"status":102,"phases":1382,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1386,"conditions":1387,"interventions":1389},"NCT02528643","A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma",[86],"2017-10-02","2021-02-09","2015-11-09",165,[1388],"Advanced Hepatocellular Carcinoma",[1320],{"nctId":1304,"briefTitle":1305,"status":130,"phases":1391,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":1392,"interventions":1393},[86],[27],[1240,1263,1238,1312],{"trials":1395,"activeCount":96},[1396],{"nctId":1397,"briefTitle":1398,"status":102,"phases":1399,"primaryCompletion":1400,"completion":999,"start":1401,"enrollment":1402,"conditions":1403,"interventions":1404},"NCT02677896","A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)",[87],"2018-10-14","2016-03-09",1150,[1249],[1320],{"trials":1406,"activeCount":96},[1407,1415],{"nctId":1408,"briefTitle":1409,"status":113,"phases":1410,"primaryCompletion":1411,"completion":1411,"start":1412,"enrollment":489,"conditions":1413,"interventions":1414},"NCT02441517","A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and\u002For Cabazitaxel Treatment",[88],"2017-03-15","2015-10-28",[1234],[1320],{"nctId":1416,"briefTitle":1417,"status":102,"phases":1418,"primaryCompletion":1419,"completion":1420,"start":1421,"enrollment":1422,"conditions":1423,"interventions":1425},"NCT01977651","A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide",[88],"2016-02-01","2019-01-11","2013-09-25",424,[1424],"Metastatic Castration-resistant Prostate Cancer (mCRPC)",[1320],{"trials":1427,"activeCount":96},[],{"intervention":1263,"totalTrials":180,"cells":1429},{"EARLY_PHASE1":1430,"PHASE1":1432,"PHASE2":1434,"PHASE3":1448,"PHASE4":1450,"NA":1452},{"trials":1431,"activeCount":96},[],{"trials":1433,"activeCount":96},[],{"trials":1435,"activeCount":219,"soonestReadout":1307},[1436,1440,1444],{"nctId":1255,"briefTitle":1256,"status":102,"phases":1437,"primaryCompletion":1258,"completion":1258,"start":1259,"enrollment":1260,"conditions":1438,"interventions":1439},[86],[1248],[1240,1263,1238],{"nctId":1282,"briefTitle":1283,"status":130,"phases":1441,"primaryCompletion":1285,"completion":1285,"start":1286,"enrollment":1287,"conditions":1442,"interventions":1443},[86],[27,1248,1249],[1251,1210,1290,1263,1291],{"nctId":1304,"briefTitle":1305,"status":130,"phases":1445,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":1446,"interventions":1447},[86],[27],[1240,1263,1238,1312],{"trials":1449,"activeCount":96},[],{"trials":1451,"activeCount":96},[],{"trials":1453,"activeCount":96},[],{"intervention":428,"totalTrials":219,"cells":1455},{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1464,"PHASE3":1470,"PHASE4":1472,"NA":1474},{"trials":1457,"activeCount":96},[],{"trials":1459,"activeCount":233,"soonestReadout":421},[1460],{"nctId":418,"briefTitle":419,"status":130,"phases":1461,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":1462,"interventions":1463},[85],[425],[318,319,320,427,322,211,428,323],{"trials":1465,"activeCount":233,"soonestReadout":522},[1466],{"nctId":519,"briefTitle":520,"status":154,"phases":1467,"primaryCompletion":522,"completion":522,"start":523,"enrollment":524,"conditions":1468,"interventions":1469},[86],[467,468,469],[41,527,179],{"trials":1471,"activeCount":96},[],{"trials":1473,"activeCount":96},[],{"trials":1475,"activeCount":96},[],{"intervention":1251,"totalTrials":219,"cells":1477},{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1486,"PHASE3":1492,"PHASE4":1494,"NA":1496},{"trials":1479,"activeCount":96},[],{"trials":1481,"activeCount":233,"soonestReadout":1245},[1482],{"nctId":1242,"briefTitle":1243,"status":130,"phases":1483,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":504,"conditions":1484,"interventions":1485},[85],[27,1248,1249],[1251,1210],{"trials":1487,"activeCount":233,"soonestReadout":1285},[1488],{"nctId":1282,"briefTitle":1283,"status":130,"phases":1489,"primaryCompletion":1285,"completion":1285,"start":1286,"enrollment":1287,"conditions":1490,"interventions":1491},[86],[27,1248,1249],[1251,1210,1290,1263,1291],{"trials":1493,"activeCount":96},[],{"trials":1495,"activeCount":96},[],{"trials":1497,"activeCount":96},[],{"intervention":1499,"totalTrials":1500,"cells":1501},"gilteritinib",17,{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1561,"PHASE3":1641,"PHASE4":1676,"NA":1678},{"trials":1503,"activeCount":96},[],{"trials":1505,"activeCount":233,"soonestReadout":1556},[1506,1519,1530,1541,1552],{"nctId":1507,"briefTitle":1508,"status":102,"phases":1509,"primaryCompletion":1510,"completion":1510,"start":1511,"enrollment":1512,"conditions":1513,"interventions":1514},"NCT02236013","A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia",[85],"2021-07-26","2015-01-07",80,[34],[1515,1516,1517,1518],"Gilteritinib","Idarubicin","Cytarabine","Daunorubicin",{"nctId":1520,"briefTitle":1521,"status":102,"phases":1522,"primaryCompletion":1523,"completion":1523,"start":1524,"enrollment":1500,"conditions":1525,"interventions":1529},"NCT04699877","A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function",[85],"2022-07-18","2021-01-28",[1526,1515,1527,1528],"Renal Impaired","Normal Renal Function","Pharmacokinetics of ASP2215",[1515],{"nctId":1531,"briefTitle":1532,"status":102,"phases":1533,"primaryCompletion":1534,"completion":1535,"start":1536,"enrollment":1537,"conditions":1538,"interventions":1539},"NCT03964038","A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects",[85],"2019-07-02","2019-07-16","2019-05-21",48,[814],[1499,1540],"gilteritinib mini",{"nctId":1542,"briefTitle":1543,"status":102,"phases":1544,"primaryCompletion":1545,"completion":1546,"start":1547,"enrollment":35,"conditions":1548,"interventions":1550},"NCT02456883","Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors",[85],"2017-05-20","2017-06-19","2016-03-04",[24,1549],"Pharmacokinetics of 14C-labeled Gilteritinib",[1499,1551],"14C-labeled gilteritinib",{"nctId":1553,"briefTitle":1554,"status":130,"phases":1555,"primaryCompletion":1556,"completion":1556,"start":115,"enrollment":1557,"conditions":1558,"interventions":1560},"NCT07140016","A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)",[85],"2029-12-31",40,[765,1559],"Anaplastic Lymphoma Kinase (ALK) Positive",[1499],{"trials":1562,"activeCount":233,"soonestReadout":1591},[1563,1574,1587,1599,1612,1622,1630],{"nctId":1564,"briefTitle":1565,"status":102,"phases":1566,"primaryCompletion":1567,"completion":1568,"start":1569,"enrollment":92,"conditions":1570,"interventions":1572},"NCT03730012","A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)",[85,86],"2021-05-14","2021-06-15","2019-06-19",[29,1571],"Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation",[1499,1573],"atezolizumab",{"nctId":1575,"briefTitle":1576,"status":113,"phases":1577,"primaryCompletion":1578,"completion":1579,"start":1580,"enrollment":30,"conditions":1581,"interventions":1583},"NCT04240002","A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)\u002FInternal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)",[85,86],"2025-03-11","2025-03-17","2020-09-04",[29,1582],"Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation \u002F Internal Tandem Duplication (ITD)",[1499,1584,1585,1586],"fludarabine","cytarabine","granulocyte colony-stimulating factor",{"nctId":1588,"briefTitle":1589,"status":154,"phases":1590,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":1594,"interventions":1596},"NCT05520567","A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia",[85,86],"2028-07-31","2023-01-31",70,[29,1595],"FLT3-mutated Acute Myeloid Leukemia",[1515,1597,1598],"Venetoclax","Azacitidine",{"nctId":1600,"briefTitle":1601,"status":102,"phases":1602,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":1607,"interventions":1608},"NCT02014558","Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia",[85,86],"2017-08-04","2018-03-07","2013-10-09",265,[34],[1515,1609,1610,1611],"Voriconazole","Midazolam","Cephalexin",{"nctId":1613,"briefTitle":1614,"status":113,"phases":1615,"primaryCompletion":1616,"completion":1616,"start":1617,"enrollment":25,"conditions":1618,"interventions":1620},"NCT02495233","A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)",[85,86],"2016-09-28","2015-09-08",[1619],"Non-Small-Cell Lung Cancer",[1515,1621],"Erlotinib",{"nctId":1623,"briefTitle":1624,"status":102,"phases":1625,"primaryCompletion":1626,"completion":1626,"start":1627,"enrollment":30,"conditions":1628,"interventions":1629},"NCT02561455","Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial",[85,86],"2020-07-28","2016-05-03",[24,34],[1515],{"nctId":1631,"briefTitle":1632,"status":102,"phases":1633,"primaryCompletion":1634,"completion":1635,"start":1636,"enrollment":1637,"conditions":1638,"interventions":1640},"NCT02927262","A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction\u002FConsolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3\u002FITD) Acute Myeloid Leukemia (AML) in First Complete Remission",[86],"2021-05-25","2024-02-19","2017-01-10",98,[29,1639],"Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) \u002F Internal Tandem Duplication (ITD) Mutation",[1515],{"trials":1642,"activeCount":96},[1643,1656,1665],{"nctId":1644,"briefTitle":1645,"status":102,"phases":1646,"primaryCompletion":1647,"completion":59,"start":1648,"enrollment":1649,"conditions":1650,"interventions":1652},"NCT02421939","A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation",[87],"2018-09-17","2015-10-20",371,[1651],"Leukemia, Acute Myeloid (AML)",[1499,1653,1598,1654,1655],"LoDAC","MEC","FLAG-IDA",{"nctId":1657,"briefTitle":1658,"status":102,"phases":1659,"primaryCompletion":1660,"completion":1661,"start":1662,"enrollment":763,"conditions":1663,"interventions":1664},"NCT02997202","A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3\u002FInternal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)",[87],"2023-01-07","2023-05-09","2017-08-16",[34],[1499],{"nctId":1666,"briefTitle":1667,"status":102,"phases":1668,"primaryCompletion":1669,"completion":1670,"start":1671,"enrollment":1672,"conditions":1673,"interventions":1674},"NCT02752035","A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy",[87],"2023-03-10","2024-12-18","2016-08-01",183,[29,1571],[1499,1675],"azacitidine",{"trials":1677,"activeCount":96},[],{"trials":1679,"activeCount":96},[1680,1688],{"nctId":1681,"briefTitle":1682,"status":1683,"phases":1684,"conditions":1685,"interventions":1687},"NCT03409081","Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)","NO_LONGER_AVAILABLE",[],[29,1686],"FMS-like Tyrosine Kinase-3 (FLT3) Mutations",[1499],{"nctId":1689,"briefTitle":1690,"status":239,"phases":1691,"conditions":1692,"interventions":1693},"NCT03070093","Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)",[],[29,1686],[1499],{"intervention":1598,"totalTrials":180,"cells":1695},{"EARLY_PHASE1":1696,"PHASE1":1698,"PHASE2":1700,"PHASE3":1706,"PHASE4":1716,"NA":1718},{"trials":1697,"activeCount":96},[],{"trials":1699,"activeCount":96},[],{"trials":1701,"activeCount":233,"soonestReadout":1591},[1702],{"nctId":1588,"briefTitle":1589,"status":154,"phases":1703,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":1704,"interventions":1705},[85,86],[29,1595],[1515,1597,1598],{"trials":1707,"activeCount":96},[1708,1712],{"nctId":1644,"briefTitle":1645,"status":102,"phases":1709,"primaryCompletion":1647,"completion":59,"start":1648,"enrollment":1649,"conditions":1710,"interventions":1711},[87],[1651],[1499,1653,1598,1654,1655],{"nctId":1666,"briefTitle":1667,"status":102,"phases":1713,"primaryCompletion":1669,"completion":1670,"start":1671,"enrollment":1672,"conditions":1714,"interventions":1715},[87],[29,1571],[1499,1675],{"trials":1717,"activeCount":96},[],{"trials":1719,"activeCount":96},[],{"intervention":284,"totalTrials":219,"cells":1721},{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1730,"PHASE3":1736,"PHASE4":1738,"NA":1740},{"trials":1723,"activeCount":96},[],{"trials":1725,"activeCount":96},[1726],{"nctId":275,"briefTitle":276,"status":102,"phases":1727,"primaryCompletion":278,"completion":278,"start":279,"enrollment":280,"conditions":1728,"interventions":1729},[85],[24],[283,284,161],{"trials":1731,"activeCount":233,"soonestReadout":82},[1732],{"nctId":348,"briefTitle":349,"status":154,"phases":1733,"primaryCompletion":82,"completion":351,"start":352,"enrollment":353,"conditions":1734,"interventions":1735},[86],[355,356,357,358,359],[41,361,362,363,139,364,284,195],{"trials":1737,"activeCount":96},[],{"trials":1739,"activeCount":96},[],{"trials":1741,"activeCount":96},[],{"intervention":75,"totalTrials":233,"cells":1743},{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1748,"PHASE3":1754,"PHASE4":1756,"NA":1758},{"trials":1745,"activeCount":96},[],{"trials":1747,"activeCount":96},[],{"trials":1749,"activeCount":233,"soonestReadout":74},[1750],{"nctId":72,"briefTitle":73,"status":154,"phases":1751,"primaryCompletion":74,"completion":74,"start":328,"enrollment":329,"conditions":1752,"interventions":1753},[85,86],[24],[75,161,332,333,195,319,320,334,322,335,141],{"trials":1755,"activeCount":96},[],{"trials":1757,"activeCount":96},[],{"trials":1759,"activeCount":96},[],{"intervention":332,"totalTrials":233,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1766,"PHASE3":1772,"PHASE4":1774,"NA":1776},{"trials":1763,"activeCount":96},[],{"trials":1765,"activeCount":96},[],{"trials":1767,"activeCount":233,"soonestReadout":74},[1768],{"nctId":72,"briefTitle":73,"status":154,"phases":1769,"primaryCompletion":74,"completion":74,"start":328,"enrollment":329,"conditions":1770,"interventions":1771},[85,86],[24],[75,161,332,333,195,319,320,334,322,335,141],{"trials":1773,"activeCount":96},[],{"trials":1775,"activeCount":96},[],{"trials":1777,"activeCount":96},[],{"intervention":333,"totalTrials":233,"cells":1779},{"EARLY_PHASE1":1780,"PHASE1":1782,"PHASE2":1784,"PHASE3":1790,"PHASE4":1792,"NA":1794},{"trials":1781,"activeCount":96},[],{"trials":1783,"activeCount":96},[],{"trials":1785,"activeCount":233,"soonestReadout":74},[1786],{"nctId":72,"briefTitle":73,"status":154,"phases":1787,"primaryCompletion":74,"completion":74,"start":328,"enrollment":329,"conditions":1788,"interventions":1789},[85,86],[24],[75,161,332,333,195,319,320,334,322,335,141],{"trials":1791,"activeCount":96},[],{"trials":1793,"activeCount":96},[],{"trials":1795,"activeCount":96},[],{"intervention":335,"totalTrials":233,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1799,"activeCount":96},[],{"trials":1801,"activeCount":96},[],{"trials":1803,"activeCount":233,"soonestReadout":74},[1804],{"nctId":72,"briefTitle":73,"status":154,"phases":1805,"primaryCompletion":74,"completion":74,"start":328,"enrollment":329,"conditions":1806,"interventions":1807},[85,86],[24],[75,161,332,333,195,319,320,334,322,335,141],{"trials":1809,"activeCount":96},[],{"trials":1811,"activeCount":96},[],{"trials":1813,"activeCount":96},[],{"intervention":1597,"totalTrials":233,"cells":1815},{"EARLY_PHASE1":1816,"PHASE1":1818,"PHASE2":1820,"PHASE3":1826,"PHASE4":1828,"NA":1830},{"trials":1817,"activeCount":96},[],{"trials":1819,"activeCount":96},[],{"trials":1821,"activeCount":233,"soonestReadout":1591},[1822],{"nctId":1588,"briefTitle":1589,"status":154,"phases":1823,"primaryCompletion":1591,"completion":1591,"start":1592,"enrollment":1593,"conditions":1824,"interventions":1825},[85,86],[29,1595],[1515,1597,1598],{"trials":1827,"activeCount":96},[],{"trials":1829,"activeCount":96},[],{"trials":1831,"activeCount":96},[],{"intervention":1833,"totalTrials":233,"cells":1834},"ASP546C",{"EARLY_PHASE1":1835,"PHASE1":1837,"PHASE2":1839,"PHASE3":1849,"PHASE4":1851,"NA":1853},{"trials":1836,"activeCount":96},[],{"trials":1838,"activeCount":96},[],{"trials":1840,"activeCount":233,"soonestReadout":1307},[1841],{"nctId":1842,"briefTitle":1843,"status":130,"phases":1844,"primaryCompletion":1307,"completion":1307,"start":1845,"enrollment":954,"conditions":1846,"interventions":1848},"NCT07488676","A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors",[85,86],"2026-03-20",[1847,316],"Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma",[1833],{"trials":1850,"activeCount":96},[],{"trials":1852,"activeCount":96},[],{"trials":1854,"activeCount":96},[],{"intervention":1290,"totalTrials":233,"cells":1856},{"EARLY_PHASE1":1857,"PHASE1":1859,"PHASE2":1861,"PHASE3":1867,"PHASE4":1869,"NA":1871},{"trials":1858,"activeCount":96},[],{"trials":1860,"activeCount":96},[],{"trials":1862,"activeCount":233,"soonestReadout":1285},[1863],{"nctId":1282,"briefTitle":1283,"status":130,"phases":1864,"primaryCompletion":1285,"completion":1285,"start":1286,"enrollment":1287,"conditions":1865,"interventions":1866},[86],[27,1248,1249],[1251,1210,1290,1263,1291],{"trials":1868,"activeCount":96},[],{"trials":1870,"activeCount":96},[],{"trials":1872,"activeCount":96},[],{"intervention":1291,"totalTrials":233,"cells":1874},{"EARLY_PHASE1":1875,"PHASE1":1877,"PHASE2":1879,"PHASE3":1885,"PHASE4":1887,"NA":1889},{"trials":1876,"activeCount":96},[],{"trials":1878,"activeCount":96},[],{"trials":1880,"activeCount":233,"soonestReadout":1285},[1881],{"nctId":1282,"briefTitle":1283,"status":130,"phases":1882,"primaryCompletion":1285,"completion":1285,"start":1286,"enrollment":1287,"conditions":1883,"interventions":1884},[86],[27,1248,1249],[1251,1210,1290,1263,1291],{"trials":1886,"activeCount":96},[],{"trials":1888,"activeCount":96},[],{"trials":1890,"activeCount":96},[],{"intervention":138,"totalTrials":233,"cells":1892},{"EARLY_PHASE1":1893,"PHASE1":1895,"PHASE2":1897,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1894,"activeCount":96},[],{"trials":1896,"activeCount":96},[],{"trials":1898,"activeCount":233,"soonestReadout":132},[1899],{"nctId":128,"briefTitle":129,"status":130,"phases":1900,"primaryCompletion":132,"completion":132,"start":133,"enrollment":134,"conditions":1901,"interventions":1902},[85,86],[136],[138,139,140,141],{"trials":1904,"activeCount":96},[],{"trials":1906,"activeCount":96},[],{"trials":1908,"activeCount":96},[],{"intervention":1312,"totalTrials":233,"cells":1910},{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1921,"PHASE4":1923,"NA":1925},{"trials":1912,"activeCount":96},[],{"trials":1914,"activeCount":96},[],{"trials":1916,"activeCount":233,"soonestReadout":1307},[1917],{"nctId":1304,"briefTitle":1305,"status":130,"phases":1918,"primaryCompletion":1307,"completion":1307,"start":1308,"enrollment":1309,"conditions":1919,"interventions":1920},[86],[27],[1240,1263,1238,1312],{"trials":1922,"activeCount":96},[],{"trials":1924,"activeCount":96},[],{"trials":1926,"activeCount":96},[],{"intervention":318,"totalTrials":219,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1941,"PHASE3":1943,"PHASE4":1945,"NA":1947},{"trials":1930,"activeCount":96},[],{"trials":1932,"activeCount":219,"soonestReadout":421},[1933,1937],{"nctId":418,"briefTitle":419,"status":130,"phases":1934,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":1935,"interventions":1936},[85],[425],[318,319,320,427,322,211,428,323],{"nctId":307,"briefTitle":308,"status":130,"phases":1938,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":1939,"interventions":1940},[85],[314,315,316],[318,139,319,320,209,321,197,322,323],{"trials":1942,"activeCount":96},[],{"trials":1944,"activeCount":96},[],{"trials":1946,"activeCount":96},[],{"trials":1948,"activeCount":96},[],{"intervention":197,"totalTrials":489,"cells":1950},{"EARLY_PHASE1":1951,"PHASE1":1953,"PHASE2":1963,"PHASE3":1980,"PHASE4":1986,"NA":1988},{"trials":1952,"activeCount":96},[],{"trials":1954,"activeCount":233,"soonestReadout":310},[1955,1959],{"nctId":729,"briefTitle":730,"status":113,"phases":1956,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":1957,"interventions":1958},[85],[736,737],[739,195,197],{"nctId":307,"briefTitle":308,"status":130,"phases":1960,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":1961,"interventions":1962},[85],[314,315,316],[318,139,319,320,209,321,197,322,323],{"trials":1964,"activeCount":96},[1965],{"nctId":1966,"briefTitle":1967,"status":102,"phases":1968,"primaryCompletion":1969,"completion":1970,"start":1971,"enrollment":1972,"conditions":1973,"interventions":1974},"NCT02057380","A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial",[86],"2016-10-14","2016-12-21","2014-04-16",13,[24],[1975,1976,1977,1978,1979],"linsitinib","erlotinib","paclitaxel","Bortezomib","Dexamethasone",{"trials":1981,"activeCount":96},[1982],{"nctId":184,"briefTitle":185,"status":102,"phases":1983,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":1984,"interventions":1985},[87],[192,173,193],[140,195,196,197],{"trials":1987,"activeCount":96},[],{"trials":1989,"activeCount":96},[],{"intervention":1979,"totalTrials":219,"cells":1991},{"EARLY_PHASE1":1992,"PHASE1":1994,"PHASE2":2000,"PHASE3":2006,"PHASE4":2008,"NA":2010},{"trials":1993,"activeCount":96},[],{"trials":1995,"activeCount":233,"soonestReadout":1230},[1996],{"nctId":1227,"briefTitle":1228,"status":130,"phases":1997,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":1998,"interventions":1999},[85],[27,1234,1235],[1237,1238,1239,1240],{"trials":2001,"activeCount":96},[2002],{"nctId":1966,"briefTitle":1967,"status":102,"phases":2003,"primaryCompletion":1969,"completion":1970,"start":1971,"enrollment":1972,"conditions":2004,"interventions":2005},[86],[24],[1975,1976,1977,1978,1979],{"trials":2007,"activeCount":96},[],{"trials":2009,"activeCount":96},[],{"trials":2011,"activeCount":96},[],{"intervention":427,"totalTrials":233,"cells":2013},{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2022,"PHASE3":2024,"PHASE4":2026,"NA":2028},{"trials":2015,"activeCount":96},[],{"trials":2017,"activeCount":233,"soonestReadout":421},[2018],{"nctId":418,"briefTitle":419,"status":130,"phases":2019,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":2020,"interventions":2021},[85],[425],[318,319,320,427,322,211,428,323],{"trials":2023,"activeCount":96},[],{"trials":2025,"activeCount":96},[],{"trials":2027,"activeCount":96},[],{"trials":2029,"activeCount":96},[],{"intervention":50,"totalTrials":233,"cells":2031},{"EARLY_PHASE1":2032,"PHASE1":2034,"PHASE2":2043,"PHASE3":2045,"PHASE4":2047,"NA":2049},{"trials":2033,"activeCount":96},[],{"trials":2035,"activeCount":233,"soonestReadout":49},[2036],{"nctId":47,"briefTitle":48,"status":154,"phases":2037,"primaryCompletion":49,"completion":226,"start":2038,"enrollment":2039,"conditions":2040,"interventions":2042},[85],"2020-09-09",28,[2041],"Allergic to House Dust Mites",[50],{"trials":2044,"activeCount":96},[],{"trials":2046,"activeCount":96},[],{"trials":2048,"activeCount":96},[],{"trials":2050,"activeCount":96},[],{"intervention":507,"totalTrials":233,"cells":2052},{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2061,"PHASE3":2063,"PHASE4":2065,"NA":2067},{"trials":2054,"activeCount":96},[],{"trials":2056,"activeCount":233,"soonestReadout":82},[2057],{"nctId":80,"briefTitle":81,"status":154,"phases":2058,"primaryCompletion":82,"completion":82,"start":503,"enrollment":504,"conditions":2059,"interventions":2060},[85],[469],[41,507],{"trials":2062,"activeCount":96},[],{"trials":2064,"activeCount":96},[],{"trials":2066,"activeCount":96},[],{"trials":2068,"activeCount":96},[],{"intervention":2070,"totalTrials":233,"cells":2071},"ASP1002",{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2084,"PHASE3":2086,"PHASE4":2088,"NA":2090},{"trials":2073,"activeCount":96},[],{"trials":2075,"activeCount":233,"soonestReadout":998},[2076],{"nctId":2077,"briefTitle":2078,"status":130,"phases":2079,"primaryCompletion":998,"completion":310,"start":2080,"enrollment":2081,"conditions":2082,"interventions":2083},"NCT05719558","A Study of ASP1002 in Adults for Treatment of Solid Tumors",[85],"2023-03-13",210,[24],[2070],{"trials":2085,"activeCount":96},[],{"trials":2087,"activeCount":96},[],{"trials":2089,"activeCount":96},[],{"trials":2091,"activeCount":96},[],{"intervention":1237,"totalTrials":233,"cells":2093},{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2102,"PHASE3":2104,"PHASE4":2106,"NA":2108},{"trials":2095,"activeCount":96},[],{"trials":2097,"activeCount":233,"soonestReadout":1230},[2098],{"nctId":1227,"briefTitle":1228,"status":130,"phases":2099,"primaryCompletion":1230,"completion":1230,"start":1231,"enrollment":1232,"conditions":2100,"interventions":2101},[85],[27,1234,1235],[1237,1238,1239,1240],{"trials":2103,"activeCount":96},[],{"trials":2105,"activeCount":96},[],{"trials":2107,"activeCount":96},[],{"trials":2109,"activeCount":96},[],{"intervention":816,"totalTrials":233,"cells":2111},{"EARLY_PHASE1":2112,"PHASE1":2114,"PHASE2":2120,"PHASE3":2122,"PHASE4":2124,"NA":2126},{"trials":2113,"activeCount":96},[],{"trials":2115,"activeCount":233,"soonestReadout":82},[2116],{"nctId":808,"briefTitle":809,"status":130,"phases":2117,"primaryCompletion":82,"completion":82,"start":811,"enrollment":812,"conditions":2118,"interventions":2119},[85],[814],[471,816,817,818],{"trials":2121,"activeCount":96},[],{"trials":2123,"activeCount":96},[],{"trials":2125,"activeCount":96},[],{"trials":2127,"activeCount":96},[],{"intervention":817,"totalTrials":233,"cells":2129},{"EARLY_PHASE1":2130,"PHASE1":2132,"PHASE2":2138,"PHASE3":2140,"PHASE4":2142,"NA":2144},{"trials":2131,"activeCount":96},[],{"trials":2133,"activeCount":233,"soonestReadout":82},[2134],{"nctId":808,"briefTitle":809,"status":130,"phases":2135,"primaryCompletion":82,"completion":82,"start":811,"enrollment":812,"conditions":2136,"interventions":2137},[85],[814],[471,816,817,818],{"trials":2139,"activeCount":96},[],{"trials":2141,"activeCount":96},[],{"trials":2143,"activeCount":96},[],{"trials":2145,"activeCount":96},[],{"intervention":818,"totalTrials":233,"cells":2147},{"EARLY_PHASE1":2148,"PHASE1":2150,"PHASE2":2156,"PHASE3":2158,"PHASE4":2160,"NA":2162},{"trials":2149,"activeCount":96},[],{"trials":2151,"activeCount":233,"soonestReadout":82},[2152],{"nctId":808,"briefTitle":809,"status":130,"phases":2153,"primaryCompletion":82,"completion":82,"start":811,"enrollment":812,"conditions":2154,"interventions":2155},[85],[814],[471,816,817,818],{"trials":2157,"activeCount":96},[],{"trials":2159,"activeCount":96},[],{"trials":2161,"activeCount":96},[],{"trials":2163,"activeCount":96},[],{"intervention":321,"totalTrials":233,"cells":2165},{"EARLY_PHASE1":2166,"PHASE1":2168,"PHASE2":2174,"PHASE3":2176,"PHASE4":2178,"NA":2180},{"trials":2167,"activeCount":96},[],{"trials":2169,"activeCount":233,"soonestReadout":310},[2170],{"nctId":307,"briefTitle":308,"status":130,"phases":2171,"primaryCompletion":310,"completion":310,"start":311,"enrollment":312,"conditions":2172,"interventions":2173},[85],[314,315,316],[318,139,319,320,209,321,197,322,323],{"trials":2175,"activeCount":96},[],{"trials":2177,"activeCount":96},[],{"trials":2179,"activeCount":96},[],{"trials":2181,"activeCount":96},[],{"intervention":2183,"totalTrials":180,"cells":2184},"avacincaptad pegol",{"EARLY_PHASE1":2185,"PHASE1":2187,"PHASE2":2189,"PHASE3":2201,"PHASE4":2214,"NA":2216},{"trials":2186,"activeCount":96},[],{"trials":2188,"activeCount":96},[],{"trials":2190,"activeCount":96},[2191],{"nctId":2192,"briefTitle":2193,"status":102,"phases":2194,"primaryCompletion":2195,"completion":2195,"start":2196,"enrollment":2197,"conditions":2198,"interventions":2200},"NCT03364153","Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)",[86],"2025-03-31","2018-01-12",121,[2199],"Stargardt's Macular Dystrophy",[2183],{"trials":2202,"activeCount":96},[2203],{"nctId":2204,"briefTitle":2205,"status":102,"phases":2206,"primaryCompletion":2207,"completion":2207,"start":2208,"enrollment":2209,"conditions":2210,"interventions":2213},"NCT05536297","Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy",[87],"2025-04-10","2022-09-26",278,[2211,2212],"Geographic Atrophy","Age-Related Macular Degeneration",[2183],{"trials":2215,"activeCount":96},[],{"trials":2217,"activeCount":233,"soonestReadout":2222},[2218],{"nctId":2219,"briefTitle":2220,"status":130,"phases":2221,"primaryCompletion":2222,"completion":2222,"start":2223,"enrollment":2224,"conditions":2225,"interventions":2227},"NCT06779773","A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy",[],"2030-01-31","2025-01-22",1000,[2211,2226],"Macular Degeneration",[2228],"Avacincaptad pegol",{"intervention":2230,"totalTrials":219,"cells":2231},"pregabalin",{"EARLY_PHASE1":2232,"PHASE1":2234,"PHASE2":2236,"PHASE3":2251,"PHASE4":2253,"NA":2255},{"trials":2233,"activeCount":96},[],{"trials":2235,"activeCount":96},[],{"trials":2237,"activeCount":96},[2238],{"nctId":2239,"briefTitle":2240,"status":113,"phases":2241,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":2244,"conditions":2245,"interventions":2247},"NCT02372578","Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy",[86],"2016-05-20","2015-05-27",115,[2246],"Painful Diabetic Peripheral Neuropathy (PDPN)",[2248,2230,2249,2250],"ASP3662","ASP3662 placebo","pregabalin placebo",{"trials":2252,"activeCount":96},[],{"trials":2254,"activeCount":96},[],{"trials":2256,"activeCount":233,"soonestReadout":64},[2257],{"nctId":62,"briefTitle":63,"status":154,"phases":2258,"primaryCompletion":64,"completion":1021,"start":1022,"enrollment":1023,"conditions":2259,"interventions":2260},[],[32],[65,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036],{"intervention":1026,"totalTrials":233,"cells":2262},{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2267,"PHASE3":2269,"PHASE4":2271,"NA":2273},{"trials":2264,"activeCount":96},[],{"trials":2266,"activeCount":96},[],{"trials":2268,"activeCount":96},[],{"trials":2270,"activeCount":96},[],{"trials":2272,"activeCount":96},[],{"trials":2274,"activeCount":233,"soonestReadout":64},[2275],{"nctId":62,"briefTitle":63,"status":154,"phases":2276,"primaryCompletion":64,"completion":1021,"start":1022,"enrollment":1023,"conditions":2277,"interventions":2278},[],[32],[65,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036],{"intervention":1027,"totalTrials":233,"cells":2280},{"EARLY_PHASE1":2281,"PHASE1":2283,"PHASE2":2285,"PHASE3":2287,"PHASE4":2289,"NA":2291},{"trials":2282,"activeCount":96},[],{"trials":2284,"activeCount":96},[],{"trials":2286,"activeCount":96},[],{"trials":2288,"activeCount":96},[],{"trials":2290,"activeCount":96},[],{"trials":2292,"activeCount":233,"soonestReadout":64},[2293],{"nctId":62,"briefTitle":63,"status":154,"phases":2294,"primaryCompletion":64,"completion":1021,"start":1022,"enrollment":1023,"conditions":2295,"interventions":2296},[],[32],[65,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036],{"intervention":1028,"totalTrials":233,"cells":2298},{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2305,"PHASE4":2307,"NA":2309},{"trials":2300,"activeCount":96},[],{"trials":2302,"activeCount":96},[],{"trials":2304,"activeCount":96},[],{"trials":2306,"activeCount":96},[],{"trials":2308,"activeCount":96},[],{"trials":2310,"activeCount":233,"soonestReadout":64},[2311],{"nctId":62,"briefTitle":63,"status":154,"phases":2312,"primaryCompletion":64,"completion":1021,"start":1022,"enrollment":1023,"conditions":2313,"interventions":2314},[],[32],[65,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036],{"intervention":1029,"totalTrials":233,"cells":2316},{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2321,"PHASE3":2323,"PHASE4":2325,"NA":2327},{"trials":2318,"activeCount":96},[],{"trials":2320,"activeCount":96},[],{"trials":2322,"activeCount":96},[],{"trials":2324,"activeCount":96},[],{"trials":2326,"activeCount":96},[],{"trials":2328,"activeCount":233,"soonestReadout":64},[2329],{"nctId":62,"briefTitle":63,"status":154,"phases":2330,"primaryCompletion":64,"completion":1021,"start":1022,"enrollment":1023,"conditions":2331,"interventions":2332},[],[32],[65,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036],{"intervention":1030,"totalTrials":233,"cells":2334},{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2341,"PHASE4":2343,"NA":2345},{"trials":2336,"activeCount":96},[],{"trials":2338,"activeCount":96},[],{"trials":2340,"activeCount":96},[],{"trials":2342,"activeCount":96},[],{"trials":2344,"activeCount":96},[],{"trials":2346,"activeCount":233,"soonestReadout":64},[2347],{"nctId":62,"briefTitle":63,"status":154,"phases":2348,"primaryCompletion":64,"completion":1021,"start":1022,"enrollment":1023,"conditions":2349,"interventions":2350},[],[32],[65,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036],{"intervention":1031,"totalTrials":233,"cells":2352},{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2359,"PHASE4":2361,"NA":2363},{"trials":2354,"activeCount":96},[],{"trials":2356,"activeCount":96},[],{"trials":2358,"activeCount":96},[],{"trials":2360,"activeCount":96},[],{"trials":2362,"activeCount":96},[],{"trials":2364,"activeCount":233,"soonestReadout":64},[2365],{"nctId":62,"briefTitle":63,"status":154,"phases":2366,"primaryCompletion":64,"completion":1021,"start":1022,"enrollment":1023,"conditions":2367,"interventions":2368},[],[32],[65,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036],{"intervention":1032,"totalTrials":233,"cells":2370},{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2375,"PHASE3":2377,"PHASE4":2379,"NA":2381},{"trials":2372,"activeCount":96},[],{"trials":2374,"activeCount":96},[],{"trials":2376,"activeCount":96},[],{"trials":2378,"activeCount":96},[],{"trials":2380,"activeCount":96},[],{"trials":2382,"activeCount":233,"soonestReadout":64},[2383],{"nctId":62,"briefTitle":63,"status":154,"phases":2384,"primaryCompletion":64,"completion":1021,"start":1022,"enrollment":1023,"conditions":2385,"interventions":2386},[],[32],[65,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036],{"intervention":1034,"totalTrials":233,"cells":2388},{"EARLY_PHASE1":2389,"PHASE1":2391,"PHASE2":2393,"PHASE3":2395,"PHASE4":2397,"NA":2399},{"trials":2390,"activeCount":96},[],{"trials":2392,"activeCount":96},[],{"trials":2394,"activeCount":96},[],{"trials":2396,"activeCount":96},[],{"trials":2398,"activeCount":96},[],{"trials":2400,"activeCount":233,"soonestReadout":64},[2401],{"nctId":62,"briefTitle":63,"status":154,"phases":2402,"primaryCompletion":64,"completion":1021,"start":1022,"enrollment":1023,"conditions":2403,"interventions":2404},[],[32],[65,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036],{"intervention":1035,"totalTrials":233,"cells":2406},{"EARLY_PHASE1":2407,"PHASE1":2409,"PHASE2":2411,"PHASE3":2413,"PHASE4":2415,"NA":2417},{"trials":2408,"activeCount":96},[],{"trials":2410,"activeCount":96},[],{"trials":2412,"activeCount":96},[],{"trials":2414,"activeCount":96},[],{"trials":2416,"activeCount":96},[],{"trials":2418,"activeCount":233,"soonestReadout":64},[2419],{"nctId":62,"briefTitle":63,"status":154,"phases":2420,"primaryCompletion":64,"completion":1021,"start":1022,"enrollment":1023,"conditions":2421,"interventions":2422},[],[32],[65,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036],{"intervention":1036,"totalTrials":233,"cells":2424},{"EARLY_PHASE1":2425,"PHASE1":2427,"PHASE2":2429,"PHASE3":2431,"PHASE4":2433,"NA":2435},{"trials":2426,"activeCount":96},[],{"trials":2428,"activeCount":96},[],{"trials":2430,"activeCount":96},[],{"trials":2432,"activeCount":96},[],{"trials":2434,"activeCount":96},[],{"trials":2436,"activeCount":233,"soonestReadout":64},[2437],{"nctId":62,"briefTitle":63,"status":154,"phases":2438,"primaryCompletion":64,"completion":1021,"start":1022,"enrollment":1023,"conditions":2439,"interventions":2440},[],[32],[65,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036],{"intervention":1279,"totalTrials":180,"cells":2442},{"EARLY_PHASE1":2443,"PHASE1":2445,"PHASE2":2447,"PHASE3":2457,"PHASE4":2459,"NA":2471},{"trials":2444,"activeCount":96},[],{"trials":2446,"activeCount":96},[],{"trials":2448,"activeCount":96},[2449,2453],{"nctId":1265,"briefTitle":1266,"status":102,"phases":2450,"primaryCompletion":1268,"completion":1269,"start":1270,"enrollment":1271,"conditions":2451,"interventions":2452},[86],[1273,1274],[1276,1277,1278,1279,1280,1210],{"nctId":1293,"briefTitle":1294,"status":102,"phases":2454,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":1299,"conditions":2455,"interventions":2456},[86],[1273],[1302,1279,1278,1277,1280,1210],{"trials":2458,"activeCount":96},[],{"trials":2460,"activeCount":96},[2461],{"nctId":2462,"briefTitle":2463,"status":102,"phases":2464,"primaryCompletion":2465,"completion":2465,"start":2466,"enrollment":2467,"conditions":2468,"interventions":2469},"NCT02723591","To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients",[88],"2019-06-14","2016-09-09",599,[1273],[1279,2470],"Tacrolimus immediate release",{"trials":2472,"activeCount":96},[],{"intervention":2470,"totalTrials":233,"cells":2474},{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2481,"PHASE4":2483,"NA":2489},{"trials":2476,"activeCount":96},[],{"trials":2478,"activeCount":96},[],{"trials":2480,"activeCount":96},[],{"trials":2482,"activeCount":96},[],{"trials":2484,"activeCount":96},[2485],{"nctId":2462,"briefTitle":2463,"status":102,"phases":2486,"primaryCompletion":2465,"completion":2465,"start":2466,"enrollment":2467,"conditions":2487,"interventions":2488},[88],[1273],[1279,2470],{"trials":2490,"activeCount":96},[],{"intervention":1079,"totalTrials":233,"cells":2492},{"EARLY_PHASE1":2493,"PHASE1":2495,"PHASE2":2497,"PHASE3":2499,"PHASE4":2501,"NA":2507},{"trials":2494,"activeCount":96},[],{"trials":2496,"activeCount":96},[],{"trials":2498,"activeCount":96},[],{"trials":2500,"activeCount":96},[],{"trials":2502,"activeCount":96},[2503],{"nctId":1068,"briefTitle":1069,"status":102,"phases":2504,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":2505,"interventions":2506},[88],[1076,1077],[1038,1079],{"trials":2508,"activeCount":96},[],{"intervention":1100,"totalTrials":233,"cells":2510},{"EARLY_PHASE1":2511,"PHASE1":2513,"PHASE2":2515,"PHASE3":2517,"PHASE4":2519,"NA":2525},{"trials":2512,"activeCount":96},[],{"trials":2514,"activeCount":96},[],{"trials":2516,"activeCount":96},[],{"trials":2518,"activeCount":96},[],{"trials":2520,"activeCount":96},[2521],{"nctId":1091,"briefTitle":1092,"status":102,"phases":2522,"primaryCompletion":1094,"completion":1095,"start":1096,"enrollment":1097,"conditions":2523,"interventions":2524},[88],[1056],[1038,1100],{"trials":2526,"activeCount":96},[],{"intervention":2528,"totalTrials":180,"cells":2529},"ASP0113",{"EARLY_PHASE1":2530,"PHASE1":2532,"PHASE2":2544,"PHASE3":2556,"PHASE4":2570,"NA":2572},{"trials":2531,"activeCount":96},[],{"trials":2533,"activeCount":96},[2534],{"nctId":2535,"briefTitle":2536,"status":102,"phases":2537,"primaryCompletion":2538,"completion":2538,"start":2539,"enrollment":1537,"conditions":2540,"interventions":2543},"NCT02103426","An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients",[85],"2016-05-10","2013-12-30",[2541,18,2542],"Dialysis","Cytomegalovirus Infection",[2528],{"trials":2545,"activeCount":96},[2546],{"nctId":2547,"briefTitle":2548,"status":102,"phases":2549,"primaryCompletion":2550,"completion":2551,"start":2552,"enrollment":954,"conditions":2553,"interventions":2555},"NCT01974206","A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor",[86],"2016-05-13","2020-11-05","2013-11-20",[2554],"Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients",[2528],{"trials":2557,"activeCount":96},[2558],{"nctId":2559,"briefTitle":2560,"status":102,"phases":2561,"primaryCompletion":2562,"completion":2563,"start":2564,"enrollment":2565,"conditions":2566,"interventions":2569},"NCT01877655","A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)",[87],"2017-09-28","2022-03-01","2013-09-11",514,[2567,2568],"Cytomegalovirus (CMV)-Positive Recipients","Allogeneic, Hematopoietic Cell Transplant (HCT)",[2528],{"trials":2571,"activeCount":96},[],{"trials":2573,"activeCount":96},[],{"intervention":2575,"totalTrials":180,"cells":2576},"pudexacianinium chloride",{"EARLY_PHASE1":2577,"PHASE1":2579,"PHASE2":2590,"PHASE3":2592,"PHASE4":2615,"NA":2617},{"trials":2578,"activeCount":96},[],{"trials":2580,"activeCount":96},[2581],{"nctId":2582,"briefTitle":2583,"status":102,"phases":2584,"primaryCompletion":2585,"completion":2586,"start":2587,"enrollment":2039,"conditions":2588,"interventions":2589},"NCT05495581","A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well",[85],"2023-04-27","2023-05-08","2022-08-25",[15,923],[2575],{"trials":2591,"activeCount":96},[],{"trials":2593,"activeCount":96},[2594,2606],{"nctId":2595,"briefTitle":2596,"status":102,"phases":2597,"primaryCompletion":2598,"completion":2599,"start":2600,"enrollment":2601,"conditions":2602,"interventions":2605},"NCT05754333","A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery",[87],"2024-12-17","2025-01-16","2023-08-02",107,[2603,2604],"Intraoperative Ureter Visualization","Abdominolpelvic Surgery",[2575],{"nctId":2607,"briefTitle":2608,"status":102,"phases":2609,"primaryCompletion":2610,"completion":2610,"start":2611,"enrollment":2612,"conditions":2613,"interventions":2614},"NCT05999747","A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease",[87],"2025-10-13","2024-03-19",95,[2603,2604],[2575],{"trials":2616,"activeCount":96},[],{"trials":2618,"activeCount":96},[],{"intervention":1621,"totalTrials":180,"cells":2620},{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2635,"PHASE4":2648,"NA":2650},{"trials":2622,"activeCount":96},[],{"trials":2624,"activeCount":96},[],{"trials":2626,"activeCount":96},[2627,2631],{"nctId":1613,"briefTitle":1614,"status":113,"phases":2628,"primaryCompletion":1616,"completion":1616,"start":1617,"enrollment":25,"conditions":2629,"interventions":2630},[85,86],[1619],[1515,1621],{"nctId":1966,"briefTitle":1967,"status":102,"phases":2632,"primaryCompletion":1969,"completion":1970,"start":1971,"enrollment":1972,"conditions":2633,"interventions":2634},[86],[24],[1975,1976,1977,1978,1979],{"trials":2636,"activeCount":96},[2637],{"nctId":2638,"briefTitle":2639,"status":113,"phases":2640,"primaryCompletion":2641,"completion":2641,"start":2642,"enrollment":2643,"conditions":2644,"interventions":2645},"NCT02588261","A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB\u002FIV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations",[87],"2017-12-21","2016-02-11",530,[765],[2646,1621,2647],"naquotinib mesilate","Gefitinib",{"trials":2649,"activeCount":96},[],{"trials":2651,"activeCount":96},[],{"intervention":2653,"totalTrials":219,"cells":2654},"micafungin",{"EARLY_PHASE1":2655,"PHASE1":2657,"PHASE2":2659,"PHASE3":2673,"PHASE4":2686,"NA":2688},{"trials":2656,"activeCount":96},[],{"trials":2658,"activeCount":96},[],{"trials":2660,"activeCount":96},[2661],{"nctId":2662,"briefTitle":2663,"status":102,"phases":2664,"primaryCompletion":2665,"completion":2665,"start":2666,"enrollment":2667,"conditions":2668,"interventions":2671},"NCT03421002","Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and\u002For Candida Meningitis",[86],"2018-04-10","2015-05-30",35,[2669,2670],"Candidiasis, Systemic","Candida Meningitis",[2672],"Micafungin",{"trials":2674,"activeCount":96},[2675],{"nctId":2676,"briefTitle":2677,"status":113,"phases":2678,"primaryCompletion":2679,"completion":2679,"start":2680,"enrollment":2681,"conditions":2682,"interventions":2684},"NCT00815516","Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis",[87],"2014-12","2013-02",30,[2683],"Candidiasis",[2653,2685],"amphotericin B deoxycholate",{"trials":2687,"activeCount":96},[],{"trials":2689,"activeCount":96},[],{"intervention":2691,"totalTrials":219,"cells":2692},"Regadenoson",{"EARLY_PHASE1":2693,"PHASE1":2695,"PHASE2":2706,"PHASE3":2708,"PHASE4":2719,"NA":2721},{"trials":2694,"activeCount":96},[],{"trials":2696,"activeCount":96},[2697],{"nctId":2698,"briefTitle":2699,"status":102,"phases":2700,"primaryCompletion":2701,"completion":2701,"start":2702,"enrollment":2703,"conditions":2704,"interventions":2705},"NCT01918995","Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects",[85],"2013-08","2013-05",36,[15],[2691],{"trials":2707,"activeCount":96},[],{"trials":2709,"activeCount":96},[2710],{"nctId":2711,"briefTitle":2712,"status":102,"phases":2713,"primaryCompletion":2679,"completion":2679,"start":2714,"enrollment":2715,"conditions":2716,"interventions":2718},"NCT01618669","A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)",[87],"2012-06",1147,[2717],"Coronary Artery Disease (CAD)",[2691],{"trials":2720,"activeCount":96},[],{"trials":2722,"activeCount":96},[],{"intervention":196,"totalTrials":233,"cells":2724},{"EARLY_PHASE1":2725,"PHASE1":2727,"PHASE2":2729,"PHASE3":2731,"PHASE4":2737,"NA":2739},{"trials":2726,"activeCount":96},[],{"trials":2728,"activeCount":96},[],{"trials":2730,"activeCount":96},[],{"trials":2732,"activeCount":96},[2733],{"nctId":184,"briefTitle":185,"status":102,"phases":2734,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":2735,"interventions":2736},[87],[192,173,193],[140,195,196,197],{"trials":2738,"activeCount":96},[],{"trials":2740,"activeCount":96},[],{"intervention":1653,"totalTrials":233,"cells":2742},{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2749,"PHASE4":2755,"NA":2757},{"trials":2744,"activeCount":96},[],{"trials":2746,"activeCount":96},[],{"trials":2748,"activeCount":96},[],{"trials":2750,"activeCount":96},[2751],{"nctId":1644,"briefTitle":1645,"status":102,"phases":2752,"primaryCompletion":1647,"completion":59,"start":1648,"enrollment":1649,"conditions":2753,"interventions":2754},[87],[1651],[1499,1653,1598,1654,1655],{"trials":2756,"activeCount":96},[],{"trials":2758,"activeCount":96},[],{"intervention":1654,"totalTrials":233,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2767,"PHASE4":2773,"NA":2775},{"trials":2762,"activeCount":96},[],{"trials":2764,"activeCount":96},[],{"trials":2766,"activeCount":96},[],{"trials":2768,"activeCount":96},[2769],{"nctId":1644,"briefTitle":1645,"status":102,"phases":2770,"primaryCompletion":1647,"completion":59,"start":1648,"enrollment":1649,"conditions":2771,"interventions":2772},[87],[1651],[1499,1653,1598,1654,1655],{"trials":2774,"activeCount":96},[],{"trials":2776,"activeCount":96},[],{"intervention":1655,"totalTrials":233,"cells":2778},{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2783,"PHASE3":2785,"PHASE4":2791,"NA":2793},{"trials":2780,"activeCount":96},[],{"trials":2782,"activeCount":96},[],{"trials":2784,"activeCount":96},[],{"trials":2786,"activeCount":96},[2787],{"nctId":1644,"briefTitle":1645,"status":102,"phases":2788,"primaryCompletion":1647,"completion":59,"start":1648,"enrollment":1649,"conditions":2789,"interventions":2790},[87],[1651],[1499,1653,1598,1654,1655],{"trials":2792,"activeCount":96},[],{"trials":2794,"activeCount":96},[],{"intervention":2685,"totalTrials":233,"cells":2796},{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2803,"PHASE4":2809,"NA":2811},{"trials":2798,"activeCount":96},[],{"trials":2800,"activeCount":96},[],{"trials":2802,"activeCount":96},[],{"trials":2804,"activeCount":96},[2805],{"nctId":2676,"briefTitle":2677,"status":113,"phases":2806,"primaryCompletion":2679,"completion":2679,"start":2680,"enrollment":2681,"conditions":2807,"interventions":2808},[87],[2683],[2653,2685],{"trials":2810,"activeCount":96},[],{"trials":2812,"activeCount":96},[],{"intervention":2646,"totalTrials":233,"cells":2814},{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2819,"PHASE3":2821,"PHASE4":2827,"NA":2829},{"trials":2816,"activeCount":96},[],{"trials":2818,"activeCount":96},[],{"trials":2820,"activeCount":96},[],{"trials":2822,"activeCount":96},[2823],{"nctId":2638,"briefTitle":2639,"status":113,"phases":2824,"primaryCompletion":2641,"completion":2641,"start":2642,"enrollment":2643,"conditions":2825,"interventions":2826},[87],[765],[2646,1621,2647],{"trials":2828,"activeCount":96},[],{"trials":2830,"activeCount":96},[],{"intervention":2647,"totalTrials":233,"cells":2832},{"EARLY_PHASE1":2833,"PHASE1":2835,"PHASE2":2837,"PHASE3":2839,"PHASE4":2845,"NA":2847},{"trials":2834,"activeCount":96},[],{"trials":2836,"activeCount":96},[],{"trials":2838,"activeCount":96},[],{"trials":2840,"activeCount":96},[2841],{"nctId":2638,"briefTitle":2639,"status":113,"phases":2842,"primaryCompletion":2641,"completion":2641,"start":2642,"enrollment":2643,"conditions":2843,"interventions":2844},[87],[765],[2646,1621,2647],{"trials":2846,"activeCount":96},[],{"trials":2848,"activeCount":96},[],{"intervention":2850,"totalTrials":489,"cells":2851},"ASP8062",{"EARLY_PHASE1":2852,"PHASE1":2854,"PHASE2":2877,"PHASE3":2895,"PHASE4":2897,"NA":2899},{"trials":2853,"activeCount":96},[],{"trials":2855,"activeCount":96},[2856,2866],{"nctId":2857,"briefTitle":2858,"status":102,"phases":2859,"primaryCompletion":2860,"completion":2860,"start":1535,"enrollment":19,"conditions":2861,"interventions":2862},"NCT04003402","A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects",[85],"2019-10-16",[15],[2850,2863,2864,2865],"Alcohol","ASP8062 Placebo","Alcohol Placebo",{"nctId":2867,"briefTitle":2868,"status":102,"phases":2869,"primaryCompletion":2870,"completion":2870,"start":2871,"enrollment":2872,"conditions":2873,"interventions":2875},"NCT04447287","A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine\u002FNaloxone in Participants With Opioid Use Disorder",[85],"2020-11-25","2020-06-29",23,[2874],"Opioid Use Disorder",[2850,2876],"buprenorphine\u002Fnaloxone",{"trials":2878,"activeCount":96},[2879,2888],{"nctId":2880,"briefTitle":2881,"status":102,"phases":2882,"primaryCompletion":2883,"completion":2883,"start":2884,"enrollment":1672,"conditions":2885,"interventions":2887},"NCT03092726","A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia",[86],"2018-03-06","2017-05-08",[2886],"Fibromyalgia",[2850],{"nctId":2889,"briefTitle":2890,"status":1355,"phases":2891,"primaryCompletion":2892,"completion":2892,"start":1010,"enrollment":96,"conditions":2893,"interventions":2894},"NCT05062577","A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine\u002FNaloxone in Participants With Opioid Use Disorder",[86],"2023-02-28",[2874],[2850,2876],{"trials":2896,"activeCount":96},[],{"trials":2898,"activeCount":96},[],{"trials":2900,"activeCount":96},[],{"intervention":1278,"totalTrials":180,"cells":2902},{"EARLY_PHASE1":2903,"PHASE1":2905,"PHASE2":2918,"PHASE3":2928,"PHASE4":2930,"NA":2932},{"trials":2904,"activeCount":96},[],{"trials":2906,"activeCount":96},[2907],{"nctId":2908,"briefTitle":2909,"status":102,"phases":2910,"primaryCompletion":2911,"completion":2911,"start":1220,"enrollment":342,"conditions":2912,"interventions":2915},"NCT01711489","A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects",[85],"2012-04",[18,21,2913,2914],"Pharmacokinetics of Plasma Mycophenolic Acid (MPA)","Pharmacokinetics of Plasma Phenolic Glucuronide of MPA (MPAG)",[2916,2917],"isavuconazole","Mycophenolate mofetil",{"trials":2919,"activeCount":96},[2920,2924],{"nctId":1265,"briefTitle":1266,"status":102,"phases":2921,"primaryCompletion":1268,"completion":1269,"start":1270,"enrollment":1271,"conditions":2922,"interventions":2923},[86],[1273,1274],[1276,1277,1278,1279,1280,1210],{"nctId":1293,"briefTitle":1294,"status":102,"phases":2925,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":1299,"conditions":2926,"interventions":2927},[86],[1273],[1302,1279,1278,1277,1280,1210],{"trials":2929,"activeCount":96},[],{"trials":2931,"activeCount":96},[],{"trials":2933,"activeCount":96},[],{"intervention":1302,"totalTrials":180,"cells":2935},{"EARLY_PHASE1":2936,"PHASE1":2938,"PHASE2":2949,"PHASE3":2963,"PHASE4":2965,"NA":2967},{"trials":2937,"activeCount":96},[],{"trials":2939,"activeCount":96},[2940],{"nctId":2941,"briefTitle":2942,"status":102,"phases":2943,"primaryCompletion":2944,"completion":2944,"start":1221,"enrollment":342,"conditions":2945,"interventions":2948},"NCT01582399","Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240",[85],"2012-09",[2946,2947,15],"Pharmacokinetics of ASKP1240","Pharmacodynamics of ASKP1240",[1302],{"trials":2950,"activeCount":96},[2951,2959],{"nctId":2952,"briefTitle":2953,"status":102,"phases":2954,"primaryCompletion":1296,"completion":1511,"start":2955,"enrollment":1260,"conditions":2956,"interventions":2958},"NCT01585233","A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis",[86],"2012-04-30",[2957],"Psoriasis",[1302],{"nctId":1293,"briefTitle":1294,"status":102,"phases":2960,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":1299,"conditions":2961,"interventions":2962},[86],[1273],[1302,1279,1278,1277,1280,1210],{"trials":2964,"activeCount":96},[],{"trials":2966,"activeCount":96},[],{"trials":2968,"activeCount":96},[],{"intervention":346,"totalTrials":219,"cells":2970},{"EARLY_PHASE1":2971,"PHASE1":2973,"PHASE2":2975,"PHASE3":2991,"PHASE4":2993,"NA":2995},{"trials":2972,"activeCount":96},[],{"trials":2974,"activeCount":96},[],{"trials":2976,"activeCount":96},[2977,2987],{"nctId":2978,"briefTitle":2979,"status":102,"phases":2980,"primaryCompletion":2981,"completion":2981,"start":2982,"enrollment":2983,"conditions":2984,"interventions":2986},"NCT04079296","A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed\u002FRefractory Acute Myeloid Leukemia (AML) and Relapsed\u002FRefractory Higher Risk Myelodysplastic Syndrome (MDS)",[85,86],"2023-04-21","2019-09-19",43,[29,2985],"Myelodysplastic Syndrome",[346],{"nctId":337,"briefTitle":338,"status":102,"phases":2988,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":2989,"interventions":2990},[85,86],[344,261],[346,139],{"trials":2992,"activeCount":96},[],{"trials":2994,"activeCount":96},[],{"trials":2996,"activeCount":96},[],{"intervention":1585,"totalTrials":219,"cells":2998},{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3007,"PHASE3":3013,"PHASE4":3015,"NA":3017},{"trials":3000,"activeCount":96},[],{"trials":3002,"activeCount":96},[3003],{"nctId":1507,"briefTitle":1508,"status":102,"phases":3004,"primaryCompletion":1510,"completion":1510,"start":1511,"enrollment":1512,"conditions":3005,"interventions":3006},[85],[34],[1515,1516,1517,1518],{"trials":3008,"activeCount":96},[3009],{"nctId":1575,"briefTitle":1576,"status":113,"phases":3010,"primaryCompletion":1578,"completion":1579,"start":1580,"enrollment":30,"conditions":3011,"interventions":3012},[85,86],[29,1582],[1499,1584,1585,1586],{"trials":3014,"activeCount":96},[],{"trials":3016,"activeCount":96},[],{"trials":3018,"activeCount":96},[],{"intervention":3020,"totalTrials":219,"cells":3021},"ASP4345",{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3035,"PHASE3":3054,"PHASE4":3056,"NA":3058},{"trials":3023,"activeCount":96},[],{"trials":3025,"activeCount":96},[3026],{"nctId":3027,"briefTitle":3028,"status":102,"phases":3029,"primaryCompletion":3030,"completion":3030,"start":3031,"enrollment":1537,"conditions":3032,"interventions":3034},"NCT02720263","A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia",[85],"2017-06-08","2016-03-28",[3033],"Schizophrenia",[3020],{"trials":3036,"activeCount":96},[3037],{"nctId":3038,"briefTitle":3039,"status":102,"phases":3040,"primaryCompletion":3041,"completion":3041,"start":3042,"enrollment":3043,"conditions":3044,"interventions":3045},"NCT03557931","A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication",[86],"2019-10-21","2018-07-13",233,[3033],[3020,3046,3047,3048,3049,3050,3051,3052,3053],"risperidone","quetiapine","olanzapine","ziprasidone","aripiprazole","brexpiprazole","paliperidone","lurasidone",{"trials":3055,"activeCount":96},[],{"trials":3057,"activeCount":96},[],{"trials":3059,"activeCount":96},[],{"intervention":3061,"totalTrials":219,"cells":3062},"midazolam",{"EARLY_PHASE1":3063,"PHASE1":3065,"PHASE2":3080,"PHASE3":3086,"PHASE4":3088,"NA":3090},{"trials":3064,"activeCount":96},[],{"trials":3066,"activeCount":96},[3067],{"nctId":3068,"briefTitle":3069,"status":102,"phases":3070,"primaryCompletion":3071,"completion":3072,"start":3073,"enrollment":3074,"conditions":3075,"interventions":3078},"NCT02113813","A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations",[85],"2017-07-28","2019-02-11","2014-04-09",133,[3076,3077],"Non-Small-Cell Lung Cancer (NSCLC)","Epidermal Growth Factor Receptor Mutations",[3079,3061],"naquotinib",{"trials":3081,"activeCount":96},[3082],{"nctId":1600,"briefTitle":1601,"status":102,"phases":3083,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":3084,"interventions":3085},[85,86],[34],[1515,1609,1610,1611],{"trials":3087,"activeCount":96},[],{"trials":3089,"activeCount":96},[],{"trials":3091,"activeCount":96},[],{"intervention":2248,"totalTrials":219,"cells":3093},{"EARLY_PHASE1":3094,"PHASE1":3096,"PHASE2":3108,"PHASE3":3114,"PHASE4":3116,"NA":3118},{"trials":3095,"activeCount":96},[],{"trials":3097,"activeCount":96},[3098],{"nctId":3099,"briefTitle":3100,"status":102,"phases":3101,"primaryCompletion":3102,"completion":3102,"start":3103,"enrollment":22,"conditions":3104,"interventions":3107},"NCT02194491","A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662",[85],"2016-05","2014-04",[3105,3106,15],"Pharmacokinetics of ASP3662","Displacement of Radiotracer",[2248],{"trials":3109,"activeCount":96},[3110],{"nctId":2239,"briefTitle":2240,"status":113,"phases":3111,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":2244,"conditions":3112,"interventions":3113},[86],[2246],[2248,2230,2249,2250],{"trials":3115,"activeCount":96},[],{"trials":3117,"activeCount":96},[],{"trials":3119,"activeCount":96},[],{"intervention":3121,"totalTrials":219,"cells":3122},"peficitinib",{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3127,"PHASE3":3148,"PHASE4":3150,"NA":3152},{"trials":3124,"activeCount":96},[],{"trials":3126,"activeCount":96},[],{"trials":3128,"activeCount":96},[3129,3139],{"nctId":3130,"briefTitle":3131,"status":102,"phases":3132,"primaryCompletion":3133,"completion":3133,"start":3134,"enrollment":3135,"conditions":3136,"interventions":3138},"NCT01711814","A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study",[86],"2016-03-25","2012-09-26",611,[3137],"Arthritis, Rheumatoid",[3121],{"nctId":3140,"briefTitle":3141,"status":102,"phases":3142,"primaryCompletion":3143,"completion":3143,"start":3144,"enrollment":3145,"conditions":3146,"interventions":3147},"NCT01565655","A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis",[86],"2013-12-02","2012-06-19",289,[3137],[3121],{"trials":3149,"activeCount":96},[],{"trials":3151,"activeCount":96},[],{"trials":3153,"activeCount":96},[],{"intervention":1277,"totalTrials":219,"cells":3155},{"EARLY_PHASE1":3156,"PHASE1":3158,"PHASE2":3160,"PHASE3":3170,"PHASE4":3172,"NA":3174},{"trials":3157,"activeCount":96},[],{"trials":3159,"activeCount":96},[],{"trials":3161,"activeCount":96},[3162,3166],{"nctId":1265,"briefTitle":1266,"status":102,"phases":3163,"primaryCompletion":1268,"completion":1269,"start":1270,"enrollment":1271,"conditions":3164,"interventions":3165},[86],[1273,1274],[1276,1277,1278,1279,1280,1210],{"nctId":1293,"briefTitle":1294,"status":102,"phases":3167,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":1299,"conditions":3168,"interventions":3169},[86],[1273],[1302,1279,1278,1277,1280,1210],{"trials":3171,"activeCount":96},[],{"trials":3173,"activeCount":96},[],{"trials":3175,"activeCount":96},[],{"intervention":1280,"totalTrials":219,"cells":3177},{"EARLY_PHASE1":3178,"PHASE1":3180,"PHASE2":3182,"PHASE3":3192,"PHASE4":3194,"NA":3196},{"trials":3179,"activeCount":96},[],{"trials":3181,"activeCount":96},[],{"trials":3183,"activeCount":96},[3184,3188],{"nctId":1265,"briefTitle":1266,"status":102,"phases":3185,"primaryCompletion":1268,"completion":1269,"start":1270,"enrollment":1271,"conditions":3186,"interventions":3187},[86],[1273,1274],[1276,1277,1278,1279,1280,1210],{"nctId":1293,"briefTitle":1294,"status":102,"phases":3189,"primaryCompletion":1296,"completion":1297,"start":1298,"enrollment":1299,"conditions":3190,"interventions":3191},[86],[1273],[1302,1279,1278,1277,1280,1210],{"trials":3193,"activeCount":96},[],{"trials":3195,"activeCount":96},[],{"trials":3197,"activeCount":96},[],{"intervention":2876,"totalTrials":219,"cells":3199},{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3208,"PHASE3":3214,"PHASE4":3216,"NA":3218},{"trials":3201,"activeCount":96},[],{"trials":3203,"activeCount":96},[3204],{"nctId":2867,"briefTitle":2868,"status":102,"phases":3205,"primaryCompletion":2870,"completion":2870,"start":2871,"enrollment":2872,"conditions":3206,"interventions":3207},[85],[2874],[2850,2876],{"trials":3209,"activeCount":96},[3210],{"nctId":2889,"briefTitle":2890,"status":1355,"phases":3211,"primaryCompletion":2892,"completion":2892,"start":1010,"enrollment":96,"conditions":3212,"interventions":3213},[86],[2874],[2850,2876],{"trials":3215,"activeCount":96},[],{"trials":3217,"activeCount":96},[],{"trials":3219,"activeCount":96},[],{"intervention":3221,"totalTrials":219,"cells":3222},"reldesemtiv",{"EARLY_PHASE1":3223,"PHASE1":3225,"PHASE2":3237,"PHASE3":3250,"PHASE4":3252,"NA":3254},{"trials":3224,"activeCount":96},[],{"trials":3226,"activeCount":96},[3227],{"nctId":3228,"briefTitle":3229,"status":113,"phases":3230,"primaryCompletion":3231,"completion":3231,"start":3232,"enrollment":3233,"conditions":3234,"interventions":3236},"NCT03065959","A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility",[85],"2018-10-10","2017-06-28",42,[3235],"Mobility Limitation",[3221],{"trials":3238,"activeCount":96},[3239],{"nctId":3240,"briefTitle":3241,"status":102,"phases":3242,"primaryCompletion":3243,"completion":3243,"start":3244,"enrollment":3245,"conditions":3246,"interventions":3248},"NCT02662582","A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease",[86],"2018-06-08","2016-06-30",46,[3247],"Chronic Obstructive Pulmonary Disease (COPD)",[3249],"Reldesemtiv",{"trials":3251,"activeCount":96},[],{"trials":3253,"activeCount":96},[],{"trials":3255,"activeCount":96},[],{"intervention":447,"totalTrials":233,"cells":3257},{"EARLY_PHASE1":3258,"PHASE1":3260,"PHASE2":3262,"PHASE3":3268,"PHASE4":3270,"NA":3272},{"trials":3259,"activeCount":96},[],{"trials":3261,"activeCount":96},[],{"trials":3263,"activeCount":96},[3264],{"nctId":436,"briefTitle":437,"status":102,"phases":3265,"primaryCompletion":439,"completion":439,"start":440,"enrollment":441,"conditions":3266,"interventions":3267},[86],[443,444,445],[447,361,448,41],{"trials":3269,"activeCount":96},[],{"trials":3271,"activeCount":96},[],{"trials":3273,"activeCount":96},[],{"intervention":3275,"totalTrials":233,"cells":3276},"ASP0819",{"EARLY_PHASE1":3277,"PHASE1":3279,"PHASE2":3281,"PHASE3":3292,"PHASE4":3294,"NA":3296},{"trials":3278,"activeCount":96},[],{"trials":3280,"activeCount":96},[],{"trials":3282,"activeCount":96},[3283],{"nctId":3284,"briefTitle":3285,"status":102,"phases":3286,"primaryCompletion":3287,"completion":3287,"start":3288,"enrollment":3289,"conditions":3290,"interventions":3291},"NCT03056690","A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia",[86],"2018-02-27","2017-03-20",186,[2886],[3275],{"trials":3293,"activeCount":96},[],{"trials":3295,"activeCount":96},[],{"trials":3297,"activeCount":96},[],{"intervention":1573,"totalTrials":233,"cells":3299},{"EARLY_PHASE1":3300,"PHASE1":3302,"PHASE2":3304,"PHASE3":3310,"PHASE4":3312,"NA":3314},{"trials":3301,"activeCount":96},[],{"trials":3303,"activeCount":96},[],{"trials":3305,"activeCount":96},[3306],{"nctId":1564,"briefTitle":1565,"status":102,"phases":3307,"primaryCompletion":1567,"completion":1568,"start":1569,"enrollment":92,"conditions":3308,"interventions":3309},[85,86],[29,1571],[1499,1573],{"trials":3311,"activeCount":96},[],{"trials":3313,"activeCount":96},[],{"trials":3315,"activeCount":96},[],{"intervention":1584,"totalTrials":233,"cells":3317},{"EARLY_PHASE1":3318,"PHASE1":3320,"PHASE2":3322,"PHASE3":3328,"PHASE4":3330,"NA":3332},{"trials":3319,"activeCount":96},[],{"trials":3321,"activeCount":96},[],{"trials":3323,"activeCount":96},[3324],{"nctId":1575,"briefTitle":1576,"status":113,"phases":3325,"primaryCompletion":1578,"completion":1579,"start":1580,"enrollment":30,"conditions":3326,"interventions":3327},[85,86],[29,1582],[1499,1584,1585,1586],{"trials":3329,"activeCount":96},[],{"trials":3331,"activeCount":96},[],{"trials":3333,"activeCount":96},[],{"intervention":1586,"totalTrials":233,"cells":3335},{"EARLY_PHASE1":3336,"PHASE1":3338,"PHASE2":3340,"PHASE3":3346,"PHASE4":3348,"NA":3350},{"trials":3337,"activeCount":96},[],{"trials":3339,"activeCount":96},[],{"trials":3341,"activeCount":96},[3342],{"nctId":1575,"briefTitle":1576,"status":113,"phases":3343,"primaryCompletion":1578,"completion":1579,"start":1580,"enrollment":30,"conditions":3344,"interventions":3345},[85,86],[29,1582],[1499,1584,1585,1586],{"trials":3347,"activeCount":96},[],{"trials":3349,"activeCount":96},[],{"trials":3351,"activeCount":96},[],{"intervention":3353,"totalTrials":233,"cells":3354},"ASP8273",{"EARLY_PHASE1":3355,"PHASE1":3357,"PHASE2":3359,"PHASE3":3368,"PHASE4":3370,"NA":3372},{"trials":3356,"activeCount":96},[],{"trials":3358,"activeCount":96},[],{"trials":3360,"activeCount":96},[3361],{"nctId":3362,"briefTitle":3363,"status":1355,"phases":3364,"primaryCompletion":1365,"completion":1365,"start":1365,"enrollment":96,"conditions":3365,"interventions":3367},"NCT03042013","A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study",[86],[3366],"Subjects With NSCLC With an EGFR Activating Mutation",[3353],{"trials":3369,"activeCount":96},[],{"trials":3371,"activeCount":96},[],{"trials":3373,"activeCount":96},[],{"intervention":1374,"totalTrials":233,"cells":3375},{"EARLY_PHASE1":3376,"PHASE1":3378,"PHASE2":3380,"PHASE3":3386,"PHASE4":3388,"NA":3390},{"trials":3377,"activeCount":96},[],{"trials":3379,"activeCount":96},[],{"trials":3381,"activeCount":96},[3382],{"nctId":1362,"briefTitle":1363,"status":102,"phases":3383,"primaryCompletion":1365,"completion":1366,"start":1367,"enrollment":1368,"conditions":3384,"interventions":3385},[86],[1370,1371,1372],[1320,1374],{"trials":3387,"activeCount":96},[],{"trials":3389,"activeCount":96},[],{"trials":3391,"activeCount":96},[],{"intervention":3393,"totalTrials":233,"cells":3394},"AGS-16C3F",{"EARLY_PHASE1":3395,"PHASE1":3397,"PHASE2":3399,"PHASE3":3410,"PHASE4":3412,"NA":3414},{"trials":3396,"activeCount":96},[],{"trials":3398,"activeCount":96},[],{"trials":3400,"activeCount":96},[3401],{"nctId":3402,"briefTitle":3403,"status":102,"phases":3404,"primaryCompletion":3405,"completion":3405,"start":1627,"enrollment":3074,"conditions":3406,"interventions":3408},"NCT02639182","A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma",[86],"2020-10-02",[3407],"Metastatic Renal Cell Carcinoma",[3393,3409],"Axitinib",{"trials":3411,"activeCount":96},[],{"trials":3413,"activeCount":96},[],{"trials":3415,"activeCount":96},[],{"intervention":3409,"totalTrials":233,"cells":3417},{"EARLY_PHASE1":3418,"PHASE1":3420,"PHASE2":3422,"PHASE3":3428,"PHASE4":3430,"NA":3432},{"trials":3419,"activeCount":96},[],{"trials":3421,"activeCount":96},[],{"trials":3423,"activeCount":96},[3424],{"nctId":3402,"briefTitle":3403,"status":102,"phases":3425,"primaryCompletion":3405,"completion":3405,"start":1627,"enrollment":3074,"conditions":3426,"interventions":3427},[86],[3407],[3393,3409],{"trials":3429,"activeCount":96},[],{"trials":3431,"activeCount":96},[],{"trials":3433,"activeCount":96},[],{"intervention":2249,"totalTrials":233,"cells":3435},{"EARLY_PHASE1":3436,"PHASE1":3438,"PHASE2":3440,"PHASE3":3446,"PHASE4":3448,"NA":3450},{"trials":3437,"activeCount":96},[],{"trials":3439,"activeCount":96},[],{"trials":3441,"activeCount":96},[3442],{"nctId":2239,"briefTitle":2240,"status":113,"phases":3443,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":2244,"conditions":3444,"interventions":3445},[86],[2246],[2248,2230,2249,2250],{"trials":3447,"activeCount":96},[],{"trials":3449,"activeCount":96},[],{"trials":3451,"activeCount":96},[],{"intervention":2250,"totalTrials":233,"cells":3453},{"EARLY_PHASE1":3454,"PHASE1":3456,"PHASE2":3458,"PHASE3":3464,"PHASE4":3466,"NA":3468},{"trials":3455,"activeCount":96},[],{"trials":3457,"activeCount":96},[],{"trials":3459,"activeCount":96},[3460],{"nctId":2239,"briefTitle":2240,"status":113,"phases":3461,"primaryCompletion":2242,"completion":2242,"start":2243,"enrollment":2244,"conditions":3462,"interventions":3463},[86],[2246],[2248,2230,2249,2250],{"trials":3465,"activeCount":96},[],{"trials":3467,"activeCount":96},[],{"trials":3469,"activeCount":96},[],{"intervention":1611,"totalTrials":233,"cells":3471},{"EARLY_PHASE1":3472,"PHASE1":3474,"PHASE2":3476,"PHASE3":3482,"PHASE4":3484,"NA":3486},{"trials":3473,"activeCount":96},[],{"trials":3475,"activeCount":96},[],{"trials":3477,"activeCount":96},[3478],{"nctId":1600,"briefTitle":1601,"status":102,"phases":3479,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":3480,"interventions":3481},[85,86],[34],[1515,1609,1610,1611],{"trials":3483,"activeCount":96},[],{"trials":3485,"activeCount":96},[],{"trials":3487,"activeCount":96},[],{"intervention":3046,"totalTrials":233,"cells":3489},{"EARLY_PHASE1":3490,"PHASE1":3492,"PHASE2":3494,"PHASE3":3500,"PHASE4":3502,"NA":3504},{"trials":3491,"activeCount":96},[],{"trials":3493,"activeCount":96},[],{"trials":3495,"activeCount":96},[3496],{"nctId":3038,"briefTitle":3039,"status":102,"phases":3497,"primaryCompletion":3041,"completion":3041,"start":3042,"enrollment":3043,"conditions":3498,"interventions":3499},[86],[3033],[3020,3046,3047,3048,3049,3050,3051,3052,3053],{"trials":3501,"activeCount":96},[],{"trials":3503,"activeCount":96},[],{"trials":3505,"activeCount":96},[],{"intervention":3047,"totalTrials":233,"cells":3507},{"EARLY_PHASE1":3508,"PHASE1":3510,"PHASE2":3512,"PHASE3":3518,"PHASE4":3520,"NA":3522},{"trials":3509,"activeCount":96},[],{"trials":3511,"activeCount":96},[],{"trials":3513,"activeCount":96},[3514],{"nctId":3038,"briefTitle":3039,"status":102,"phases":3515,"primaryCompletion":3041,"completion":3041,"start":3042,"enrollment":3043,"conditions":3516,"interventions":3517},[86],[3033],[3020,3046,3047,3048,3049,3050,3051,3052,3053],{"trials":3519,"activeCount":96},[],{"trials":3521,"activeCount":96},[],{"trials":3523,"activeCount":96},[],{"intervention":3048,"totalTrials":233,"cells":3525},{"EARLY_PHASE1":3526,"PHASE1":3528,"PHASE2":3530,"PHASE3":3536,"PHASE4":3538,"NA":3540},{"trials":3527,"activeCount":96},[],{"trials":3529,"activeCount":96},[],{"trials":3531,"activeCount":96},[3532],{"nctId":3038,"briefTitle":3039,"status":102,"phases":3533,"primaryCompletion":3041,"completion":3041,"start":3042,"enrollment":3043,"conditions":3534,"interventions":3535},[86],[3033],[3020,3046,3047,3048,3049,3050,3051,3052,3053],{"trials":3537,"activeCount":96},[],{"trials":3539,"activeCount":96},[],{"trials":3541,"activeCount":96},[],{"intervention":3049,"totalTrials":233,"cells":3543},{"EARLY_PHASE1":3544,"PHASE1":3546,"PHASE2":3548,"PHASE3":3554,"PHASE4":3556,"NA":3558},{"trials":3545,"activeCount":96},[],{"trials":3547,"activeCount":96},[],{"trials":3549,"activeCount":96},[3550],{"nctId":3038,"briefTitle":3039,"status":102,"phases":3551,"primaryCompletion":3041,"completion":3041,"start":3042,"enrollment":3043,"conditions":3552,"interventions":3553},[86],[3033],[3020,3046,3047,3048,3049,3050,3051,3052,3053],{"trials":3555,"activeCount":96},[],{"trials":3557,"activeCount":96},[],{"trials":3559,"activeCount":96},[],{"intervention":3050,"totalTrials":233,"cells":3561},{"EARLY_PHASE1":3562,"PHASE1":3564,"PHASE2":3566,"PHASE3":3572,"PHASE4":3574,"NA":3576},{"trials":3563,"activeCount":96},[],{"trials":3565,"activeCount":96},[],{"trials":3567,"activeCount":96},[3568],{"nctId":3038,"briefTitle":3039,"status":102,"phases":3569,"primaryCompletion":3041,"completion":3041,"start":3042,"enrollment":3043,"conditions":3570,"interventions":3571},[86],[3033],[3020,3046,3047,3048,3049,3050,3051,3052,3053],{"trials":3573,"activeCount":96},[],{"trials":3575,"activeCount":96},[],{"trials":3577,"activeCount":96},[],{"intervention":3051,"totalTrials":233,"cells":3579},{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3590,"PHASE4":3592,"NA":3594},{"trials":3581,"activeCount":96},[],{"trials":3583,"activeCount":96},[],{"trials":3585,"activeCount":96},[3586],{"nctId":3038,"briefTitle":3039,"status":102,"phases":3587,"primaryCompletion":3041,"completion":3041,"start":3042,"enrollment":3043,"conditions":3588,"interventions":3589},[86],[3033],[3020,3046,3047,3048,3049,3050,3051,3052,3053],{"trials":3591,"activeCount":96},[],{"trials":3593,"activeCount":96},[],{"trials":3595,"activeCount":96},[],{"intervention":3052,"totalTrials":233,"cells":3597},{"EARLY_PHASE1":3598,"PHASE1":3600,"PHASE2":3602,"PHASE3":3608,"PHASE4":3610,"NA":3612},{"trials":3599,"activeCount":96},[],{"trials":3601,"activeCount":96},[],{"trials":3603,"activeCount":96},[3604],{"nctId":3038,"briefTitle":3039,"status":102,"phases":3605,"primaryCompletion":3041,"completion":3041,"start":3042,"enrollment":3043,"conditions":3606,"interventions":3607},[86],[3033],[3020,3046,3047,3048,3049,3050,3051,3052,3053],{"trials":3609,"activeCount":96},[],{"trials":3611,"activeCount":96},[],{"trials":3613,"activeCount":96},[],{"intervention":3053,"totalTrials":233,"cells":3615},{"EARLY_PHASE1":3616,"PHASE1":3618,"PHASE2":3620,"PHASE3":3626,"PHASE4":3628,"NA":3630},{"trials":3617,"activeCount":96},[],{"trials":3619,"activeCount":96},[],{"trials":3621,"activeCount":96},[3622],{"nctId":3038,"briefTitle":3039,"status":102,"phases":3623,"primaryCompletion":3041,"completion":3041,"start":3042,"enrollment":3043,"conditions":3624,"interventions":3625},[86],[3033],[3020,3046,3047,3048,3049,3050,3051,3052,3053],{"trials":3627,"activeCount":96},[],{"trials":3629,"activeCount":96},[],{"trials":3631,"activeCount":96},[],{"intervention":1276,"totalTrials":233,"cells":3633},{"EARLY_PHASE1":3634,"PHASE1":3636,"PHASE2":3638,"PHASE3":3644,"PHASE4":3646,"NA":3648},{"trials":3635,"activeCount":96},[],{"trials":3637,"activeCount":96},[],{"trials":3639,"activeCount":96},[3640],{"nctId":1265,"briefTitle":1266,"status":102,"phases":3641,"primaryCompletion":1268,"completion":1269,"start":1270,"enrollment":1271,"conditions":3642,"interventions":3643},[86],[1273,1274],[1276,1277,1278,1279,1280,1210],{"trials":3645,"activeCount":96},[],{"trials":3647,"activeCount":96},[],{"trials":3649,"activeCount":96},[],{"intervention":3651,"totalTrials":233,"cells":3652},"ASP0739",{"EARLY_PHASE1":3653,"PHASE1":3655,"PHASE2":3657,"PHASE3":3670,"PHASE4":3672,"NA":3674},{"trials":3654,"activeCount":96},[],{"trials":3656,"activeCount":96},[],{"trials":3658,"activeCount":96},[3659],{"nctId":3660,"briefTitle":3661,"status":113,"phases":3662,"primaryCompletion":3663,"completion":3663,"start":3664,"enrollment":245,"conditions":3665,"interventions":3669},"NCT04939701","Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants",[85,86],"2023-06-01","2021-12-23",[3666,3667,3668,260],"Ovarian Cancer","NSCLC","ESCC",[3651],{"trials":3671,"activeCount":96},[],{"trials":3673,"activeCount":96},[],{"trials":3675,"activeCount":96},[],{"intervention":1975,"totalTrials":233,"cells":3677},{"EARLY_PHASE1":3678,"PHASE1":3680,"PHASE2":3682,"PHASE3":3688,"PHASE4":3690,"NA":3692},{"trials":3679,"activeCount":96},[],{"trials":3681,"activeCount":96},[],{"trials":3683,"activeCount":96},[3684],{"nctId":1966,"briefTitle":1967,"status":102,"phases":3685,"primaryCompletion":1969,"completion":1970,"start":1971,"enrollment":1972,"conditions":3686,"interventions":3687},[86],[24],[1975,1976,1977,1978,1979],{"trials":3689,"activeCount":96},[],{"trials":3691,"activeCount":96},[],{"trials":3693,"activeCount":96},[],{"intervention":1978,"totalTrials":233,"cells":3695},{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3700,"PHASE3":3706,"PHASE4":3708,"NA":3710},{"trials":3697,"activeCount":96},[],{"trials":3699,"activeCount":96},[],{"trials":3701,"activeCount":96},[3702],{"nctId":1966,"briefTitle":1967,"status":102,"phases":3703,"primaryCompletion":1969,"completion":1970,"start":1971,"enrollment":1972,"conditions":3704,"interventions":3705},[86],[24],[1975,1976,1977,1978,1979],{"trials":3707,"activeCount":96},[],{"trials":3709,"activeCount":96},[],{"trials":3711,"activeCount":96},[],{"intervention":3713,"totalTrials":233,"cells":3714},"ASP1650",{"EARLY_PHASE1":3715,"PHASE1":3717,"PHASE2":3719,"PHASE3":3732,"PHASE4":3734,"NA":3736},{"trials":3716,"activeCount":96},[],{"trials":3718,"activeCount":96},[],{"trials":3720,"activeCount":96},[3721],{"nctId":3722,"briefTitle":3723,"status":102,"phases":3724,"primaryCompletion":3725,"completion":3725,"start":3726,"enrollment":3727,"conditions":3728,"interventions":3731},"NCT03760081","A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors",[86],"2020-10-16","2019-03-19",19,[3729,3730],"Incurable Platinum Refractory Germ Cell Tumors","Tumors",[3713],{"trials":3733,"activeCount":96},[],{"trials":3735,"activeCount":96},[],{"trials":3737,"activeCount":96},[],{"intervention":3739,"totalTrials":233,"cells":3740},"ASP0598",{"EARLY_PHASE1":3741,"PHASE1":3743,"PHASE2":3745,"PHASE3":3756,"PHASE4":3758,"NA":3760},{"trials":3742,"activeCount":96},[],{"trials":3744,"activeCount":96},[],{"trials":3746,"activeCount":96},[3747],{"nctId":3748,"briefTitle":3749,"status":113,"phases":3750,"primaryCompletion":3751,"completion":3751,"start":3752,"enrollment":2703,"conditions":3753,"interventions":3755},"NCT04305184","A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)",[85,86],"2023-01-24","2020-09-10",[3754],"Chronic Tympanic Membrane Perforation",[3739],{"trials":3757,"activeCount":96},[],{"trials":3759,"activeCount":96},[],{"trials":3761,"activeCount":96},[],{"intervention":1225,"totalTrials":3727,"cells":3763},{"EARLY_PHASE1":3764,"PHASE1":3766,"PHASE2":3925,"PHASE3":3927,"PHASE4":3929,"NA":3931},{"trials":3765,"activeCount":96},[],{"trials":3767,"activeCount":96},[3768,3776,3785,3795,3803,3812,3816,3826,3836,3843,3847,3855,3863,3871,3882,3892,3900,3908,3917],{"nctId":3769,"briefTitle":3770,"status":102,"phases":3771,"primaryCompletion":3772,"completion":3772,"start":2714,"enrollment":2039,"conditions":3773,"interventions":3775},"NCT01657890","Study of the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects",[85],"2013-01",[21,15,3774],"Safety and Tolerability in Elderly",[2916],{"nctId":3777,"briefTitle":3778,"status":102,"phases":3779,"primaryCompletion":3780,"completion":3780,"start":2714,"enrollment":342,"conditions":3781,"interventions":3783},"NCT01635972","Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion",[85],"2012-07",[21,3782,15],"Pharmacokinetics of Bupropion",[1225,3784],"bupropion hydrochloride",{"nctId":3786,"briefTitle":3787,"status":102,"phases":3788,"primaryCompletion":3789,"completion":3789,"start":2680,"enrollment":342,"conditions":3790,"interventions":3793},"NCT01884636","A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate",[85],"2013-03",[21,3791,3792,18],"Pharmacokinetics of Methotrexate","Pharmacokinetics of 7-hydroxymethotrexate",[2916,3794],"methotrexate",{"nctId":3796,"briefTitle":3797,"status":102,"phases":3798,"primaryCompletion":2714,"completion":2714,"start":2911,"enrollment":342,"conditions":3799,"interventions":3801},"NCT01582425","Drug Interaction Study of Isavuconazole and Methadone",[85],[21,3800,15],"Pharmacokinetics of Methadone",[1225,3802],"Methadone",{"nctId":3804,"briefTitle":3805,"status":102,"phases":3806,"primaryCompletion":3807,"completion":3807,"start":3808,"enrollment":342,"conditions":3809,"interventions":3810},"NCT02128893","A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole",[85],"2014-02","2014-01",[21,18],[1225,3811],"Esomeprazole",{"nctId":1217,"briefTitle":1218,"status":102,"phases":3813,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":734,"conditions":3814,"interventions":3815},[85],[18,21,1223],[1225,1210],{"nctId":3817,"briefTitle":3818,"status":102,"phases":3819,"primaryCompletion":3820,"completion":3820,"start":3820,"enrollment":342,"conditions":3821,"interventions":3824},"NCT01651325","Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects",[85],"2012-05",[21,3822,3823],"Pharmacokinetics of Dextromethorphan","Healthy Adult Volunteers",[1225,3825],"dextromethorphan",{"nctId":3827,"briefTitle":3828,"status":102,"phases":3829,"primaryCompletion":3830,"completion":3830,"start":2714,"enrollment":3831,"conditions":3832,"interventions":3834},"NCT01660477","Drug-drug Interaction Study Between Lopinavir\u002FRitonavir and Isavuconazole",[85],"2012-10",68,[21,3833,15],"Pharmacokinetics of Lopinavir\u002FRitonavir",[1225,3835],"Lopinavir\u002Fritonavir",{"nctId":3837,"briefTitle":3838,"status":102,"phases":3839,"primaryCompletion":3820,"completion":3820,"start":1220,"enrollment":342,"conditions":3840,"interventions":3842},"NCT01582412","Drug Interaction Study of Isavuconazole and Digoxin",[85],[21,3841,15],"Pharmacokinetics of Digoxin",[1225,1339],{"nctId":2908,"briefTitle":2909,"status":102,"phases":3844,"primaryCompletion":2911,"completion":2911,"start":1220,"enrollment":342,"conditions":3845,"interventions":3846},[85],[18,21,2913,2914],[2916,2917],{"nctId":3848,"briefTitle":3849,"status":102,"phases":3850,"primaryCompletion":1358,"completion":1358,"start":1358,"enrollment":342,"conditions":3851,"interventions":3853},"NCT01635946","Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Atorvastatin",[85],[21,3852,15],"Pharmacokinetics of Atorvastatin",[1225,3854],"atorvastatin",{"nctId":3856,"briefTitle":3857,"status":102,"phases":3858,"primaryCompletion":2714,"completion":2714,"start":1220,"enrollment":3859,"conditions":3860,"interventions":3861},"NCT01565720","Study of the Effect of Repeat Doses of Isavuconazole on Cardiac Repolarization",[85],161,[21,15],[1225,3862],"Moxifloxacin",{"nctId":3864,"briefTitle":3865,"status":102,"phases":3866,"primaryCompletion":2714,"completion":2714,"start":2911,"enrollment":342,"conditions":3867,"interventions":3869},"NCT01597986","Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone",[85],[21,3868,15],"Pharmacokinetics of Ethinyl Estradiol and Norethindrone",[2916,3870],"Oral Contraceptive",{"nctId":3872,"briefTitle":3873,"status":102,"phases":3874,"primaryCompletion":3875,"completion":3875,"start":3876,"enrollment":3877,"conditions":3878,"interventions":3880},"NCT01809860","A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects",[85],"2012-01","2011-11",22,[18,21,3879],"Pharmacokinetics of Sirolimus",[2916,3881],"sirolimus",{"nctId":3883,"briefTitle":3884,"status":102,"phases":3885,"primaryCompletion":3807,"completion":3807,"start":3808,"enrollment":342,"conditions":3886,"interventions":3889},"NCT02128321","A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine",[85],[3887,3888,18],"Pharmacokinetics of Repaglinide","Pharmacokinetics of Caffeine",[1225,3890,3891],"Repaglinide","Caffeine",{"nctId":3893,"briefTitle":3894,"status":102,"phases":3895,"primaryCompletion":3820,"completion":3820,"start":3820,"enrollment":342,"conditions":3896,"interventions":3898},"NCT01657838","Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects",[85],[21,3897,3823],"Pharmacokinetics of Ketoconazole",[1225,3899],"Ketoconazole",{"nctId":3901,"briefTitle":3902,"status":102,"phases":3903,"primaryCompletion":3904,"completion":3904,"start":1220,"enrollment":3905,"conditions":3906,"interventions":3907},"NCT01555866","Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.",[85],"2013-04",49,[21,15,1526],[2916],{"nctId":3909,"briefTitle":3910,"status":102,"phases":3911,"primaryCompletion":3780,"completion":3780,"start":2714,"enrollment":19,"conditions":3912,"interventions":3915},"NCT01657825","Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects",[85],[21,3913,3914,15],"Pharmacokinetics of S- and R-warfarin","Pharmacodynamics of Warfarin",[1225,3916],"Warfarin",{"nctId":3918,"briefTitle":3919,"status":102,"phases":3920,"primaryCompletion":2680,"completion":2680,"start":2680,"enrollment":342,"conditions":3921,"interventions":3923},"NCT01884558","A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin",[85],[21,3922,18],"Pharmacokinetics of Metformin",[2916,3924],"metformin",{"trials":3926,"activeCount":96},[],{"trials":3928,"activeCount":96},[],{"trials":3930,"activeCount":96},[],{"trials":3932,"activeCount":96},[],{"intervention":3934,"totalTrials":489,"cells":3935},"ASP015K",{"EARLY_PHASE1":3936,"PHASE1":3938,"PHASE2":3973,"PHASE3":3975,"PHASE4":3977,"NA":3979},{"trials":3937,"activeCount":96},[],{"trials":3939,"activeCount":96},[3940,3948,3956,3965],{"nctId":3941,"briefTitle":3942,"status":102,"phases":3943,"primaryCompletion":3103,"completion":3103,"start":3944,"enrollment":245,"conditions":3945,"interventions":3947},"NCT02141425","A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects",[85],"2014-03",[15,3946],"Pharmacokinetics of ASP015K",[3934],{"nctId":3949,"briefTitle":3950,"status":102,"phases":3951,"primaryCompletion":3952,"completion":3952,"start":2702,"enrollment":342,"conditions":3953,"interventions":3954},"NCT01959399","Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin",[85],"2013-07",[18,3946],[3934,3955],"Rosuvastatin",{"nctId":3957,"briefTitle":3958,"status":102,"phases":3959,"primaryCompletion":3960,"completion":3960,"start":3961,"enrollment":342,"conditions":3962,"interventions":3963},"NCT02111317","A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects",[85],"2013-11","2013-10",[18,3946],[3934,3964],"verapamil",{"nctId":3966,"briefTitle":3967,"status":102,"phases":3968,"primaryCompletion":2701,"completion":2701,"start":2702,"enrollment":2703,"conditions":3969,"interventions":3972},"NCT01929577","A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects",[85],[3970,18,3946,3971],"Bioavailability of ASP015K","Food Effect of ASP015K",[3934],{"trials":3974,"activeCount":96},[],{"trials":3976,"activeCount":96},[],{"trials":3978,"activeCount":96},[],{"trials":3980,"activeCount":96},[],{"intervention":3982,"totalTrials":180,"cells":3983},"Bocidelpar",{"EARLY_PHASE1":3984,"PHASE1":3986,"PHASE2":4015,"PHASE3":4017,"PHASE4":4019,"NA":4021},{"trials":3985,"activeCount":96},[],{"trials":3987,"activeCount":96},[3988,3997,4006],{"nctId":3989,"briefTitle":3990,"status":113,"phases":3991,"primaryCompletion":3992,"completion":3992,"start":1231,"enrollment":3993,"conditions":3994,"interventions":3996},"NCT04855201","A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction",[85],"2022-12-16",31,[3995],"Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction",[3982],{"nctId":3998,"briefTitle":3999,"status":102,"phases":4000,"primaryCompletion":4001,"completion":4002,"start":4003,"enrollment":1972,"conditions":4004,"interventions":4005},"NCT05117294","A Study of ASP0367 in People With Kidneys That do Not Work Well and in Healthy People",[85],"2022-11-13","2022-11-22","2021-12-21",[923,15],[3982],{"nctId":4007,"briefTitle":4008,"status":102,"phases":4009,"primaryCompletion":4010,"completion":4011,"start":4012,"enrollment":423,"conditions":4013,"interventions":4014},"NCT04942964","A Study to Evaluate ASP0367 in Participants With Mild\u002FModerate Hepatic Impairment Compared to Participants With Normal Hepatic Function",[85],"2022-01-11","2022-01-20","2021-09-13",[934,15],[3982],{"trials":4016,"activeCount":96},[],{"trials":4018,"activeCount":96},[],{"trials":4020,"activeCount":96},[],{"trials":4022,"activeCount":96},[],{"intervention":3079,"totalTrials":180,"cells":4024},{"EARLY_PHASE1":4025,"PHASE1":4027,"PHASE2":4050,"PHASE3":4052,"PHASE4":4054,"NA":4056},{"trials":4026,"activeCount":96},[],{"trials":4028,"activeCount":96},[4029,4038,4042],{"nctId":4030,"briefTitle":4031,"status":1355,"phases":4032,"primaryCompletion":4033,"completion":4033,"start":4033,"enrollment":96,"conditions":4034,"interventions":4036},"NCT02674555","A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors",[85],"2016-11-15",[4035,260],"Epidermal Growth Factor Receptor (EGFR) Mutations",[4037,3079],"radio-labeled naquotinib",{"nctId":3068,"briefTitle":3069,"status":102,"phases":4039,"primaryCompletion":3071,"completion":3072,"start":3073,"enrollment":3074,"conditions":4040,"interventions":4041},[85],[3076,3077],[3079,3061],{"nctId":4043,"briefTitle":4044,"status":113,"phases":4045,"primaryCompletion":4046,"completion":1546,"start":4047,"enrollment":180,"conditions":4048,"interventions":4049},"NCT03082300","A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations",[85],"2017-05-12","2017-03-24",[765,4035],[3079],{"trials":4051,"activeCount":96},[],{"trials":4053,"activeCount":96},[],{"trials":4055,"activeCount":96},[],{"trials":4057,"activeCount":96},[],{"intervention":4059,"totalTrials":180,"cells":4060},"ASP2408",{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4090,"PHASE3":4092,"PHASE4":4094,"NA":4096},{"trials":4062,"activeCount":96},[],{"trials":4064,"activeCount":96},[4065,4074,4082],{"nctId":4066,"briefTitle":4067,"status":102,"phases":4068,"primaryCompletion":3820,"completion":3820,"start":4069,"enrollment":4070,"conditions":4071,"interventions":4073},"NCT02125435","A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects",[85],"2011-01",65,[18,4072],"Pharmacokinetics of ASP2408",[4059],{"nctId":4075,"briefTitle":4076,"status":102,"phases":4077,"primaryCompletion":4078,"completion":4078,"start":2714,"enrollment":342,"conditions":4079,"interventions":4081},"NCT02052375","A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate",[85],"2013-12",[4080,4072],"Rheumatoid Arthritis",[4059],{"nctId":4083,"briefTitle":4084,"status":102,"phases":4085,"primaryCompletion":2714,"completion":2714,"start":4086,"enrollment":4087,"conditions":4088,"interventions":4089},"NCT02150070","A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections",[85],"2011-08",32,[4072,18],[4059],{"trials":4091,"activeCount":96},[],{"trials":4093,"activeCount":96},[],{"trials":4095,"activeCount":96},[],{"trials":4097,"activeCount":96},[],{"intervention":3794,"totalTrials":219,"cells":4099},{"EARLY_PHASE1":4100,"PHASE1":4102,"PHASE2":4117,"PHASE3":4119,"PHASE4":4121,"NA":4123},{"trials":4101,"activeCount":96},[],{"trials":4103,"activeCount":96},[4104,4108],{"nctId":3786,"briefTitle":3787,"status":102,"phases":4105,"primaryCompletion":3789,"completion":3789,"start":2680,"enrollment":342,"conditions":4106,"interventions":4107},[85],[21,3791,3792,18],[2916,3794],{"nctId":4109,"briefTitle":4110,"status":102,"phases":4111,"primaryCompletion":4112,"completion":4112,"start":4113,"enrollment":25,"conditions":4114,"interventions":4115},"NCT02867306","A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis",[85],"2016-08-30","2016-07-25",[4080],[4116,3794],"ASP1707",{"trials":4118,"activeCount":96},[],{"trials":4120,"activeCount":96},[],{"trials":4122,"activeCount":96},[],{"trials":4124,"activeCount":96},[],{"intervention":3955,"totalTrials":219,"cells":4126},{"EARLY_PHASE1":4127,"PHASE1":4129,"PHASE2":4139,"PHASE3":4141,"PHASE4":4143,"NA":4145},{"trials":4128,"activeCount":96},[],{"trials":4130,"activeCount":96},[4131,4135],{"nctId":3949,"briefTitle":3950,"status":102,"phases":4132,"primaryCompletion":3952,"completion":3952,"start":2702,"enrollment":342,"conditions":4133,"interventions":4134},[85],[18,3946],[3934,3955],{"nctId":1331,"briefTitle":1332,"status":102,"phases":4136,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":342,"conditions":4137,"interventions":4138},[85],[27],[1240,1338,1339,1340],{"trials":4140,"activeCount":96},[],{"trials":4142,"activeCount":96},[],{"trials":4144,"activeCount":96},[],{"trials":4146,"activeCount":96},[],{"intervention":1339,"totalTrials":219,"cells":4148},{"EARLY_PHASE1":4149,"PHASE1":4151,"PHASE2":4161,"PHASE3":4163,"PHASE4":4165,"NA":4167},{"trials":4150,"activeCount":96},[],{"trials":4152,"activeCount":96},[4153,4157],{"nctId":3837,"briefTitle":3838,"status":102,"phases":4154,"primaryCompletion":3820,"completion":3820,"start":1220,"enrollment":342,"conditions":4155,"interventions":4156},[85],[21,3841,15],[1225,1339],{"nctId":1331,"briefTitle":1332,"status":102,"phases":4158,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":342,"conditions":4159,"interventions":4160},[85],[27],[1240,1338,1339,1340],{"trials":4162,"activeCount":96},[],{"trials":4164,"activeCount":96},[],{"trials":4166,"activeCount":96},[],{"trials":4168,"activeCount":96},[],{"intervention":4170,"totalTrials":219,"cells":4171},"AGS67E",{"EARLY_PHASE1":4172,"PHASE1":4174,"PHASE2":4196,"PHASE3":4198,"PHASE4":4200,"NA":4202},{"trials":4173,"activeCount":96},[],{"trials":4175,"activeCount":96},[4176,4185],{"nctId":4177,"briefTitle":4178,"status":113,"phases":4179,"primaryCompletion":4180,"completion":4181,"start":4182,"enrollment":2872,"conditions":4183,"interventions":4184},"NCT02610062","A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)",[85],"2017-09-22","2017-11-21","2016-03-29",[34],[4170],{"nctId":4186,"briefTitle":4187,"status":102,"phases":4188,"primaryCompletion":4189,"completion":4189,"start":4190,"enrollment":4191,"conditions":4192,"interventions":4195},"NCT02175433","A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies",[85],"2019-10-29","2014-10-14",71,[4193,4194],"Relapsed Lymphoid Malignancy","Refractory Lymphoid Malignancy",[4170],{"trials":4197,"activeCount":96},[],{"trials":4199,"activeCount":96},[],{"trials":4201,"activeCount":96},[],{"trials":4203,"activeCount":96},[],{"intervention":4205,"totalTrials":233,"cells":4206},"ASP1617",{"EARLY_PHASE1":4207,"PHASE1":4209,"PHASE2":4219,"PHASE3":4221,"PHASE4":4223,"NA":4225},{"trials":4208,"activeCount":96},[],{"trials":4210,"activeCount":96},[4211],{"nctId":4212,"briefTitle":4213,"status":102,"phases":4214,"primaryCompletion":4215,"completion":4215,"start":2982,"enrollment":4216,"conditions":4217,"interventions":4218},"NCT04077879","Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect",[85],"2021-06-12",97,[15],[4205],{"trials":4220,"activeCount":96},[],{"trials":4222,"activeCount":96},[],{"trials":4224,"activeCount":96},[],{"trials":4226,"activeCount":96},[],{"intervention":4228,"totalTrials":233,"cells":4229},"ASP8731",{"EARLY_PHASE1":4230,"PHASE1":4232,"PHASE2":4243,"PHASE3":4245,"PHASE4":4247,"NA":4249},{"trials":4231,"activeCount":96},[],{"trials":4233,"activeCount":96},[4234],{"nctId":4235,"briefTitle":4236,"status":113,"phases":4237,"primaryCompletion":4238,"completion":4238,"start":4239,"enrollment":2703,"conditions":4240,"interventions":4242},"NCT05167526","A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults",[85],"2022-11-10","2022-03-07",[4241],"Healthy Participants",[4228],{"trials":4244,"activeCount":96},[],{"trials":4246,"activeCount":96},[],{"trials":4248,"activeCount":96},[],{"trials":4250,"activeCount":96},[],{"intervention":4252,"totalTrials":233,"cells":4253},"ASP2713",{"EARLY_PHASE1":4254,"PHASE1":4256,"PHASE2":4266,"PHASE3":4268,"PHASE4":4270,"NA":4272},{"trials":4255,"activeCount":96},[],{"trials":4257,"activeCount":96},[4258],{"nctId":4259,"briefTitle":4260,"status":1355,"phases":4261,"primaryCompletion":4262,"completion":4262,"start":4263,"enrollment":96,"conditions":4264,"interventions":4265},"NCT04017208","A Study to Assess ASP2713 in Healthy Subjects",[85],"2020-08","2019-07",[15],[4252],{"trials":4267,"activeCount":96},[],{"trials":4269,"activeCount":96},[],{"trials":4271,"activeCount":96},[],{"trials":4273,"activeCount":96},[],{"intervention":4275,"totalTrials":233,"cells":4276},"isavuconazonium sulfate - intravenous",{"EARLY_PHASE1":4277,"PHASE1":4279,"PHASE2":4290,"PHASE3":4292,"PHASE4":4294,"NA":4296},{"trials":4278,"activeCount":96},[],{"trials":4280,"activeCount":96},[4281],{"nctId":4282,"briefTitle":4283,"status":102,"phases":4284,"primaryCompletion":4285,"completion":4285,"start":1383,"enrollment":3905,"conditions":4286,"interventions":4288},"NCT03241550","A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients",[85],"2019-07-05",[4287],"Hematological Malignancy",[4275,4289],"isavuconazonium sulfate -",{"trials":4291,"activeCount":96},[],{"trials":4293,"activeCount":96},[],{"trials":4295,"activeCount":96},[],{"trials":4297,"activeCount":96},[],{"intervention":4289,"totalTrials":233,"cells":4299},{"EARLY_PHASE1":4300,"PHASE1":4302,"PHASE2":4308,"PHASE3":4310,"PHASE4":4312,"NA":4314},{"trials":4301,"activeCount":96},[],{"trials":4303,"activeCount":96},[4304],{"nctId":4282,"briefTitle":4283,"status":102,"phases":4305,"primaryCompletion":4285,"completion":4285,"start":1383,"enrollment":3905,"conditions":4306,"interventions":4307},[85],[4287],[4275,4289],{"trials":4309,"activeCount":96},[],{"trials":4311,"activeCount":96},[],{"trials":4313,"activeCount":96},[],{"trials":4315,"activeCount":96},[],{"intervention":739,"totalTrials":233,"cells":4317},{"EARLY_PHASE1":4318,"PHASE1":4320,"PHASE2":4326,"PHASE3":4328,"PHASE4":4330,"NA":4332},{"trials":4319,"activeCount":96},[],{"trials":4321,"activeCount":96},[4322],{"nctId":729,"briefTitle":730,"status":113,"phases":4323,"primaryCompletion":732,"completion":732,"start":733,"enrollment":734,"conditions":4324,"interventions":4325},[85],[736,737],[739,195,197],{"trials":4327,"activeCount":96},[],{"trials":4329,"activeCount":96},[],{"trials":4331,"activeCount":96},[],{"trials":4333,"activeCount":96},[],{"intervention":4335,"totalTrials":233,"cells":4336},"ASP2409",{"EARLY_PHASE1":4337,"PHASE1":4339,"PHASE2":4349,"PHASE3":4351,"PHASE4":4353,"NA":4355},{"trials":4338,"activeCount":96},[],{"trials":4340,"activeCount":96},[4341],{"nctId":4342,"briefTitle":4343,"status":102,"phases":4344,"primaryCompletion":3103,"completion":3103,"start":2911,"enrollment":4345,"conditions":4346,"interventions":4348},"NCT02171143","A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate",[85],58,[4080,4347],"Pharmacokinetics of ASP2409",[4335],{"trials":4350,"activeCount":96},[],{"trials":4352,"activeCount":96},[],{"trials":4354,"activeCount":96},[],{"trials":4356,"activeCount":96},[],{"intervention":4358,"totalTrials":233,"cells":4359},"ASP5094",{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4373,"PHASE3":4375,"PHASE4":4377,"NA":4379},{"trials":4361,"activeCount":96},[],{"trials":4363,"activeCount":96},[4364],{"nctId":4365,"briefTitle":4366,"status":102,"phases":4367,"primaryCompletion":4368,"completion":4368,"start":4369,"enrollment":2681,"conditions":4370,"interventions":4372},"NCT02698657","A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate",[85],"2017-09-07","2016-02-23",[4371],"Rheumatoid Arthritis (RA)",[4358],{"trials":4374,"activeCount":96},[],{"trials":4376,"activeCount":96},[],{"trials":4378,"activeCount":96},[],{"trials":4380,"activeCount":96},[],{"intervention":263,"totalTrials":233,"cells":4382},{"EARLY_PHASE1":4383,"PHASE1":4385,"PHASE2":4391,"PHASE3":4393,"PHASE4":4395,"NA":4397},{"trials":4384,"activeCount":96},[],{"trials":4386,"activeCount":96},[4387],{"nctId":252,"briefTitle":253,"status":102,"phases":4388,"primaryCompletion":255,"completion":255,"start":256,"enrollment":257,"conditions":4389,"interventions":4390},[85],[259,260,261],[263,139],{"trials":4392,"activeCount":96},[],{"trials":4394,"activeCount":96},[],{"trials":4396,"activeCount":96},[],{"trials":4398,"activeCount":96},[],{"intervention":4400,"totalTrials":233,"cells":4401},"ASP4058",{"EARLY_PHASE1":4402,"PHASE1":4404,"PHASE2":4416,"PHASE3":4418,"PHASE4":4420,"NA":4422},{"trials":4403,"activeCount":96},[],{"trials":4405,"activeCount":96},[4406],{"nctId":4407,"briefTitle":4408,"status":102,"phases":4409,"primaryCompletion":3780,"completion":3780,"start":4410,"enrollment":4411,"conditions":4412,"interventions":4415},"NCT01998646","A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses",[85],"2010-08",130,[4413,18,4414],"Pharmacokinetics of ASP4058","Food Effect of ASP4058",[4400],{"trials":4417,"activeCount":96},[],{"trials":4419,"activeCount":96},[],{"trials":4421,"activeCount":96},[],{"trials":4423,"activeCount":96},[],{"intervention":273,"totalTrials":233,"cells":4425},{"EARLY_PHASE1":4426,"PHASE1":4428,"PHASE2":4434,"PHASE3":4436,"PHASE4":4438,"NA":4440},{"trials":4427,"activeCount":96},[],{"trials":4429,"activeCount":96},[4430],{"nctId":265,"briefTitle":266,"status":113,"phases":4431,"primaryCompletion":268,"completion":268,"start":269,"enrollment":270,"conditions":4432,"interventions":4433},[85],[24],[273,161],{"trials":4435,"activeCount":96},[],{"trials":4437,"activeCount":96},[],{"trials":4439,"activeCount":96},[],{"trials":4441,"activeCount":96},[],{"intervention":4443,"totalTrials":233,"cells":4444},"ASP0892",{"EARLY_PHASE1":4445,"PHASE1":4447,"PHASE2":4458,"PHASE3":4460,"PHASE4":4462,"NA":4464},{"trials":4446,"activeCount":96},[],{"trials":4448,"activeCount":96},[4449],{"nctId":4450,"briefTitle":4451,"status":102,"phases":4452,"primaryCompletion":4453,"completion":4453,"start":4454,"enrollment":19,"conditions":4455,"interventions":4457},"NCT03755713","A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine",[85],"2021-10-11","2019-03-12",[4456],"Peanut Allergy",[4443],{"trials":4459,"activeCount":96},[],{"trials":4461,"activeCount":96},[],{"trials":4463,"activeCount":96},[],{"trials":4465,"activeCount":96},[],{"intervention":1516,"totalTrials":233,"cells":4467},{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4476,"PHASE3":4478,"PHASE4":4480,"NA":4482},{"trials":4469,"activeCount":96},[],{"trials":4471,"activeCount":96},[4472],{"nctId":1507,"briefTitle":1508,"status":102,"phases":4473,"primaryCompletion":1510,"completion":1510,"start":1511,"enrollment":1512,"conditions":4474,"interventions":4475},[85],[34],[1515,1516,1517,1518],{"trials":4477,"activeCount":96},[],{"trials":4479,"activeCount":96},[],{"trials":4481,"activeCount":96},[],{"trials":4483,"activeCount":96},[],{"intervention":1518,"totalTrials":233,"cells":4485},{"EARLY_PHASE1":4486,"PHASE1":4488,"PHASE2":4494,"PHASE3":4496,"PHASE4":4498,"NA":4500},{"trials":4487,"activeCount":96},[],{"trials":4489,"activeCount":96},[4490],{"nctId":1507,"briefTitle":1508,"status":102,"phases":4491,"primaryCompletion":1510,"completion":1510,"start":1511,"enrollment":1512,"conditions":4492,"interventions":4493},[85],[34],[1515,1516,1517,1518],{"trials":4495,"activeCount":96},[],{"trials":4497,"activeCount":96},[],{"trials":4499,"activeCount":96},[],{"trials":4501,"activeCount":96},[],{"intervention":4503,"totalTrials":233,"cells":4504},"14C-labeled prodrug isavuconazonium sulfate",{"EARLY_PHASE1":4505,"PHASE1":4507,"PHASE2":4517,"PHASE3":4519,"PHASE4":4521,"NA":4523},{"trials":4506,"activeCount":96},[],{"trials":4508,"activeCount":96},[4509],{"nctId":4510,"briefTitle":4511,"status":102,"phases":4512,"primaryCompletion":4513,"completion":4513,"start":3830,"enrollment":495,"conditions":4514,"interventions":4516},"NCT01813461","Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects",[85],"2012-11",[4515,18],"Pharmacokinetics of 14C-labeled Isavuconazole",[4503],{"trials":4518,"activeCount":96},[],{"trials":4520,"activeCount":96},[],{"trials":4522,"activeCount":96},[],{"trials":4524,"activeCount":96},[],{"intervention":1540,"totalTrials":233,"cells":4526},{"EARLY_PHASE1":4527,"PHASE1":4529,"PHASE2":4535,"PHASE3":4537,"PHASE4":4539,"NA":4541},{"trials":4528,"activeCount":96},[],{"trials":4530,"activeCount":96},[4531],{"nctId":1531,"briefTitle":1532,"status":102,"phases":4532,"primaryCompletion":1534,"completion":1535,"start":1536,"enrollment":1537,"conditions":4533,"interventions":4534},[85],[814],[1499,1540],{"trials":4536,"activeCount":96},[],{"trials":4538,"activeCount":96},[],{"trials":4540,"activeCount":96},[],{"trials":4542,"activeCount":96},[],{"intervention":4544,"totalTrials":233,"cells":4545},"ASP1235",{"EARLY_PHASE1":4546,"PHASE1":4548,"PHASE2":4558,"PHASE3":4560,"PHASE4":4562,"NA":4564},{"trials":4547,"activeCount":96},[],{"trials":4549,"activeCount":96},[4550],{"nctId":4551,"briefTitle":4552,"status":113,"phases":4553,"primaryCompletion":4554,"completion":4554,"start":4555,"enrollment":2983,"conditions":4556,"interventions":4557},"NCT02864290","A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)",[85],"2020-09-03","2016-11-10",[34],[4544],{"trials":4559,"activeCount":96},[],{"trials":4561,"activeCount":96},[],{"trials":4563,"activeCount":96},[],{"trials":4565,"activeCount":96},[],{"intervention":3784,"totalTrials":233,"cells":4567},{"EARLY_PHASE1":4568,"PHASE1":4570,"PHASE2":4576,"PHASE3":4578,"PHASE4":4580,"NA":4582},{"trials":4569,"activeCount":96},[],{"trials":4571,"activeCount":96},[4572],{"nctId":3777,"briefTitle":3778,"status":102,"phases":4573,"primaryCompletion":3780,"completion":3780,"start":2714,"enrollment":342,"conditions":4574,"interventions":4575},[85],[21,3782,15],[1225,3784],{"trials":4577,"activeCount":96},[],{"trials":4579,"activeCount":96},[],{"trials":4581,"activeCount":96},[],{"trials":4583,"activeCount":96},[],{"intervention":4585,"totalTrials":233,"cells":4586},"Isavuconazonium sulfate IV",{"EARLY_PHASE1":4587,"PHASE1":4589,"PHASE2":4600,"PHASE3":4602,"PHASE4":4604,"NA":4606},{"trials":4588,"activeCount":96},[],{"trials":4590,"activeCount":96},[4591],{"nctId":4592,"briefTitle":4593,"status":102,"phases":4594,"primaryCompletion":4595,"completion":4595,"start":4596,"enrollment":1500,"conditions":4597,"interventions":4598},"NCT04096157","A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants",[85],"2020-01-16","2019-09-24",[18],[4585,4599],"Isavuconazonium sulfate",{"trials":4601,"activeCount":96},[],{"trials":4603,"activeCount":96},[],{"trials":4605,"activeCount":96},[],{"trials":4607,"activeCount":96},[],{"intervention":4609,"totalTrials":233,"cells":4610},"ASP2074",{"EARLY_PHASE1":4611,"PHASE1":4613,"PHASE2":4622,"PHASE3":4624,"PHASE4":4626,"NA":4628},{"trials":4612,"activeCount":96},[],{"trials":4614,"activeCount":96},[4615],{"nctId":4616,"briefTitle":4617,"status":113,"phases":4618,"primaryCompletion":4619,"completion":4619,"start":2892,"enrollment":2872,"conditions":4620,"interventions":4621},"NCT05646797","A Study of ASP2074 in Adults With Solid Tumors",[85],"2024-10-17",[24],[4609],{"trials":4623,"activeCount":96},[],{"trials":4625,"activeCount":96},[],{"trials":4627,"activeCount":96},[],{"trials":4629,"activeCount":96},[],{"intervention":3802,"totalTrials":233,"cells":4631},{"EARLY_PHASE1":4632,"PHASE1":4634,"PHASE2":4640,"PHASE3":4642,"PHASE4":4644,"NA":4646},{"trials":4633,"activeCount":96},[],{"trials":4635,"activeCount":96},[4636],{"nctId":3796,"briefTitle":3797,"status":102,"phases":4637,"primaryCompletion":2714,"completion":2714,"start":2911,"enrollment":342,"conditions":4638,"interventions":4639},[85],[21,3800,15],[1225,3802],{"trials":4641,"activeCount":96},[],{"trials":4643,"activeCount":96},[],{"trials":4645,"activeCount":96},[],{"trials":4647,"activeCount":96},[],{"intervention":4037,"totalTrials":233,"cells":4649},{"EARLY_PHASE1":4650,"PHASE1":4652,"PHASE2":4658,"PHASE3":4660,"PHASE4":4662,"NA":4664},{"trials":4651,"activeCount":96},[],{"trials":4653,"activeCount":96},[4654],{"nctId":4030,"briefTitle":4031,"status":1355,"phases":4655,"primaryCompletion":4033,"completion":4033,"start":4033,"enrollment":96,"conditions":4656,"interventions":4657},[85],[4035,260],[4037,3079],{"trials":4659,"activeCount":96},[],{"trials":4661,"activeCount":96},[],{"trials":4663,"activeCount":96},[],{"trials":4665,"activeCount":96},[],{"intervention":3811,"totalTrials":233,"cells":4667},{"EARLY_PHASE1":4668,"PHASE1":4670,"PHASE2":4676,"PHASE3":4678,"PHASE4":4680,"NA":4682},{"trials":4669,"activeCount":96},[],{"trials":4671,"activeCount":96},[4672],{"nctId":3804,"briefTitle":3805,"status":102,"phases":4673,"primaryCompletion":3807,"completion":3807,"start":3808,"enrollment":342,"conditions":4674,"interventions":4675},[85],[21,18],[1225,3811],{"trials":4677,"activeCount":96},[],{"trials":4679,"activeCount":96},[],{"trials":4681,"activeCount":96},[],{"trials":4683,"activeCount":96},[],{"intervention":4685,"totalTrials":233,"cells":4686},"ASP2802",{"EARLY_PHASE1":4687,"PHASE1":4689,"PHASE2":4701,"PHASE3":4703,"PHASE4":4705,"NA":4707},{"trials":4688,"activeCount":96},[],{"trials":4690,"activeCount":96},[4691],{"nctId":4692,"briefTitle":4693,"status":113,"phases":4694,"primaryCompletion":4695,"completion":4695,"start":4696,"enrollment":233,"conditions":4697,"interventions":4699},"NCT06248086","A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas",[85],"2024-12-01","2024-09-06",[4698],"B-cell Lymphoma",[4685,4700],"MA-20",{"trials":4702,"activeCount":96},[],{"trials":4704,"activeCount":96},[],{"trials":4706,"activeCount":96},[],{"trials":4708,"activeCount":96},[],{"intervention":4700,"totalTrials":233,"cells":4710},{"EARLY_PHASE1":4711,"PHASE1":4713,"PHASE2":4719,"PHASE3":4721,"PHASE4":4723,"NA":4725},{"trials":4712,"activeCount":96},[],{"trials":4714,"activeCount":96},[4715],{"nctId":4692,"briefTitle":4693,"status":113,"phases":4716,"primaryCompletion":4695,"completion":4695,"start":4696,"enrollment":233,"conditions":4717,"interventions":4718},[85],[4698],[4685,4700],{"trials":4720,"activeCount":96},[],{"trials":4722,"activeCount":96},[],{"trials":4724,"activeCount":96},[],{"trials":4726,"activeCount":96},[],{"intervention":4728,"totalTrials":233,"cells":4729},"ASP1893",{"EARLY_PHASE1":4730,"PHASE1":4732,"PHASE2":4747,"PHASE3":4749,"PHASE4":4751,"NA":4753},{"trials":4731,"activeCount":96},[],{"trials":4733,"activeCount":96},[4734],{"nctId":4735,"briefTitle":4736,"status":1355,"phases":4737,"primaryCompletion":4738,"completion":4738,"start":4739,"enrollment":96,"conditions":4740,"interventions":4746},"NCT06681870","A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors",[85],"2029-03-31","2024-12-31",[4741,3666,4742,4743,4744,4745],"CLDN6-positive Solid Tumor","Endometrial Cancer","Non-small Cell Lung Cancer","Testicular Cancer","Metastatic or Locally Advanced Solid Tumor Cancer",[4728],{"trials":4748,"activeCount":96},[],{"trials":4750,"activeCount":96},[],{"trials":4752,"activeCount":96},[],{"trials":4754,"activeCount":96},[],{"intervention":3825,"totalTrials":233,"cells":4756},{"EARLY_PHASE1":4757,"PHASE1":4759,"PHASE2":4765,"PHASE3":4767,"PHASE4":4769,"NA":4771},{"trials":4758,"activeCount":96},[],{"trials":4760,"activeCount":96},[4761],{"nctId":3817,"briefTitle":3818,"status":102,"phases":4762,"primaryCompletion":3820,"completion":3820,"start":3820,"enrollment":342,"conditions":4763,"interventions":4764},[85],[21,3822,3823],[1225,3825],{"trials":4766,"activeCount":96},[],{"trials":4768,"activeCount":96},[],{"trials":4770,"activeCount":96},[],{"trials":4772,"activeCount":96},[],{"intervention":283,"totalTrials":233,"cells":4774},{"EARLY_PHASE1":4775,"PHASE1":4777,"PHASE2":4783,"PHASE3":4785,"PHASE4":4787,"NA":4789},{"trials":4776,"activeCount":96},[],{"trials":4778,"activeCount":96},[4779],{"nctId":275,"briefTitle":276,"status":102,"phases":4780,"primaryCompletion":278,"completion":278,"start":279,"enrollment":280,"conditions":4781,"interventions":4782},[85],[24],[283,284,161],{"trials":4784,"activeCount":96},[],{"trials":4786,"activeCount":96},[],{"trials":4788,"activeCount":96},[],{"trials":4790,"activeCount":96},[],{"intervention":4792,"totalTrials":233,"cells":4793},"ASP2215",{"EARLY_PHASE1":4794,"PHASE1":4796,"PHASE2":4807,"PHASE3":4809,"PHASE4":4811,"NA":4813},{"trials":4795,"activeCount":96},[],{"trials":4797,"activeCount":96},[4798],{"nctId":4799,"briefTitle":4800,"status":102,"phases":4801,"primaryCompletion":4802,"completion":4802,"start":4803,"enrollment":342,"conditions":4804,"interventions":4806},"NCT02571816","A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215",[85],"2016-03-05","2015-10-23",[934,4805],"Healthy",[4792],{"trials":4808,"activeCount":96},[],{"trials":4810,"activeCount":96},[],{"trials":4812,"activeCount":96},[],{"trials":4814,"activeCount":96},[],{"intervention":3835,"totalTrials":233,"cells":4816},{"EARLY_PHASE1":4817,"PHASE1":4819,"PHASE2":4825,"PHASE3":4827,"PHASE4":4829,"NA":4831},{"trials":4818,"activeCount":96},[],{"trials":4820,"activeCount":96},[4821],{"nctId":3827,"briefTitle":3828,"status":102,"phases":4822,"primaryCompletion":3830,"completion":3830,"start":2714,"enrollment":3831,"conditions":4823,"interventions":4824},[85],[21,3833,15],[1225,3835],{"trials":4826,"activeCount":96},[],{"trials":4828,"activeCount":96},[],{"trials":4830,"activeCount":96},[],{"trials":4832,"activeCount":96},[],{"intervention":4834,"totalTrials":233,"cells":4835},"Pyridinylmethyl-14C-labeled isavuconazonium sulfate",{"EARLY_PHASE1":4836,"PHASE1":4838,"PHASE2":4847,"PHASE3":4849,"PHASE4":4851,"NA":4853},{"trials":4837,"activeCount":96},[],{"trials":4839,"activeCount":96},[4840],{"nctId":4841,"briefTitle":4842,"status":102,"phases":4843,"primaryCompletion":3904,"completion":3904,"start":3904,"enrollment":35,"conditions":4844,"interventions":4846},"NCT02059590","A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects",[85],[4845,18],"Pharmacokinetics of 14C-labeled Isavuconazonium Sulfate",[4834],{"trials":4848,"activeCount":96},[],{"trials":4850,"activeCount":96},[],{"trials":4852,"activeCount":96},[],{"trials":4854,"activeCount":96},[],{"intervention":2863,"totalTrials":233,"cells":4856},{"EARLY_PHASE1":4857,"PHASE1":4859,"PHASE2":4865,"PHASE3":4867,"PHASE4":4869,"NA":4871},{"trials":4858,"activeCount":96},[],{"trials":4860,"activeCount":96},[4861],{"nctId":2857,"briefTitle":2858,"status":102,"phases":4862,"primaryCompletion":2860,"completion":2860,"start":1535,"enrollment":19,"conditions":4863,"interventions":4864},[85],[15],[2850,2863,2864,2865],{"trials":4866,"activeCount":96},[],{"trials":4868,"activeCount":96},[],{"trials":4870,"activeCount":96},[],{"trials":4872,"activeCount":96},[],{"intervention":2864,"totalTrials":233,"cells":4874},{"EARLY_PHASE1":4875,"PHASE1":4877,"PHASE2":4883,"PHASE3":4885,"PHASE4":4887,"NA":4889},{"trials":4876,"activeCount":96},[],{"trials":4878,"activeCount":96},[4879],{"nctId":2857,"briefTitle":2858,"status":102,"phases":4880,"primaryCompletion":2860,"completion":2860,"start":1535,"enrollment":19,"conditions":4881,"interventions":4882},[85],[15],[2850,2863,2864,2865],{"trials":4884,"activeCount":96},[],{"trials":4886,"activeCount":96},[],{"trials":4888,"activeCount":96},[],{"trials":4890,"activeCount":96},[],{"intervention":2865,"totalTrials":233,"cells":4892},{"EARLY_PHASE1":4893,"PHASE1":4895,"PHASE2":4901,"PHASE3":4903,"PHASE4":4905,"NA":4907},{"trials":4894,"activeCount":96},[],{"trials":4896,"activeCount":96},[4897],{"nctId":2857,"briefTitle":2858,"status":102,"phases":4898,"primaryCompletion":2860,"completion":2860,"start":1535,"enrollment":19,"conditions":4899,"interventions":4900},[85],[15],[2850,2863,2864,2865],{"trials":4902,"activeCount":96},[],{"trials":4904,"activeCount":96},[],{"trials":4906,"activeCount":96},[],{"trials":4908,"activeCount":96},[],{"intervention":3854,"totalTrials":233,"cells":4910},{"EARLY_PHASE1":4911,"PHASE1":4913,"PHASE2":4919,"PHASE3":4921,"PHASE4":4923,"NA":4925},{"trials":4912,"activeCount":96},[],{"trials":4914,"activeCount":96},[4915],{"nctId":3848,"briefTitle":3849,"status":102,"phases":4916,"primaryCompletion":1358,"completion":1358,"start":1358,"enrollment":342,"conditions":4917,"interventions":4918},[85],[21,3852,15],[1225,3854],{"trials":4920,"activeCount":96},[],{"trials":4922,"activeCount":96},[],{"trials":4924,"activeCount":96},[],{"trials":4926,"activeCount":96},[],{"intervention":3862,"totalTrials":233,"cells":4928},{"EARLY_PHASE1":4929,"PHASE1":4931,"PHASE2":4937,"PHASE3":4939,"PHASE4":4941,"NA":4943},{"trials":4930,"activeCount":96},[],{"trials":4932,"activeCount":96},[4933],{"nctId":3856,"briefTitle":3857,"status":102,"phases":4934,"primaryCompletion":2714,"completion":2714,"start":1220,"enrollment":3859,"conditions":4935,"interventions":4936},[85],[21,15],[1225,3862],{"trials":4938,"activeCount":96},[],{"trials":4940,"activeCount":96},[],{"trials":4942,"activeCount":96},[],{"trials":4944,"activeCount":96},[],{"intervention":4946,"totalTrials":233,"cells":4947},"ASP015K ER",{"EARLY_PHASE1":4948,"PHASE1":4950,"PHASE2":4960,"PHASE3":4962,"PHASE4":4964,"NA":4966},{"trials":4949,"activeCount":96},[],{"trials":4951,"activeCount":96},[4952],{"nctId":4953,"briefTitle":4954,"status":102,"phases":4955,"primaryCompletion":3780,"completion":3780,"start":2714,"enrollment":2681,"conditions":4956,"interventions":4958},"NCT01686217","A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K",[85],[3946,4957,15],"Food Effect",[4946,4959],"ASP015K IR",{"trials":4961,"activeCount":96},[],{"trials":4963,"activeCount":96},[],{"trials":4965,"activeCount":96},[],{"trials":4967,"activeCount":96},[],{"intervention":4959,"totalTrials":233,"cells":4969},{"EARLY_PHASE1":4970,"PHASE1":4972,"PHASE2":4978,"PHASE3":4980,"PHASE4":4982,"NA":4984},{"trials":4971,"activeCount":96},[],{"trials":4973,"activeCount":96},[4974],{"nctId":4953,"briefTitle":4954,"status":102,"phases":4975,"primaryCompletion":3780,"completion":3780,"start":2714,"enrollment":2681,"conditions":4976,"interventions":4977},[85],[3946,4957,15],[4946,4959],{"trials":4979,"activeCount":96},[],{"trials":4981,"activeCount":96},[],{"trials":4983,"activeCount":96},[],{"trials":4985,"activeCount":96},[],{"intervention":3964,"totalTrials":233,"cells":4987},{"EARLY_PHASE1":4988,"PHASE1":4990,"PHASE2":4996,"PHASE3":4998,"PHASE4":5000,"NA":5002},{"trials":4989,"activeCount":96},[],{"trials":4991,"activeCount":96},[4992],{"nctId":3957,"briefTitle":3958,"status":102,"phases":4993,"primaryCompletion":3960,"completion":3960,"start":3961,"enrollment":342,"conditions":4994,"interventions":4995},[85],[18,3946],[3934,3964],{"trials":4997,"activeCount":96},[],{"trials":4999,"activeCount":96},[],{"trials":5001,"activeCount":96},[],{"trials":5003,"activeCount":96},[],{"intervention":5005,"totalTrials":233,"cells":5006},"ASP6981",{"EARLY_PHASE1":5007,"PHASE1":5009,"PHASE2":5019,"PHASE3":5021,"PHASE4":5023,"NA":5025},{"trials":5008,"activeCount":96},[],{"trials":5010,"activeCount":96},[5011],{"nctId":5012,"briefTitle":5013,"status":102,"phases":5014,"primaryCompletion":5015,"completion":5015,"start":5016,"enrollment":4087,"conditions":5017,"interventions":5018},"NCT03356639","A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia",[85],"2018-05-30","2018-01-22",[3033],[5005],{"trials":5020,"activeCount":96},[],{"trials":5022,"activeCount":96},[],{"trials":5024,"activeCount":96},[],{"trials":5026,"activeCount":96},[],{"intervention":5028,"totalTrials":233,"cells":5029},"ASP4132",{"EARLY_PHASE1":5030,"PHASE1":5032,"PHASE2":5045,"PHASE3":5047,"PHASE4":5049,"NA":5051},{"trials":5031,"activeCount":96},[],{"trials":5033,"activeCount":96},[5034],{"nctId":5035,"briefTitle":5036,"status":102,"phases":5037,"primaryCompletion":5038,"completion":5038,"start":5039,"enrollment":5040,"conditions":5041,"interventions":5044},"NCT02383368","A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma",[85],"2018-04-27","2015-03-23",39,[5042,5043,261],"Lymphoma","Refractory Solid Tumors",[5028],{"trials":5046,"activeCount":96},[],{"trials":5048,"activeCount":96},[],{"trials":5050,"activeCount":96},[],{"trials":5052,"activeCount":96},[],{"intervention":3870,"totalTrials":233,"cells":5054},{"EARLY_PHASE1":5055,"PHASE1":5057,"PHASE2":5063,"PHASE3":5065,"PHASE4":5067,"NA":5069},{"trials":5056,"activeCount":96},[],{"trials":5058,"activeCount":96},[5059],{"nctId":3864,"briefTitle":3865,"status":102,"phases":5060,"primaryCompletion":2714,"completion":2714,"start":2911,"enrollment":342,"conditions":5061,"interventions":5062},[85],[21,3868,15],[2916,3870],{"trials":5064,"activeCount":96},[],{"trials":5066,"activeCount":96},[],{"trials":5068,"activeCount":96},[],{"trials":5070,"activeCount":96},[],{"intervention":5072,"totalTrials":233,"cells":5073},"14C-labeled ASP0367",{"EARLY_PHASE1":5074,"PHASE1":5076,"PHASE2":5087,"PHASE3":5089,"PHASE4":5091,"NA":5093},{"trials":5075,"activeCount":96},[],{"trials":5077,"activeCount":96},[5078],{"nctId":5079,"briefTitle":5080,"status":102,"phases":5081,"primaryCompletion":5082,"completion":5083,"start":5084,"enrollment":30,"conditions":5085,"interventions":5086},"NCT05217901","A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men",[85],"2022-04-30","2022-05-09","2022-01-21",[15],[5072],{"trials":5088,"activeCount":96},[],{"trials":5090,"activeCount":96},[],{"trials":5092,"activeCount":96},[],{"trials":5094,"activeCount":96},[],{"intervention":5096,"totalTrials":233,"cells":5097},"ASP8082",{"EARLY_PHASE1":5098,"PHASE1":5100,"PHASE2":5111,"PHASE3":5113,"PHASE4":5115,"NA":5117},{"trials":5099,"activeCount":96},[],{"trials":5101,"activeCount":96},[5102],{"nctId":5103,"briefTitle":5104,"status":102,"phases":5105,"primaryCompletion":5106,"completion":5106,"start":5107,"enrollment":342,"conditions":5108,"interventions":5109},"NCT04448561","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants",[85],"2020-09-11","2020-06-30",[2874],[5096,5110],"morphine",{"trials":5112,"activeCount":96},[],{"trials":5114,"activeCount":96},[],{"trials":5116,"activeCount":96},[],{"trials":5118,"activeCount":96},[],{"intervention":5110,"totalTrials":233,"cells":5120},{"EARLY_PHASE1":5121,"PHASE1":5123,"PHASE2":5129,"PHASE3":5131,"PHASE4":5133,"NA":5135},{"trials":5122,"activeCount":96},[],{"trials":5124,"activeCount":96},[5125],{"nctId":5103,"briefTitle":5104,"status":102,"phases":5126,"primaryCompletion":5106,"completion":5106,"start":5107,"enrollment":342,"conditions":5127,"interventions":5128},[85],[2874],[5096,5110],{"trials":5130,"activeCount":96},[],{"trials":5132,"activeCount":96},[],{"trials":5134,"activeCount":96},[],{"trials":5136,"activeCount":96},[],{"intervention":5138,"totalTrials":233,"cells":5139},"ASP5502",{"EARLY_PHASE1":5140,"PHASE1":5142,"PHASE2":5153,"PHASE3":5155,"PHASE4":5157,"NA":5159},{"trials":5141,"activeCount":96},[],{"trials":5143,"activeCount":96},[5144],{"nctId":5145,"briefTitle":5146,"status":113,"phases":5147,"primaryCompletion":952,"completion":952,"start":5148,"enrollment":5149,"conditions":5150,"interventions":5152},"NCT06544642","A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome",[85],"2024-08-21",116,[15,5151],"Sjögren's Syndrome",[5138],{"trials":5154,"activeCount":96},[],{"trials":5156,"activeCount":96},[],{"trials":5158,"activeCount":96},[],{"trials":5160,"activeCount":96},[],{"intervention":3881,"totalTrials":233,"cells":5162},{"EARLY_PHASE1":5163,"PHASE1":5165,"PHASE2":5171,"PHASE3":5173,"PHASE4":5175,"NA":5177},{"trials":5164,"activeCount":96},[],{"trials":5166,"activeCount":96},[5167],{"nctId":3872,"briefTitle":3873,"status":102,"phases":5168,"primaryCompletion":3875,"completion":3875,"start":3876,"enrollment":3877,"conditions":5169,"interventions":5170},[85],[18,21,3879],[2916,3881],{"trials":5172,"activeCount":96},[],{"trials":5174,"activeCount":96},[],{"trials":5176,"activeCount":96},[],{"trials":5178,"activeCount":96},[],{"intervention":1551,"totalTrials":233,"cells":5180},{"EARLY_PHASE1":5181,"PHASE1":5183,"PHASE2":5189,"PHASE3":5191,"PHASE4":5193,"NA":5195},{"trials":5182,"activeCount":96},[],{"trials":5184,"activeCount":96},[5185],{"nctId":1542,"briefTitle":1543,"status":102,"phases":5186,"primaryCompletion":1545,"completion":1546,"start":1547,"enrollment":35,"conditions":5187,"interventions":5188},[85],[24,1549],[1499,1551],{"trials":5190,"activeCount":96},[],{"trials":5192,"activeCount":96},[],{"trials":5194,"activeCount":96},[],{"trials":5196,"activeCount":96},[],{"intervention":3890,"totalTrials":233,"cells":5198},{"EARLY_PHASE1":5199,"PHASE1":5201,"PHASE2":5207,"PHASE3":5209,"PHASE4":5211,"NA":5213},{"trials":5200,"activeCount":96},[],{"trials":5202,"activeCount":96},[5203],{"nctId":3883,"briefTitle":3884,"status":102,"phases":5204,"primaryCompletion":3807,"completion":3807,"start":3808,"enrollment":342,"conditions":5205,"interventions":5206},[85],[3887,3888,18],[1225,3890,3891],{"trials":5208,"activeCount":96},[],{"trials":5210,"activeCount":96},[],{"trials":5212,"activeCount":96},[],{"trials":5214,"activeCount":96},[],{"intervention":3891,"totalTrials":233,"cells":5216},{"EARLY_PHASE1":5217,"PHASE1":5219,"PHASE2":5225,"PHASE3":5227,"PHASE4":5229,"NA":5231},{"trials":5218,"activeCount":96},[],{"trials":5220,"activeCount":96},[5221],{"nctId":3883,"briefTitle":3884,"status":102,"phases":5222,"primaryCompletion":3807,"completion":3807,"start":3808,"enrollment":342,"conditions":5223,"interventions":5224},[85],[3887,3888,18],[1225,3890,3891],{"trials":5226,"activeCount":96},[],{"trials":5228,"activeCount":96},[],{"trials":5230,"activeCount":96},[],{"trials":5232,"activeCount":96},[],{"intervention":5234,"totalTrials":233,"cells":5235},"ASP1941",{"EARLY_PHASE1":5236,"PHASE1":5238,"PHASE2":5249,"PHASE3":5251,"PHASE4":5253,"NA":5255},{"trials":5237,"activeCount":96},[],{"trials":5239,"activeCount":96},[5240],{"nctId":5241,"briefTitle":5242,"status":102,"phases":5243,"primaryCompletion":5244,"completion":5244,"start":5245,"enrollment":4070,"conditions":5246,"interventions":5248},"NCT01678287","Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults",[85],"2008-01","2007-11",[15,5247],"Pharmacokinetics of ASP1941",[5234],{"trials":5250,"activeCount":96},[],{"trials":5252,"activeCount":96},[],{"trials":5254,"activeCount":96},[],{"trials":5256,"activeCount":96},[],{"intervention":3899,"totalTrials":233,"cells":5258},{"EARLY_PHASE1":5259,"PHASE1":5261,"PHASE2":5267,"PHASE3":5269,"PHASE4":5271,"NA":5273},{"trials":5260,"activeCount":96},[],{"trials":5262,"activeCount":96},[5263],{"nctId":3893,"briefTitle":3894,"status":102,"phases":5264,"primaryCompletion":3820,"completion":3820,"start":3820,"enrollment":342,"conditions":5265,"interventions":5266},[85],[21,3897,3823],[1225,3899],{"trials":5268,"activeCount":96},[],{"trials":5270,"activeCount":96},[],{"trials":5272,"activeCount":96},[],{"trials":5274,"activeCount":96},[],{"intervention":5276,"totalTrials":233,"cells":5277},"ASP1240",{"EARLY_PHASE1":5278,"PHASE1":5280,"PHASE2":5291,"PHASE3":5293,"PHASE4":5295,"NA":5297},{"trials":5279,"activeCount":96},[],{"trials":5281,"activeCount":96},[5282],{"nctId":5283,"briefTitle":5284,"status":102,"phases":5285,"primaryCompletion":5286,"completion":5286,"start":5287,"enrollment":5288,"conditions":5289,"interventions":5290},"NCT01565681","Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects",[85],"2009-12","2009-01",109,[2946,15],[5276],{"trials":5292,"activeCount":96},[],{"trials":5294,"activeCount":96},[],{"trials":5296,"activeCount":96},[],{"trials":5298,"activeCount":96},[],{"intervention":1338,"totalTrials":233,"cells":5300},{"EARLY_PHASE1":5301,"PHASE1":5303,"PHASE2":5309,"PHASE3":5311,"PHASE4":5313,"NA":5315},{"trials":5302,"activeCount":96},[],{"trials":5304,"activeCount":96},[5305],{"nctId":1331,"briefTitle":1332,"status":102,"phases":5306,"primaryCompletion":1334,"completion":1334,"start":1335,"enrollment":342,"conditions":5307,"interventions":5308},[85],[27],[1240,1338,1339,1340],{"trials":5310,"activeCount":96},[],{"trials":5312,"activeCount":96},[],{"trials":5314,"activeCount":96},[],{"trials":5316,"activeCount":96},[],{"intervention":294,"totalTrials":233,"cells":5318},{"EARLY_PHASE1":5319,"PHASE1":5321,"PHASE2":5327,"PHASE3":5329,"PHASE4":5331,"NA":5333},{"trials":5320,"activeCount":96},[],{"trials":5322,"activeCount":96},[5323],{"nctId":286,"briefTitle":287,"status":102,"phases":5324,"primaryCompletion":289,"completion":289,"start":290,"enrollment":291,"conditions":5325,"interventions":5326},[85],[24],[294,139],{"trials":5328,"activeCount":96},[],{"trials":5330,"activeCount":96},[],{"trials":5332,"activeCount":96},[],{"trials":5334,"activeCount":96},[],{"intervention":5336,"totalTrials":233,"cells":5337},"AGS15E",{"EARLY_PHASE1":5338,"PHASE1":5340,"PHASE2":5352,"PHASE3":5354,"PHASE4":5356,"NA":5358},{"trials":5339,"activeCount":96},[],{"trials":5341,"activeCount":96},[5342],{"nctId":5343,"briefTitle":5344,"status":102,"phases":5345,"primaryCompletion":5346,"completion":5346,"start":5347,"enrollment":5348,"conditions":5349,"interventions":5351},"NCT01963052","ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer",[85],"2019-07-08","2013-11-14",93,[5350],"Metastatic Urothelial Cancer",[5336],{"trials":5353,"activeCount":96},[],{"trials":5355,"activeCount":96},[],{"trials":5357,"activeCount":96},[],{"trials":5359,"activeCount":96},[],{"intervention":4116,"totalTrials":233,"cells":5361},{"EARLY_PHASE1":5362,"PHASE1":5364,"PHASE2":5370,"PHASE3":5372,"PHASE4":5374,"NA":5376},{"trials":5363,"activeCount":96},[],{"trials":5365,"activeCount":96},[5366],{"nctId":4109,"briefTitle":4110,"status":102,"phases":5367,"primaryCompletion":4112,"completion":4112,"start":4113,"enrollment":25,"conditions":5368,"interventions":5369},[85],[4080],[4116,3794],{"trials":5371,"activeCount":96},[],{"trials":5373,"activeCount":96},[],{"trials":5375,"activeCount":96},[],{"trials":5377,"activeCount":96},[],{"intervention":5379,"totalTrials":233,"cells":5380},"radio-labeled OSI-906",{"EARLY_PHASE1":5381,"PHASE1":5383,"PHASE2":5396,"PHASE3":5398,"PHASE4":5400,"NA":5402},{"trials":5382,"activeCount":96},[],{"trials":5384,"activeCount":96},[5385],{"nctId":5386,"briefTitle":5387,"status":102,"phases":5388,"primaryCompletion":5389,"completion":5390,"start":5391,"enrollment":381,"conditions":5392,"interventions":5394},"NCT01529684","A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body",[85],"2012-12-08","2013-02-20","2012-03-19",[24,5393],"Pharmacokinetics of 14C-OSI-906",[5379,5395],"OSI-906",{"trials":5397,"activeCount":96},[],{"trials":5399,"activeCount":96},[],{"trials":5401,"activeCount":96},[],{"trials":5403,"activeCount":96},[],{"intervention":5395,"totalTrials":233,"cells":5405},{"EARLY_PHASE1":5406,"PHASE1":5408,"PHASE2":5414,"PHASE3":5416,"PHASE4":5418,"NA":5420},{"trials":5407,"activeCount":96},[],{"trials":5409,"activeCount":96},[5410],{"nctId":5386,"briefTitle":5387,"status":102,"phases":5411,"primaryCompletion":5389,"completion":5390,"start":5391,"enrollment":381,"conditions":5412,"interventions":5413},[85],[24,5393],[5379,5395],{"trials":5415,"activeCount":96},[],{"trials":5417,"activeCount":96},[],{"trials":5419,"activeCount":96},[],{"trials":5421,"activeCount":96},[],{"intervention":3916,"totalTrials":233,"cells":5423},{"EARLY_PHASE1":5424,"PHASE1":5426,"PHASE2":5432,"PHASE3":5434,"PHASE4":5436,"NA":5438},{"trials":5425,"activeCount":96},[],{"trials":5427,"activeCount":96},[5428],{"nctId":3909,"briefTitle":3910,"status":102,"phases":5429,"primaryCompletion":3780,"completion":3780,"start":2714,"enrollment":19,"conditions":5430,"interventions":5431},[85],[21,3913,3914,15],[1225,3916],{"trials":5433,"activeCount":96},[],{"trials":5435,"activeCount":96},[],{"trials":5437,"activeCount":96},[],{"trials":5439,"activeCount":96},[],{"intervention":5441,"totalTrials":233,"cells":5442},"MA-0211",{"EARLY_PHASE1":5443,"PHASE1":5445,"PHASE2":5456,"PHASE3":5458,"PHASE4":5460,"NA":5462},{"trials":5444,"activeCount":96},[],{"trials":5446,"activeCount":96},[5447],{"nctId":5448,"briefTitle":5449,"status":102,"phases":5450,"primaryCompletion":5451,"completion":5451,"start":5452,"enrollment":5453,"conditions":5454,"interventions":5455},"NCT03682484","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort",[85],"2018-03-26","2017-06-29",320,[15],[5441],{"trials":5457,"activeCount":96},[],{"trials":5459,"activeCount":96},[],{"trials":5461,"activeCount":96},[],{"trials":5463,"activeCount":96},[],{"intervention":5465,"totalTrials":233,"cells":5466},"ASP5354",{"EARLY_PHASE1":5467,"PHASE1":5469,"PHASE2":5479,"PHASE3":5481,"PHASE4":5483,"NA":5485},{"trials":5468,"activeCount":96},[],{"trials":5470,"activeCount":96},[5471],{"nctId":5472,"briefTitle":5473,"status":102,"phases":5474,"primaryCompletion":5475,"completion":5475,"start":5476,"enrollment":2681,"conditions":5477,"interventions":5478},"NCT03698305","A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product",[85],"2019-05-20","2018-10-25",[18],[5465],{"trials":5480,"activeCount":96},[],{"trials":5482,"activeCount":96},[],{"trials":5484,"activeCount":96},[],{"trials":5486,"activeCount":96},[],{"intervention":5488,"totalTrials":233,"cells":5489},"fezolinetant - test formulation",{"EARLY_PHASE1":5490,"PHASE1":5492,"PHASE2":5503,"PHASE3":5505,"PHASE4":5507,"NA":5509},{"trials":5491,"activeCount":96},[],{"trials":5493,"activeCount":96},[5494],{"nctId":5495,"briefTitle":5496,"status":102,"phases":5497,"primaryCompletion":941,"completion":5498,"start":5499,"enrollment":3877,"conditions":5500,"interventions":5501},"NCT04277624","A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants",[85],"2021-02-26","2020-02-20",[15],[5488,5502],"fezolinetant - reference formulation",{"trials":5504,"activeCount":96},[],{"trials":5506,"activeCount":96},[],{"trials":5508,"activeCount":96},[],{"trials":5510,"activeCount":96},[],{"intervention":5502,"totalTrials":233,"cells":5512},{"EARLY_PHASE1":5513,"PHASE1":5515,"PHASE2":5521,"PHASE3":5523,"PHASE4":5525,"NA":5527},{"trials":5514,"activeCount":96},[],{"trials":5516,"activeCount":96},[5517],{"nctId":5495,"briefTitle":5496,"status":102,"phases":5518,"primaryCompletion":941,"completion":5498,"start":5499,"enrollment":3877,"conditions":5519,"interventions":5520},[85],[15],[5488,5502],{"trials":5522,"activeCount":96},[],{"trials":5524,"activeCount":96},[],{"trials":5526,"activeCount":96},[],{"trials":5528,"activeCount":96},[],{"intervention":5530,"totalTrials":233,"cells":5531},"IMAB362",{"EARLY_PHASE1":5532,"PHASE1":5534,"PHASE2":5546,"PHASE3":5548,"PHASE4":5550,"NA":5552},{"trials":5533,"activeCount":96},[],{"trials":5535,"activeCount":96},[5536],{"nctId":5537,"briefTitle":5538,"status":102,"phases":5539,"primaryCompletion":5540,"completion":5540,"start":5541,"enrollment":16,"conditions":5542,"interventions":5543},"NCT01671774","Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer",[85],"2014-10-13","2012-10-16",[445,443,444],[5530,5544,5545,5545],"Zoledronic acid","Interleukin-2",{"trials":5547,"activeCount":96},[],{"trials":5549,"activeCount":96},[],{"trials":5551,"activeCount":96},[],{"trials":5553,"activeCount":96},[],{"intervention":5544,"totalTrials":233,"cells":5555},{"EARLY_PHASE1":5556,"PHASE1":5558,"PHASE2":5564,"PHASE3":5566,"PHASE4":5568,"NA":5570},{"trials":5557,"activeCount":96},[],{"trials":5559,"activeCount":96},[5560],{"nctId":5537,"briefTitle":5538,"status":102,"phases":5561,"primaryCompletion":5540,"completion":5540,"start":5541,"enrollment":16,"conditions":5562,"interventions":5563},[85],[445,443,444],[5530,5544,5545,5545],{"trials":5565,"activeCount":96},[],{"trials":5567,"activeCount":96},[],{"trials":5569,"activeCount":96},[],{"trials":5571,"activeCount":96},[],{"intervention":5545,"totalTrials":233,"cells":5573},{"EARLY_PHASE1":5574,"PHASE1":5576,"PHASE2":5582,"PHASE3":5584,"PHASE4":5586,"NA":5588},{"trials":5575,"activeCount":96},[],{"trials":5577,"activeCount":96},[5578],{"nctId":5537,"briefTitle":5538,"status":102,"phases":5579,"primaryCompletion":5540,"completion":5540,"start":5541,"enrollment":16,"conditions":5580,"interventions":5581},[85],[445,443,444],[5530,5544,5545,5545],{"trials":5583,"activeCount":96},[],{"trials":5585,"activeCount":96},[],{"trials":5587,"activeCount":96},[],{"trials":5589,"activeCount":96},[],{"intervention":3924,"totalTrials":233,"cells":5591},{"EARLY_PHASE1":5592,"PHASE1":5594,"PHASE2":5600,"PHASE3":5602,"PHASE4":5604,"NA":5606},{"trials":5593,"activeCount":96},[],{"trials":5595,"activeCount":96},[5596],{"nctId":3918,"briefTitle":3919,"status":102,"phases":5597,"primaryCompletion":2680,"completion":2680,"start":2680,"enrollment":342,"conditions":5598,"interventions":5599},[85],[21,3922,18],[2916,3924],{"trials":5601,"activeCount":96},[],{"trials":5603,"activeCount":96},[],{"trials":5605,"activeCount":96},[],{"trials":5607,"activeCount":96},[],{"intervention":5609,"totalTrials":233,"cells":5610},"Fidaxomicin",{"EARLY_PHASE1":5611,"PHASE1":5613,"PHASE2":5622,"PHASE3":5624,"PHASE4":5626,"NA":5628},{"trials":5612,"activeCount":96},[],{"trials":5614,"activeCount":96},[5615],{"nctId":5616,"briefTitle":5617,"status":102,"phases":5618,"primaryCompletion":3904,"completion":3904,"start":2680,"enrollment":2703,"conditions":5619,"interventions":5621},"NCT01813448","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects",[85],[5620,18],"Pharmacokinetics of Fidaxomicin",[5609],{"trials":5623,"activeCount":96},[],{"trials":5625,"activeCount":96},[],{"trials":5627,"activeCount":96},[],{"trials":5629,"activeCount":96},[],{"intervention":305,"totalTrials":233,"cells":5631},{"EARLY_PHASE1":5632,"PHASE1":5634,"PHASE2":5640,"PHASE3":5642,"PHASE4":5644,"NA":5646},{"trials":5633,"activeCount":96},[],{"trials":5635,"activeCount":96},[5636],{"nctId":296,"briefTitle":297,"status":113,"phases":5637,"primaryCompletion":299,"completion":299,"start":300,"enrollment":301,"conditions":5638,"interventions":5639},[85],[303],[305,139],{"trials":5641,"activeCount":96},[],{"trials":5643,"activeCount":96},[],{"trials":5645,"activeCount":96},[],{"trials":5647,"activeCount":96},[],{"intervention":5649,"totalTrials":233,"cells":5650},"ASP0892 Intradermal",{"EARLY_PHASE1":5651,"PHASE1":5653,"PHASE2":5664,"PHASE3":5666,"PHASE4":5668,"NA":5670},{"trials":5652,"activeCount":96},[],{"trials":5654,"activeCount":96},[5655],{"nctId":5656,"briefTitle":5657,"status":102,"phases":5658,"primaryCompletion":5659,"completion":5659,"start":5660,"enrollment":3993,"conditions":5661,"interventions":5662},"NCT02851277","A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine",[85],"2018-12-06","2016-12-13",[4456],[5649,5663],"ASP0892 Intramuscular",{"trials":5665,"activeCount":96},[],{"trials":5667,"activeCount":96},[],{"trials":5669,"activeCount":96},[],{"trials":5671,"activeCount":96},[],{"intervention":5663,"totalTrials":233,"cells":5673},{"EARLY_PHASE1":5674,"PHASE1":5676,"PHASE2":5682,"PHASE3":5684,"PHASE4":5686,"NA":5688},{"trials":5675,"activeCount":96},[],{"trials":5677,"activeCount":96},[5678],{"nctId":5656,"briefTitle":5657,"status":102,"phases":5679,"primaryCompletion":5659,"completion":5659,"start":5660,"enrollment":3993,"conditions":5680,"interventions":5681},[85],[4456],[5649,5663],{"trials":5683,"activeCount":96},[],{"trials":5685,"activeCount":96},[],{"trials":5687,"activeCount":96},[],{"trials":5689,"activeCount":96},[],{"intervention":4599,"totalTrials":180,"cells":5691},{"EARLY_PHASE1":5692,"PHASE1":5694,"PHASE2":5700,"PHASE3":5712,"PHASE4":5714,"NA":5716},{"trials":5693,"activeCount":96},[],{"trials":5695,"activeCount":96},[5696],{"nctId":4592,"briefTitle":4593,"status":102,"phases":5697,"primaryCompletion":4595,"completion":4595,"start":4596,"enrollment":1500,"conditions":5698,"interventions":5699},[85],[18],[4585,4599],{"trials":5701,"activeCount":96},[5702],{"nctId":5703,"briefTitle":5704,"status":102,"phases":5705,"primaryCompletion":5706,"completion":5706,"start":5707,"enrollment":3993,"conditions":5708,"interventions":5711},"NCT03816176","A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants",[86],"2022-12-14","2019-08-22",[5709,5710],"Invasive Mucormycosis","Invasive Aspergillosis",[4599,4599],{"trials":5713,"activeCount":96},[],{"trials":5715,"activeCount":96},[],{"trials":5717,"activeCount":96},[5718],{"nctId":5719,"briefTitle":5720,"status":102,"phases":5721,"primaryCompletion":5722,"completion":5722,"start":5723,"enrollment":5724,"conditions":5725,"interventions":5727},"NCT03066011","Registry of Patients Treated With Systemic Mold-Active Triazoles",[],"2020-04-24","2017-03-16",2015,[5726],"Invasive Fungal Infection",[4599,1609,5728],"Posaconazole",{"intervention":1609,"totalTrials":219,"cells":5730},{"EARLY_PHASE1":5731,"PHASE1":5733,"PHASE2":5735,"PHASE3":5741,"PHASE4":5743,"NA":5745},{"trials":5732,"activeCount":96},[],{"trials":5734,"activeCount":96},[],{"trials":5736,"activeCount":96},[5737],{"nctId":1600,"briefTitle":1601,"status":102,"phases":5738,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":5739,"interventions":5740},[85,86],[34],[1515,1609,1610,1611],{"trials":5742,"activeCount":96},[],{"trials":5744,"activeCount":96},[],{"trials":5746,"activeCount":96},[5747],{"nctId":5719,"briefTitle":5720,"status":102,"phases":5748,"primaryCompletion":5722,"completion":5722,"start":5723,"enrollment":5724,"conditions":5749,"interventions":5750},[],[5726],[4599,1609,5728],{"intervention":5728,"totalTrials":233,"cells":5752},{"EARLY_PHASE1":5753,"PHASE1":5755,"PHASE2":5757,"PHASE3":5759,"PHASE4":5761,"NA":5763},{"trials":5754,"activeCount":96},[],{"trials":5756,"activeCount":96},[],{"trials":5758,"activeCount":96},[],{"trials":5760,"activeCount":96},[],{"trials":5762,"activeCount":96},[],{"trials":5764,"activeCount":96},[5765],{"nctId":5719,"briefTitle":5720,"status":102,"phases":5766,"primaryCompletion":5722,"completion":5722,"start":5723,"enrollment":5724,"conditions":5767,"interventions":5768},[],[5726],[4599,1609,5728],{"intervention":5770,"totalTrials":233,"cells":5771},"MDV3100",{"EARLY_PHASE1":5772,"PHASE1":5774,"PHASE2":5776,"PHASE3":5778,"PHASE4":5780,"NA":5782},{"trials":5773,"activeCount":96},[],{"trials":5775,"activeCount":96},[],{"trials":5777,"activeCount":96},[],{"trials":5779,"activeCount":96},[],{"trials":5781,"activeCount":96},[],{"trials":5783,"activeCount":96},[5784],{"nctId":5785,"briefTitle":5786,"status":239,"phases":5787,"conditions":5788,"interventions":5789},"NCT01606982","Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy",[],[1248],[5770]]